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Neuroscience is a relatively small and emerging clinical pharmacy specialism 
focusing on drug therapy for neurological disease. Against a professional 
momentum for specialist practice within pharmacy, there is paucity both of 
relevant research, and a clearly defined role for specialist pharmacy practice in 
neuroscience.  
A qualitative research study was undertaken, using constructivist grounded 
theory method, to explore how hospital based pharmacists practicing in 
neuroscience define and develop their role and specialism. Data were 
concurrently generated and analysed, through verbatim transcription of 
telephone interviews with fourteen pharmacists.  
Data analysis resulted in the identification of three processes: (1) Acquiring and 
utilising knowledge in practice; (2) Gatekeeping access to drug therapies; (3) 
Integrating into the neuroscience service. The key findings within each process 
are: (1) Pharmacists utilise different forms of knowledge and there can be 
barriers to gaining knowledge. Pharmacists identify strengths in their breadth of 
clinical knowledge and holistic consideration of patients’ drug therapy. (2) 
Pharmacists act as barriers to drug therapy but also act to expedite and secure 
access to drug therapy. (3) Pharmacists act as an organisational nexus 
between pharmacy and neuroscience services and identify the importance in 
practice of forming working relationships within neuroscience services, 
underpinned by trust. 
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The study identified a basic social process: Maintaining an overview of drug 
therapy for patients with neurological disease. This process conceptualises the 
tensions experienced by the pharmacists between their role as near-patient 
facing clinical specialists, but also as pharmacist generalists. The study findings 
have implications for supporting pharmacy practice in neuroscience.  
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Notes to the reader 
 
1. This thesis is intentionally written in a first person narrative to convey my 
involvement in this qualitative research project as an instrument of data 
generation and analysis.  
2. Referencing uses the University of Bradford version of the Harvard 
system, with Endnote software version X5. 
3. Direct quotations, taken either from reference sources, or the interview 
data collected within the project, are presented in italicised font within 
double quotation marks. More substantial direct quotation text is 
presented in a separate paragraph, indented into the page.  
4. Interview data are presented verbatim but with the removal of any text 
that may serve to identify individuals e.g. name of hospital, colleagues 
etc. Bold text represents the speech of the interviewer. Grammatical 
errors within the transcripts are acknowledged by the placement of [sic] 
adjacent to the text. Unless stated otherwise, the placement of ellipses 
(…) within quotation paragraphs indicate the sentence was not finished 
by the participant. Ellipses at the beginning or end of paragraphs indicate 
truncated text.  
5. The terms drug(s) and medicine(s) are often used interchangeably in 
healthcare to describe a substance administered to a person for 
diagnostic or therapeutic purposes. For consistency I have used the term 
drug but I have left any referenced quotes or interview data unaltered 
which contain the term medicine or other synonym. 
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1 Introduction 
 
1.1 A reflexive statement about the research 
The thesis presented is the summary of a research project exploring the role of 
clinical pharmacists within the adult clinical neuroscience services of the 
National Health Service (NHS). As a neuroscience pharmacist myself, this 
thesis represents an analysis of my own area of professional practice. 
Reflexivity is a key consideration in the rigour of qualitative research. The 
concept of reflexivity is discussed further in section 3.3.2.3 (p.70) but in 
essence, being reflexive is acknowledging the experience and beliefs that the 
researcher brings to the research project and the effects this can have on the 
research process (Holloway and Brown, 2012). I therefore think it is appropriate 
at the outset to provide some personal context and background to this piece of 
research.  
This thesis represents the second stage of, and contributes to the completion 
of, a professional doctoral degree programme - the Doctor of Pharmacy 
(DPharm). The DPharm programme has a broad aim of advancing the practice 
and research skills of professionally practicing pharmacists. The first stage of a 
DPharm programme comprises completion of a number of taught modules and 
the submission of three professional practice portfolios.  
Reflective practice is entrenched in the DPharm programme and it has had 
quite a profound effect on my practice. One of the reflections that I made at the 
completion of the first stage of this degree was to consider how the 
development of my practice had taken place in relative isolation to other 
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pharmacists who practice in neuroscience. What interaction I had experienced 
with my peers, often brief conversations at national meetings, had suggested 
they faced similar issues and challenges in practice.  
My own practice has evolved from the DPharm programme and I have delivered 
educational presentations of neurological diseases at local and national forums, 
often with emphasis on the role that the non-specialist pharmacist can play in 
the care of patients. In preparing these presentations I have reflected on my 
own practice, questioning what makes it ‘specialised’. I also began to review 
guidance around neurological disease to try and understand the organisational 
positioning of pharmacists within neurological services.  
During the first stage of the DPharm programme I became a committee member 
of the neuroscience group of the United Kingdom Clinical Pharmacy Association 
(UKCPA). This group has aims of advancing and supporting clinical pharmacy 
practice in neuroscience (see section 1.5.1). I believe that to achieve these 
aims requires a wider understanding of pharmacy practice in neuroscience.  
The ongoing reflections which I consider to now imbue my practice, in tandem 
with the challenges of the ever changing nature of healthcare provision within 
the NHS, has fuelled an increasing curiosity in defining and understanding the 
role of a specialist clinical pharmacist in the medical speciality of neuroscience. 
If the UKCPA group is to achieve its intended aims of supporting and 
developing practice then some form of empirical investigation to attain a deeper 
understanding of current practice and how it is progressed seem necessary; 
that is what this study aims to achieve. 
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1.2 Setting out the chapter 
An introduction chapter should provide background information and context for 
an intended piece of research and lead into a justification for the research 
(Holloway and Brown, 2012 , Wisker, 2001). This chapter is intended to 
orientate the reader to the substantive focus of the research: hospital clinical 
pharmacy practice in the NHS, within the specialism of neuroscience. The 
chapter provides a concise overview of the NHS, the pharmacy profession and 
the provision of neurological services. Recent changes and developments both 
within the NHS and pharmacy are described to provide some professional 
context to the study. The chapter then focuses on the role of pharmacy within 
the specialism of neuroscience and concludes with the key relevant 
considerations to the research.  
 
1.3 The National Health Service 
The NHS encompasses the health services provided to the four countries of the 
United Kingdom (UK): England, Wales, Scotland and Northern Ireland. The 
NHS was founded in 1948 on the principle that healthcare should be free to all 
at the point of need (Rivett, 1998). That mantra largely remains true today 
although not all services remain free, for example, prescriptions for medicines in 
England (with some exemptions). 
The NHS has undergone several reorganisations since its inception. The health 
services of the four countries now function independently of each other. One of 
the most significant changes arose in 1991 out of the NHS and Community 
Care Act 1990 which introduced the idea of an internal market within the NHS 
4 
 
and of the discrete functions of ‘purchasers’ and ‘providers’ of healthcare. The 
purchaser and provider model, although slightly altered and assigned different 
terminology through subsequent governmental reforms, exists in the NHS 
today. At the time of writing NHS England was undergoing significant changes 
resulting from the Health and Social Care Act 2012 which came into effect from 
1st April 2013. 
Hospitals are providers of acute and specialised healthcare services. NHS 
hospitals or groups of hospitals are managed by acute Trusts. NHS Trusts are 
effectively public sector corporations with responsibility for managing hospital 
services. NHS Foundation Trusts (NHSFTs) were introduced into the NHS in 
2004. NHSFTs are allowed greater managerial and financial autonomy with the 
intention of devolving centralised decision making and providing services based 
on local need.  
The services and treatments provided by acute NHS Trusts are commissioned, 
a NHS term for the planning, purchasing and monitoring of services, by clinical 
commissioning groups (CCGs). CCGs came into existence on 1st April 2013 in 
place of Primary Care Trusts (PCTs). Within the NHS, CCGs are now 
responsible for commissioning the majority of services for patients within its 
locality. CCGs can commission non-NHS services that meet appropriate 
standards introducing external competition to NHS provider Trusts.  
More specialised services for rarer diseases are commissioned directly by NHS 
England through a process known as specialised commissioning. These 
services are generally provided from specialist centres only. Clinical reference 
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groups (CRGs) guide the commissioning strategy around each specialised 
service. 
This section has set out how hospitals, the substantive setting for this research, 
serve as the main providers for acute and specialised care within the NHS. I will 
now provide an overview of the pharmacy profession and its evolution before 
narrowing the focus to pharmacy practice, and more specifically to clinical 
pharmacy practice within hospitals, the empirical focus of this research. 
 
1.4 The pharmacy profession  
Pharmacy is one of the healthcare professions, concerned primarily with the 
use of drugs. Pharmacists are the traditional exponents of the profession and 
are the focus of this research project. However, pharmacy technicians are 
playing an increasingly prominent and important role in the work of pharmacy 
e.g. Millen et al. (2010). Pharmacy technicians are now formally recognised and 
regulated by the pharmacy profession (Rodgers et al., 2010).  
In comparison to the other main healthcare professions, medicine and nursing, 
the pharmacy profession, although growing, remains relatively small. The most 
recent workforce survey for pharmacy in the UK recorded approximately 46,000 
registered pharmacists (Seston and Hassell, 2013). 
1.4.1 What is a pharmacist? 
 
A contemporary lay definition of a pharmacist is “A person who is professionally 
qualified to prepare and dispense medicinal drugs.” (Oxford Dictionaries, 
2013b). 
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Although this definition encompasses some of the activities of pharmacy 
practice it is unsatisfactory in capturing the contribution that pharmacists make 
towards healthcare. But defining the generic role of a pharmacist is difficult 
because pharmacists practice within a range of sectors which include 
community (retail), hospitals, primary care, industry and academia. 
The Royal Pharmaceutical Society (RPS), the broad professional representative 
body for pharmacists in Great Britain, describes pharmacists as “… key players 
in the future of healthcare across the UK. To put it bluntly, they have greater 
expertise in medicines than any other health professional.” (Royal 
Pharmaceutical Society, 2013). 
Drugs, or medicines, feature prominently within both of the above definitions of 
a pharmacist. A brief history of the profession of pharmacy in Britain is provided 
in the next section to illuminate the pharmacy profession’s connection with 
drugs, and the evolution of the profession. 
1.4.2 The history of the pharmacy profession 
 
The history of pharmacy has strong roots in the compounding and supply of 
drugs as medicinal products. The origins of the pharmacy profession can be 
traced back to the apothecaries (Liaw and Peterson, 2009). By the sixteenth 
century in London, the term ‘apothecary’ had become synonymous with a 
person involved in the preparation and sale of amongst more general items, 
substances such as herbs for medicinal use. These medicinal substances were 
either sold by the apothecaries in accordance with a physician’s prescription or 
by their own recommendation (The Worshipful Society of Apothecaries of 
London, 2013). As the role of the apothecary evolved to a more advisory one, 
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the role of the preparation and supply of medicinal products was taken on by 
the ‘chemist and druggist’ who would become pharmacists although the term 
‘pharmacist’ would not come into more common parlance until later in the 19th 
century. 
Regulation of the pharmacy profession dates back to 1841 with the formation of 
the Pharmaceutical Society, the forerunner of the RPS, by Jacob Bell (Rodgers 
et al., 2010). At that time, professional regulation to ensure standards of 
practice was seen as a way to protect against a perceived threat from the 
apothecaries to the trade of the chemists and druggists. Inclusion to the 
Pharmaceutical Society was on the basis of professional qualification. This was 
written into law by the Pharmacy Act of 1852 although membership for 
professional practice did not become compulsory until the Pharmacy Act of 
1933 (Rodgers et al., 2010).  
Well into mid-20th century the practice of pharmacy in Britain maintained its 
roots within the apothecaries and chemists and druggists, being primarily 
concerned with the compounding and dispensing of drug products. Beyond the 
mid-20th century, notably from the decades of the 1960s and 1970s, rapid 
scientific and medical advances and the commercial industrialisation of 
pharmaceutical development drove drug discovery (Abraham, 2009). This 
acceleration of drug discovery greatly widened the therapeutic armoury 
available for the drug treatment of disease.  
As a result of commercialisation, drugs were increasingly being manufactured in 
ready to administer dosage forms and the traditional compounding and 
formulation skills of the pharmacist were becoming redundant. These changes 
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in drug development raised questions about the role of pharmacists and how 
the pharmacy profession could and should evolve to survive (Silcock et al., 
2004).  
As a consequence of the commercial industrialisation of drug preparation, the 
practice of pharmacy has evolved over the last three to four decades. 
Pharmacists have developed expertise in drugs and drug use, to have greater 
involvement with the clinical care of patients, and public health initiatives. Today 
registration as a practicing pharmacist in the United Kingdom requires 
successful completion of an accredited four year Master of Pharmacy (MPharm) 
degree and one year of professional ‘pre-registration’ training culminating in 
professional examination by the pharmacy regulatory body, the General 
Pharmaceutical Council (GPhC).  
1.4.2.1 Regulation and leadership of the pharmacy profession 
 
The RPS was a rather unique body for the healthcare professions in that it 
carried out both a regulatory and leadership role for the pharmacy profession. 
These two functions were misaligned. In September 2010, following on from the 
recommendations of the ‘Carter’ report into the pharmacy profession 
(Department of Health, 2007), professional regulation of pharmacy was 
transferred to a newly formed body, the GPhC. 
Within the pharmacy profession the formation of the GPhC was viewed as a 
pivotal opportunity for the RPS to advance the pharmacy profession, free from 
its previous regulatory responsibilities. One of the key recommendations of the 
Carter report was the formation of a Royal College of Pharmacy, with functions 
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akin to the royal medical colleges to advance the practice of pharmacy by 
providing support with professional development. In 2013 the RPS launched the 
Faculty (Duggan, 2013). The Faculty has a broad aim of supporting, through 
frameworks and curricula, and recognising through accreditation, advancing 
and specialist pharmacy practice. 
The work of the Faculty builds on from work undertaken elsewhere, notably the 
general and advanced consultant level frameworks (Competency Development 
& Evaluation Group, 2009), and the work of some UKCPA groups in 
credentialing practice and developing specialist curricula (McKenzie et al., 
2011). In 2011 the RPS and UKCPA formed a partnership to advance the 
practice of pharmacy. Included within the themes of the partnership are plans 
to: 
 Develop professional curricula for advanced and specialist pharmacy 
across pharmacy disciplines. 
 Set professional standards and guidance for practice beyond those 
required for regulation. 
 
The work of the RPS and UKCPA is further supported by recommendations 
from Modernising Pharmacy Careers (MPC) to develop advanced and specialist 
practice (Howe and Wilson, 2012). MPC is a work programme, reporting to the 
Department of Health and Medical Education England (MEE) and tasked with 
ensuring both undergraduate and post-graduate training is sufficient for the 
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English pharmacy workforce to meet future challenges of delivering effective 
healthcare. 
The profession of pharmacy is evolving. The discussion now turns to hospital 
pharmacy practice with particular emphasis on clinical pharmacy.  
1.4.3 Hospital pharmacy 
 
Hospital pharmacy is the second most common sector of practice for 
pharmacists after community pharmacy, which accounts for the majority of 
practicing pharmacists. Most recent estimates place 21% of UK pharmacists 
practicing in the hospital sector (Centre for Workforce Intelligence, 2013). 
Pharmacists working in NHS hospitals are NHS employees. Pharmacists within 
the NHS are increasingly working across traditional healthcare sector 
boundaries to meet the ever increasing complex needs of providing patient 
care. 
Articulating what hospital pharmacy is within the NHS is not straightforward, as 
it encompasses a broad range of services, with the individual extent of provision 
being dependent on the nature of the hospital and the pharmacy department 
within it. Table 1, adapted from Stephens (2011), summarises the common 
services provided within a hospital pharmacy. The provision of these pharmacy 
services does not occur in mutual exclusivity to each other; pharmacists can be 
involved in the provision of several aspects of a hospital pharmacy service. 
Table 1 illustrates that clinical pharmacy, described in the next section, is just 
one facet of a hospital pharmacy service. 
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Table 1. Common services provided by hospital pharmacies. 
Service Brief description 
Drug Procurement The cost-effective purchasing of drugs often through locally or nationally negotiated 
contracts.  
Drug Supply The safe and secure supply of drugs, either for ready use within clinical area, or for 
individual use by a patient dispensed against an authorised prescription.  
Clinical Pharmacy Providing direct patient care within a ward or clinic setting (see section 1.4.4 for a more 
detailed discussion of clinical pharmacy). 
Technical Services The compounding and provision of products such as specific intravenous medications, 
chemotherapy, and parenteral nutrition, often under aseptic conditions. 
Risk Management Proactively and reactively identifying the risks associated with drugs and their use and 
implementing strategies to reduce risk. 
Medicines Information Provision of accurate, unbiased and evidence-based advice on drug use on a single-patient 
and more widespread basis to facilitate the optimal use of drugs. 
Medicines Management Ensuring the controlled entry of new drugs into clinical practice to manage associated 
clinical and financial risks; encompassing drug supply and clinical pharmacy services. 
Initiatives like hospital drug formularies (a list of medicinal products that is kept within the 
hospital) managed by multidisciplinary committees are common within hospitals. 
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1.4.4 Clinical pharmacy 
 
Clinical pharmacy has been defined as: 
… a health science discipline in which pharmacists provide patient care 
that optimizes medication therapy and promotes health, wellness, and 
disease prevention. The practice of clinical pharmacy embraces the 
philosophy of pharmaceutical care…  
(American College of Clinical Pharmacy, 2008 p.816) 
Clinical pharmacy is the provision of pharmaceutical care, a concept defined by 
Hepler and Strand (1990) but practiced prior to their conceptualisation of it. The 
‘clinical’ prefix denotes a move from a product-based focus (drug supply) to a 
patient-based focus, using the pharmacist’s specialist drug knowledge to 
improve patient outcomes with drug therapy. Clinical pharmacy is more than 
just a transition from the pharmacists’ traditional work setting of the dispensary 
and professional activity of dispensing drugs. Clinical pharmacy embraces an 
ethos of putting the patient at the centre of pharmacists activities, using values 
and judgements as well as the application of scientific and pharmaceutical 
knowledge (American College of Clinical Pharmacy, 2008 , UKCPA, 2013). 
Clinical pharmacy is practiced in all the direct patient-facing sectors of 
pharmacy. Clinical pharmacy originated within hospital pharmacy in the 1960s 
when pharmacists began to visit wards and review drug prescription charts, 
making recommendations for drug use and drug monitoring. This move 
occurred in response to a number of factors, not least the increasing complexity 
of drug therapy (Child et al., 2011). The practice of pharmacists visiting wards 
continued to evolve and ‘clinical pharmacy’ was first formally acknowledged in 
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the 1986 Nuffield Report into hospital pharmacy with a recommendation that it 
should be practiced in all hospitals (Watson and Bond, 2004).  
Clinical pharmacy and the role of the pharmacy profession generally has 
continued to evolve, with the development of an evidence base for practice 
(Child et al., 2004) and increasing recognition that pharmacists have a role to 
play in healthcare provision (Department of Health, 2008b). Child et al. (2011) 
argue that the ‘clinical’ prefix of clinical pharmacy is possibly no longer 
necessary as pharmacy is now recognised within the NHS as a clinical 
profession providing patient care.   
The evolution of clinical pharmacy has led to pharmacists developing 
specialisms within certain areas of medicine and healthcare. Examples of 
clinical pharmacy specialism include critical care, antimicrobial stewardship, 
mental health and oncology. A traditional ‘clinical’ route of career progression 
for pharmacists practicing in hospital, beyond standardised post-registration 
training, is to undertake a role with responsibility for one, or a small number of 
often related medical specialities.  
1.4.4.1 Clinical pharmacy groups 
 
The evolution of clinical pharmacy in the UK has spawned a number of 
professional groups. Some groups are specific to medical specialities e.g. 
British Oncology Pharmacists Association (BOPA); UK Renal Pharmacy Group. 
One of the larger and broader clinical pharmacy networks is the UKCPA, 
founded in 1981. The UKCPA has several thousand members from different 
sectors and specialities of pharmacy practice and its mission is to promote 
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expert practice in clinical pharmacy. There are a number of subgroups reflecting 
different specialities, sectors of work and job roles. 
All clinical pharmacy organisations are voluntarily subscribed; their ongoing 
existence demonstrates a momentum amongst pharmacists to advance their 
practice within defined areas of medicine or healthcare. 
Section 1.4 has described the evolution of the pharmacy profession and the 
recent regulatory changes within the profession. The current work of pharmacy 
bodies highlights a momentum to advance specialist practice within the 
profession. To complete the orientation, the medical and clinical pharmacy 
specialism of neuroscience is outlined in the following section. 
 
1.5 The medical speciality of neuroscience 
Neuroscience deals with diseases of the nervous system, commonly termed 
neurological diseases. Neuroscience typically encompasses the medical 
(neurology) and surgical (neurosurgery) treatment of neurological disease. 
When including headache syndromes, It has been estimated that ten million 
people in the UK live with a neurological condition (Neurological Alliance, 2003). 
The prevalence of common diseases of the nervous system, taken from the 
Neurological Alliance (2003) is presented in Figure 1. These conditions 
represent a small portion of the spectrum of neurological diseases. The more 
prevalent neurological diseases identified in Figure 1 are relatively less common 
in comparison to diabetes, cardiovascular or respiratory diseases. For example, 
the estimated UK prevalence of chronic obstructive pulmonary disease is 
850,000 and for asthma, in England alone, is between 3 and 5.4 million 
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(Department of Health, 2011b).  So although neurological disease is relatively 
common per se, individual conditions are less so. 
 
Figure 1. Estimated prevalence of chronic neurological diseases. 
 
Neurology is a relatively modern medical speciality, with neurology departments 
only becoming common place in the large UK hospitals in the 1980s (Warlow et 
al., 2008). The provision of neurological services within the NHS largely follows 
a ‘hub and spoke’ model (Bateman, 2011). In such a model, consultant medical 
staff are often based in regional hospital centres which have the infrastructure 
to support the diagnosis and treatment of neurological diseases. These centres, 
which consist of neurology and neurosurgery services or neurology services 
alone, are often referred to as tertiary services. Medical staff also provide 
outreach services by visiting surrounding hospitals to undertake outpatient 
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clinics and receive referrals to review patients from non-specialised clinical 
teams. 
As there are a large number of rare neurological disorders a significant number 
of the neurological services provided within NHS England come under 
specialised commissioning. There is a CRG for neuroscience to oversee the 
specialist commissioning which recognises 25 specialist neuroscience centres 
(NHS Commissioning Board, 2013). 
1.5.1 Clinical pharmacy in neuroscience 
 
There are clinical pharmacy posts in NHS hospitals specialising in 
neuroscience, either in neurology, neurosurgery or both. As with the medical 
discipline, neuroscience is a relatively recent clinical pharmacy specialism. 
There is no register of clinical pharmacy posts in neuroscience and the number 
of posts and specially practicing pharmacists is not known but I assume the 
figure to be relatively small in relation to other clinical pharmacy specialisms. An 
informal e-mail network for neuroscience pharmacists to exchange queries was 
in existence from early 2000. In 2009 a formal neuroscience subgroup of the 
UKCPA was formed with the following aims: 
 Broaden the awareness of adult neurological conditions and their 
treatment. 
 Share ideas, experience, evidence and resources. 
 Encourage and support practice based research. 
 Produce collaborative work to influence and establish national standards. 
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 Provide education and training events.  
Since its inception the neuroscience group has functioned largely as an 
electronic forum for members to post questions to the wider professional group 
relating to specific drug or disease issues, superseding the previous e-mail 
forum. There has been little interaction through the group around collective 
recognition, enhancement or development of the pharmacist’s role within 
neuroscience.  
1.5.2 Pharmacist inclusion in guidelines for neurological disease 
 
In beginning to ascertain the place of specialist pharmacists in neuroscience 
services I undertook a review of key national guidance relating to neurological 
disease to identify the inclusion of a role for pharmacy or pharmacists. This 
section summarises the findings. 
1.5.2.1 National Institute for Health and Care Excellence 
 
The National Institute for Health and Care Excellence (NICE) is a non-
departmental body of the Department of Health with a remit in England and 
Wales to publish guidance on health technologies, including drugs, and best 
clinical practice for the care of specific diseases. NICE have produced clinical 
guidelines for the more prevalent neurological diseases - the epilepsies, 
multiple sclerosis (MS) and Parkinson’s disease. Amongst these conditions 
drug therapy is a principal treatment modality.  
Making an assumption that pharmacists, as the experts in drug therapies, would 
have a pivotal role in optimising drug therapies for these conditions I undertook 
a keyword search of the aforementioned guidelines for the terms ‘pharmacist’ or 
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‘pharmacy’ to test this assumption. For comparison I repeated the search using 
the search terms of other healthcare professional groups routinely involved in 
the care of patients with neurological disease. The search results are 
summarised in Table 2; they illustrate an omission, amongst NICE guidelines, of 
a recognised role for the pharmacist in the management of these common 
neurological diseases. 
Table 2. The citation frequency of healthcare professionals within NICE 
guidance. 
Professional keyword search 
term 
Epilepsy1 Parkinson’s 
disease2 
Multiple 
sclerosis3 
Pharmacist / pharmacy 0 0 0 
Nurse 4 4 3 
Neurologist 2 2 3 
Physiotherapist / physiotherapy      0 12 7 
Occupational therapist /  
occupational therapy 
1 11 1 
 
1.5.2.2 National Service Framework (NSF) for long term conditions 
 
The NSF for long term conditions (Department of Health, 2005) is a 10 year 
strategy to improve health and social care services for people with long term 
conditions with particular emphasis on neurological conditions. It contains the 
following recommendations in relation to pharmacists: 
                                                             
1
 National Institute for Health and Care Excellence. (2012). The epilepsies: the diagnosis and 
management of epilepsies in adults and children in primary and secondary care. Clinical 
Guideline 137. London: NICE 
2
 National Institute for Health and Care Excellence. (2006). Parkinson’s disease: Diagnosis and 
management in primary and secondary care. Clinical Guideline 35. London: NICE 
3
 National Institute for Health and Care Excellence. (2003). Multiple sclerosis: Management of 
multiple sclerosis in primary and secondary care. Clinical Guideline 8. London: NICE 
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 Pharmacists are recognised as possible people to undertake regular 
medication reviews. 
 Pharmacists can provide support concerning medicines for the carers of 
people with long term conditions. 
 Pharmacists to practice as independent prescribers of medicines for 
people with long term conditions. 
 Developing community pharmacists with specialist interest in Parkinson’s 
disease to support people in managing their medicines in the community.  
The recommendations from the policy allude to roles for pharmacist with 
particular emphasis on community pharmacists. This is aligned with a more 
general ethos within the NHS to bring care nearer to the patient. The role for a 
pharmacist in the acute care setting of a hospital is less well defined.  
 
1.6 Chapter summary 
This chapter has illustrated how the practice of pharmacy within the UK has 
evolved greatly over the last 30 to 40 years. Pharmacists have moved from a 
drug compounding and supply role to develop expertise in all aspects of drug 
use, exemplified by the emergence of clinical pharmacy. Clinical pharmacy is 
the provision of pharmaceutical care which embraces the ethos of putting the 
patient at the centre of practice and applying specialist drug (pharmaceutical) 
knowledge to optimise the outcomes from drug use.  
The emergence of clinical pharmacy has resulted in specialisation, particularly 
in hospital practice where pharmacist roles are aligned to specific medical 
specialities. Within UK pharmacy, there is momentum and will to further develop 
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and formally acknowledge higher levels of clinical pharmacy specialism. 
Accreditation programmes and professional curriculums have been created for 
a number of the clinical pharmacy specialisms. 
Neuroscience is an emerging and relatively small clinical pharmacy specialism. 
Within current national guidance on managing neurological disease the role of a 
specialist clinical pharmacist is not well defined. Furthermore, within the 
specialty there have been no attempts by practitioners to collectively define the 
role and there is currently no formal support to develop as a clinical pharmacist 
in neuroscience. These observations form the basis on which to pursue further 
empirical investigation for pharmacy practice within neuroscience and 
undertake a more comprehensive literature review around this area. The next 
chapter describes the approach taken to reviewing the literature and an analysis 
of the findings.  
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2 Literature review 
 
2.1 Introduction 
Literature reviewing can be and was throughout this study, an iterative and 
ongoing process of the research (Wisker, 2001). The literature review for this 
study can be considered to have four strategies. 
1. A documentary analysis of relevant UK clinical guidelines, general health 
and pharmacy practice policies, and documents, in relation to 
neurological disease to identify a role for pharmacists. 
2. A review of the literature and empirical evidence of pharmacist 
involvement and pharmaceutical care in neurological diseases and 
neuroscience services. 
3. A review of literature in relation into the concept of the role, and a wider 
review of the healthcare literature, examining nursing roles. 
4. A literature review around the emerging concepts from the analysis of the 
empirical data generated in this study, adding to the discussion chapter 
(p.212). 
This chapter explains and summarises the second and third literature searches 
in the above list, two distinct searches with differing approaches and methods. 
Both searches have been included to illustrate that I did not enter the research 
project with a preconceived intention to undertake qualitative research. I intend 
this chapter to illuminate the transition to qualitative research from my 
professional background as a pharmacist with a predominant exposure to 
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quantitative research. The chapter concludes with the research questions of the 
study. 
The rest of section 2.1 identifies the need for a literature review and its place in 
grounded theory research. Section 2.2 examines the empirical evidence for 
pharmacist involvement in neurological disease. Section 2.3 examines the 
literature around roles and a wider examination of healthcare roles. Section 2.4 
reflects on the literature findings in helping understand specialist clinical 
pharmacy practice in neuroscience, leading to the setting of research questions 
for the study in section 2.5.  
2.1.1 The purpose of a literature review   
 
The practice of research is concerned with adding knowledge and 
understanding to an area. A literature review helps to understand the existing 
knowledge and where the proposed research fits within and adds to that 
knowledge base (Wisker, 2001).  
Punch (2005) advocates that a literature review can add to the planning of a 
research project in its early stages; my reflections and critical appraisal of the 
evidence helped to inform my decision to undertake qualitative research which 
is further explicated in section 3.2 (p.46). There is extensive overlap of the 
considerations between reviewing the literature, and the methodology; as a 
consequence, within this chapter frequent cross-reference is made to sections 
of the methodology chapter. 
A documentary analysis was undertaken and incorporated into chapter 1, 
helping to form justification of the investigation into the role of the neuroscience 
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pharmacist. Further documentary analysis took place in conjunction with the 
fourth literature review around the emerging concepts of the study and 
integrated into chapters 5, 6, and 7. From the initial inception of the grounded 
theory method, literature and relevant documents were regarded as sources 
that help to construct the resultant theory (Glaser and Strauss, 1967). The use 
of literature as a data source is still advocated (Birks and Mills, 2011 , Charmaz, 
2006 , Holloway and Brown, 2012). 
2.1.2 Literature reviews in grounded theory studies 
 
The role and positioning of a literature review in qualitative research and in 
particular within grounded theory research, is contested (Birks and Mills, 2011 , 
Holloway and Brown, 2012 , McGhee et al., 2007). The characteristics of 
grounded theory research, as well as being inductive, are that it is often iterative 
and non-linear. Therefore the positioning of a literature review chapter at this 
position in the thesis is a pragmatic compromise; it seems most appropriate 
because of the contribution that the literature review has in informing the 
methodological approach to the study.  
Grounded theory method was developed to generate theory about phenomena 
through the collection and analysis of data without preconceived theoretical 
notions. Grounded theory method contrasts to deductive methods of research 
which, seek to verify theory by experimental testing of hypotheses generated 
from a priori assumptions (Glaser and Strauss, 1967).   
Section 3.2.4.1 (p.56) describes the divergence in grounded theory method; this 
divergence is mirrored in the methods literature by varying opinions on the 
timing of a literature review and illuminated by Bryant and Charmaz (2007). 
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Concerns exist that early engagement with literature may influence what 
researchers see coming from the analysis of their data (Hallberg, 2010), running 
contrary to the inductive nature of grounded theory research, which should 
allow theoretical conceptualisation to arise, unforced from the data. There is 
however recognition that even in grounded theory studies  researchers are 
often not new to the area of research, bringing a personal and professional 
history which is partly shaped from previous engagement in literature which will 
in turn influence interpretation of data (Birks and Mills, 2011 , Charmaz, 2006 , 
Hallberg, 2010 , McGhee et al., 2007).  
I discuss the influence of both the literature and my background on my 
theoretical sensitivity to the research further in section 3.3.2.3 (p.70). 
Reflexivity, acknowledging your position within the research, links to theoretical 
sensitivity. McGhee et al. (2007) present a dialectic discussion of the place of 
literature searching in grounded theory studies, concluding that reflexivity is 
important in acknowledging prior interaction with related literature, which they 
perceive to be common in professional practice research and is applicable to 
this research situation. By being reflexive and acknowledging the role of the 
literature and personal experience it allows the researcher to consider and 
question how this affects their research as they proceed with it. This is an 
approach that I attempted to incorporate into this project.    
2.1.3 Practical considerations for undertaking a literature review 
 
For the purposes of this project there were also some practical considerations 
affecting the decision to undertake a literature search before entering into the 
research phase of the study. A research proposal was an academic 
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requirement of the degree programme, and provides justification of a need for 
the research to me, my academic supervisors, my employing NHS Trust funding 
my education, and to the various ethical and research bodies I was required to 
obtain permission from in order to conduct the research (3.4.2, p.73).  
Part of the justification of this research is built on the premise that it addresses a 
gap in the literature. The requirement to undertake a literature search in 
grounded theory studies prior to the research in order to satisfy institutional and 
ethical requirements is an acknowledged consideration (Birks and Mills, 2011 , 
Holloway and Brown, 2012).  
I was also advised by my supervisors to review the literature as an exercise in 
academic and scholarly development. Reviewing literature in pharmacy practice 
research and more widely in nursing and general healthcare research was a 
very valuable undertaking for the development and expansion of my own 
general knowledge of health services policy, practice and research. This 
exercise enabled me to contextualise my research. A literature review and 
analysis illuminated new ways to think about research, examine the empirical 
world, and the application of research methods. Undertaking critical analysis of 
literature helped me to develop my understanding of applied research 
methodology.   
 
2.2 Pharmaceutical care in neurological diseases and services 
A review of the current relevant UK clinical guidance and policy around 
neurological disease did not identify a defined role for a specialist clinical 
pharmacist. A strategy towards understanding this position was to identify and 
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appraise the literature and evidence for pharmacist involvement in neurological 
services, and the direct care of people with neurological disease which from 
here-on-in is referred as pharmaceutical care, embracing the concept of clinical 
pharmacy (see section 1.4.4, p.12).  
2.2.1 Search strategy 
 
A search was undertaken to identify literature examining the involvement of 
pharmacists in the care of adult patients with neurological disease, and in adult 
neurological services. Although I endeavoured to undertake a literature review 
with the principles of a systematic review, I did not undertake a systematic 
review in the sense of producing a meta-analysis from which to synthesise a 
more robust collaborative body of evidence supporting the effectiveness for 
pharmaceutical care in neurological disease (Ashcroft, 2011). Rather, I 
undertook a comprehensive and a reproducible literature search that identified 
as much relevant literature documenting pharmaceutical care in neurological 
disease and assessing the methodological approaches.   
Using the guidance of Aveyard (2010) I iteratively developed a search strategy, 
initially using intuitive keyword search terms and developing that list further. I 
also reviewed the reference sections of the retrieved citations to identify further 
potentially appropriate literature. Appendix 1 summarises the search strategies.  
I searched the traditional medical databases of Medline and EMBASE, and also 
CINAHL and AMED because of their coverage of allied health professional 
journals and potential to yield further relevant citations. I manually searched 
International Journal of Clinical Pharmacy and International Journal of 
Pharmacy Practice through their own search engines. As a result of the 
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database searches a number of relevant citations were identified within these 
publications. I was also able to add further citations I had collected in the course 
of my own professional practice. 
I reviewed citations by title and abstract for appropriateness of inclusion. The 
criteria for inclusion were papers in the English language specifically examining 
pharmacists’ involvement with neurological diseases or involvement in 
neurological services in adult populations in the UK. I also retrieved publications 
originating from mainland Europe, Australasia and North America where there 
are developed healthcare systems comparable to the UK. I had undertaken 
previous, less rigorous, literature searches in this practice area and perceived a 
paucity of literature to exist. Hence I did not place any restrictions around the 
study or publication type e.g. only randomised controlled trials in peer reviewed 
journals.  
Pharmacy practice and healthcare services continually evolve expanding the 
literature base around it (Ashcroft, 2011). To ensure that the literature review 
was contemporary and relevant I restricted retrieval of publications to those 
since the year 2000 and repeated the search at regular intervals through the 
research.  
I did not include literature that pertained to pharmacist involvement in stroke 
services. Although stroke is considered as a neurological condition, it is not 
exclusively treated by neurologists in the UK. The emergence of effective acute 
treatments for stroke and the national stroke strategy for the NHS has 
revolutionised stroke treatment with the development of stroke pathways. 
Stroke medicine is emerging as a clinical pharmacy speciality in its own right; a 
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speciality stroke group exists within the UKCPA. Stroke is not a condition 
included within the NSF for long-term conditions, being covered by the NSF for 
older people (Department of Health, 2005).  
2.2.2 Literature review results 
 
The results of the literature search are summarised and tabulated in Appendix 
2. Studies are ordered by disease area and subsequently by the year of 
publication. A varying body of literature was identified with a predominance of 
studies from the United States, studies set in primary care or community 
pharmacy, and studies involving pharmacist interventions in specific disease 
states, notably headache and epilepsy syndromes. Headache and epilepsy 
syndromes are two of the most prevalent neurological disorders in the UK 
(Neurological Alliance, 2003). The observation I made of UK practice, that 
neuroscience is a relatively small clinical pharmacy specialism, has also been 
made in the United States (Welty, 2006). The search results confirmed my 
perceived paucity of literature around specialist UK hospital-based clinical 
pharmacy practice in neuroscience: two relevant citations were identified 
(Bourne and Dorward, 2011 , Harris, 2012).  
Rather than critiquing each individual publication I will summarise the 
methodological issues I have identified within the literature findings. These run 
under three themes which are summarised in the following subsections. 
 Methodological issues for bias and controlling for confounding variables, 
i.e. the effect of other healthcare professionals (2.2.2.1). 
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 The use of validated outcomes to measure the effects of pharmacists 
(2.2.2.2). 
 Translating the findings to NHS hospital practice (2.2.2.3). 
2.2.2.1 Methodological assessment of the studies 
 
Using the criteria for experimental research cited as manipulation, control and 
randomization (Lawson, 2011 p.73), two primary care studies evaluating the 
impact of pharmaceutical care in patients with migraine (Stepkova et al., 2011) 
and/or headache (Hoffmann et al., 2008) fulfil this criteria. The rest of the 
identified literature can be described as non-experimental or self-proclaimed 
quasi-experimental (Skomo et al., 2008) studies providing descriptive 
observational accounts of pharmacy services or interventions.  
The non-experimental research ranges from a statistical quantification of clinical 
interventions made by pharmacists (Bourne and Dorward, 2011 , Jefferies and 
Bromberg, 2012 , Swain, 2012) to more narrative accounts of a specialist 
pharmacist role in UK primary care (Barnes, 2011 , Barnes, 2012). These 
studies could be described as service evaluations as they frequently evaluate, 
using varying measures, new or enhanced clinical pharmacy services.  
Within a positivist viewpoint of scientific inquiry, undertaking quantitative 
methods, the tenets of any credible investigation are that the findings stand up 
to scrutiny of reliability and validity (Creswell, 2003 , Elliott and Lazenbett, 2004 
, Smith, 2010) in that the findings arise from meticulous and consistent data 
collection and measurement, and they accurately depict the phenomenon of 
interest under study (Smith, 2010).  
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The everyday human world of professional practice does not always lend itself 
to the tightly controlled experiments of science. Aparasu (2011 p.9) notes 
pharmacy practice research, as a form of applied research, involves 
“…implementation of research methodologies in realistic settings. The extent of 
control in applied research is not the same as in the natural sciences”. There 
are a number of pragmatic compromises that sometimes need to be made and 
acknowledged with practice research. These compromises are evident amongst 
this body of literature. 
No study summarised the overall effect of pharmacists’ services or interventions 
to be neutral or negative. The generally positive findings of the identified studies 
raise a question of whether a publication bias exists amongst this body of 
literature. Publication bias is a well-recognised and discussed phenomenon 
generally in clinical research e.g. Goldacre (2012).  
Pharmacy services need to be funded for, amongst other factors, appropriate 
professional remuneration. Pharmacy practice research can generate an 
evidence base for pharmacy services to support their successful commissioning 
(Roberts and Kennington, 2010); there can be an inherent agenda behind 
research. Bond and Raehl (2006 p. 1370) also cite the potential for “intervener’s 
bias” in pharmacist studies, where observed interventions promote greater 
diligence in practice from those being observed, posing a threat to the validity of 
the findings (Smith, 2010). 
Studies producing neutral or negative results would be equally as informative, 
particularly to understand the reasons why a new service or intervention was 
not successful. This knowledge could assist the progression of services and 
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interventions by modification. Within the literature, the descriptions of how 
interventions were made or how services were implemented and provided were 
often limited, accepting probable editorial constraints on word counts and that a 
number of the identified citations were conference abstracts.  
There are some examples of clearly described interventions; for example, 
Brown (2012) included a defined patient checklist as the basis for her primary 
care consultations with epilepsy patients. This checklist is well aligned to the 
epilepsy care plan domain of the NICE quality standard for the epilepsies in 
adults (National Institute for Health and Care Excellence, 2013). 
Non-experimental research that makes measures prior to and after an 
intervention generally has weaker internal validity and limits confidence to make 
inferential cause and effect assumptions from the study results (Johnson, 
2011). Weant et al. (2009) assessed the effect of implementing a dedicated 
clinical pharmacy service to a neurosurgical intensive care unit (ICU) by 
comparing financial and clinical outcomes in the two-year periods prior to and 
after service implementation. A significant number of pharmacist interventions 
into patient care were recorded (11,250) and statistically significant reductions 
in average drug costs and length of stay per patient were observed after the 
implementation of the pharmacist. A direct cause and effect inference, that the 
interventions made by the pharmacist led to the observed reduction in drug 
costs and length of patient stay, cannot be concluded beyond doubt from these 
data although the multidisciplinary authors note there were no other significant 
changes in service provision, protocols or pathways during the study period. 
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Similar pre and post analyses of pharmacist interventions were undertaken in 
the therapeutic areas of epilepsy (Fogg et al., 2012) and headache (Hoffmann 
et al., 2008). Fogg et al. (2012) undertook measurements of patient self-
reported medication adherence, quality of life and satisfaction with medicines 
information provided before and two months after an interview and medication 
review with a primary care practice pharmacist. Statistically significant 
improvements in self-reported medication adherence and psychological 
wellbeing were noted after the pharmacist intervention. The validity of this study 
is challenged because it did not include a control for the study subjects’ 
interactions with other health care professionals such as neurologists, general 
practitioners, or epilepsy nurse specialists during the study period. A further 
limitation is the assessment of a singular intervention in what is routinely a long-
term or life-long condition. 
In another UK primary care study of pharmacist involvement in epilepsy, Brown 
(2012) noted, although did not quantify, reduced emergency hospital 
admissions and hospital appointments after the involvement of a primary care 
pharmacist. As well as the issues towards validity, as discussed with the 
previous study, by not controlling for the interventions of other healthcare 
professionals, without characterising the nature of epilepsy in each patient there 
is a risk of prevalence bias. Prevalence bias does not control for the point in a 
disease where an intervention is made within a study (Johnson, 2011). For 
example the pharmacist may become involved in a patient’s care after an initial 
diagnosis of epilepsy and instigation of anti-epileptic drug therapy, which initially 
in monotherapy is effective at controlling further seizures in up to 50% of adult 
patients (Perucca and Tomson, 2011) i.e. the effect on hospital admissions 
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could have been observed regardless of the pharmacist intervention.  Therefore 
the observation of reduced hospital admissions and appointments after 
involvement of the pharmacist is an interesting one, but not one from which a 
cause and effect inference that the intervention of the pharmacist reduced 
hospital admissions, can be confidently concluded. 
Introducing a control, or comparison group where no intervention occurs can 
improve confidence in the inferential interpretation of a pre and post-intervention 
analysis (Johnson, 2011) but it is not always feasible in everyday practice. 
Pharmacy services need to be developed around what works best to deliver the 
service, above considerations of the methodological rigour of its evaluation.  
Bond and Raehl (2006) were able to include a control group in their 
retrospective multi-centre analysis of pharmacist inpatient management of anti-
epileptic drugs, under a scheme of collaborative drug therapy management in 
US Medicare hospitals.  Collaborative drug therapy management is a US 
scheme that allows pharmacists to have an agreed level of autonomy to control 
drug therapy; it is defined by Hammond et al. (2003 p. 1210) as: 
…a collaborative practice agreement between one or more physicians 
and pharmacists wherein qualified pharmacists working within the 
context of a defined protocol are permitted to assume professional 
responsibility performing patient assessments; ordering drug-therapy 
related laboratory tests; administering drugs and selecting, initiating, 
monitoring, continuing and adjusting dose regimes. 
   
Routinely collected clinical outcome and financial data were collected and 
compared for patients admitted with a diagnosis of epilepsy or seizure disorder 
between hospitals that ran collaborative drug therapy management, and 
hospitals that did not. Statistically significant differences in mortality rates, 
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length of patient stay, healthcare costs and rates of aspiration pneumonia were 
observed in favour of the hospitals which ran a collaborative drug therapy 
management service for anti-epileptic drugs. The general severity of patient 
illness as measured by a case mix index was comparable between the two sets 
of hospitals. No other comparisons of overall hospital performance were made 
and the omission to identify and mitigate for confounders of the measured 
outcomes limits the internal validity of these findings in making confident 
assumptions that the observed differences were due to collaborative drug 
therapy management, and not other factors within the running of the hospitals.    
2.2.2.2 Outcome measures for pharmaceutical care interventions 
 
Several studies provided descriptive analyses of the number and type of the 
clinical interventions made by pharmacists (Bourne and Dorward, 2011 , Brown, 
2012 , Jefferies and Bromberg, 2012 , Poon et al., 2012 , Schröder et al., 2011 , 
Swain, 2012 , Weant et al., 2009 , Weitzel et al., 2004). Most of these studies 
quantify and categorise the interventions being made. The studies generally 
conclude with claims of pharmacists contributing to the safety, quality and 
productivity of patient care. These studies may help to inform where 
pharmaceutical care is best placed or should be prioritized.  
Observational studies of pharmacists’ interventions serve as a proxy measure 
of what pharmacists do in the direct patient care aspect of their role and the 
sorts of interventions that are made. Studies of this nature do not allow 
assignment of a valuation, or quantification of the impact of the interventions 
made by pharmacists although this is an acknowledged challenge in clinical 
pharmacy services (Pawloski et al., 2012). This leads to a question of what is 
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the construct that a measure of pharmacist interventions represents. This 
depends on how one chooses to measure the intervention and the context in 
which to measure it. In the context of the studies identified I would take the 
construct to be patient care and one surmises that the interventions improve 
patient care although in most studies patients were not assessed for the effect 
of the intervention. Therefore the validity of pharmacist interventions to measure 
the construct of patient care (construct validity) is weak in this context. 
Bourne and Dorward (2011)4 attempted to assess the clinical significance of 
interventions made in a two week service evaluation on a neurosurgical ICU by 
a validated method of the mean score of potential harm avoidance made from a 
panel of 5 healthcare professionals independently assessing the interventions. 
Using a visual analogue assessment scale of 0 (no harm) to 10 (death), the 
mean score of 246 interventions was 3.7. Similar studies have been undertaken 
in other clinical pharmacy specialisms such as oncology; the study of Knez et 
al. (2008) concluded more significant interventions were made by pharmacists 
of higher grades in cancer services. 
The generalisability of observational studies measuring pharmacist 
interventions is limited by claims that could be made of the variation in relative 
clinical competence and experience of the pharmacists in the study and the 
practice setting. For example one may hypothesize that pharmacists need to 
make fewer interventions in clinical departments or hospitals having more 
thorough working practices and protocols in relation to drug use. A strategy to 
make observational studies of this kind more generalisable is to conduct studies 
                                                             
4
 The manuscript for this paper is within Appendix 9 as an example of previous practice research I have 
undertaken.  
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within multiple hospitals or Trusts, with multiple pharmacists. The Protected ICU 
study is a multi-centre UK observational study (yet to be published) of clinical 
pharmacy activity in intensive care units using similar methodology to Bourne 
and Dorward (2011) to assess the clinical significance of interventions and 
capturing a national snapshot of clinical pharmacy activity in intensive care units 
(Bourne, 2014, Pers. Comm., 30th Sept).  
A number of studies used questionnaires or surveys to assess patients’ 
perceptions of pharmacist’s interventions. Surveys can be useful in assessing 
thoughts and perceptions of pharmacy services (Worley, 2011). Patient 
questionnaires were used in studies of pharmacist interventions in epilepsy 
(Brown, 2012 , Fogg et al., 2012) and headache (Harris, 2012 , Skomo et al., 
2008 , Stepkova et al., 2011 , Wenzel and Schommer, 2002).  Where 
described, the surveys used appear largely closed question, using rating scales 
for response allowing a measure of the responses but no opportunity to further 
explore patients’ perceptions of the intervention or service.  
Quality of life measures were used to assess the effect of pharmaceutical care 
in populations with epilepsy (Fogg et al., 2012), headache (Hoffmann et al., 
2008 , Stepkova et al., 2011), and Parkinson’s disease (Schröder et al., 2011). 
These are all long term neurological conditions. Moving away from a biomedical 
understanding of these conditions, which measures outcomes such as the 
frequency of seizures or headache, assessing quality of life facilitates an 
assessment of how pharmacists support people to live with a long-term 
neurological condition (Fitzpatrick, 1997). Of the four studies that used quality of 
life measures only one reported a statistically significant improvement post 
pharmacist intervention (Hoffmann et al., 2008). 
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2.2.2.3 Transferring the current evidence to specialist practice 
 
Pharmacy practice research, as a form of applied health research, is concerned 
with understanding and improving the provision of pharmaceutical services. 
External validity is an important consideration in healthcare research and may 
be termed generalisation in the sense that the findings could be applicable 
when applied to other people, in other places and at other times (Aparasu, 
2011). In many respects practice research is concerned with the sharing of 
good practice and desirably, successful interventions would produce 
comparable beneficial results if replicated in other healthcare or pharmacy 
settings. Given the findings from pharmacist intervention study in oncology 
(Knez et al., 2008), one might hypothesize that interventions made by specialist 
neuroscience pharmacists would be more significant and of higher patient 
benefit than those identified from non-specialist clinical pharmacy practice. 
There are limitations however in translating the findings from the identified 
literature, especially primary care studies, into clinical pharmacy practice in 
hospital-based neuroscience centres. These concerns arise not only from the 
identified methodological issues of bias, internal validity, and reliability, but also 
from a consideration that the experimental conditions of primary care studies 
are not translatable into a specialist hospital setting. Translating that viewpoint 
in terms of pharmacy practice I take the view that the practice conditions of a 
hospital based specialist pharmacist are different when encountering patients 
with neurological disease.    
My a priori assumption of the neuroscience pharmacist role, based on my 
previous interaction and discussion with peers, is that if the pharmacists do 
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participate in outpatient clinic settings it is a minor component of their role. The 
majority of pharmacists’ clinical, near-patient role occurs on inpatient wards. 
People with neurological disease invariably do not need to be admitted to 
hospital. UK healthcare policy generally is increasingly focused on optimising 
healthcare provision in the community and reducing hospital admissions 
(Edwards, 2014). Hospital admissions incur an associated expensive, cause 
disruption to patients and their families, and carry risks to the patient such as 
hospital acquired infection (National Institute for Health and Care Excellence, 
2014).  
Based on my experience of clinical neuroscience, admission to hospital for 
patients with a neurological disease inevitably represents:  
 Exacerbation of a condition e.g. a relapse of MS, seizures in epilepsy, 
acute deterioration of myasthenia gravis.  
 Acute monophasic illness e.g. Guillain-Barre Syndrome, viral 
encephalitis. 
 Progression of neurodegenerative disorders e.g. Parkinson’s disease, 
motor neurone disease. 
 A requirement for specialist treatment or surgery that can only be 
administered or performed within a hospital.  
So in contrast to many of the identified studies in primary care and community 
pharmacy, hospital based pharmacists practicing in inpatient hospital settings 
are not dealing with long term neurological conditions in relative stability, they 
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deal with those patients at times of disease exacerbation, or whose condition 
lies more towards the challenging end of a particular disease-spectrum. 
Due to the acuity and nature of their illness, a person with a neurological 
condition admitted to hospital may need to be cared for by a multidisciplinary 
team. This team could include doctors, ward-based and specialist nurses, 
healthcare assistants, physiotherapists, occupational therapists, pharmacists, 
speech and language therapists. All these professional groups can apply their 
expertise to affect a particular aspect of a patient’s condition and influence both 
the outcome, and the patient’s experience of that care. Multidisciplinary care is 
important for many patients with long term conditions (Department of Health, 
2005); in an inpatient hospital setting a patient is likely to experience a more 
concentrated overlapping of interaction with differing healthcare professionals. 
In such a scenario eliciting the effect of pharmacists’ contribution to the care of 
neurological inpatients, while controlling for confounders such as the 
contribution of other members of the multidisciplinary team, is an inherently 
complex undertaking. 
Given the emphasis on multidisciplinary treatment of long term neurological 
disease, none of the literature has focused on how pharmacists work within a 
multidisciplinary team with complex neurological patients. Brown (2012) 
described establishing good working relationships with neurologists and 
epilepsy specialist nurses in the primary care management of epilepsy. Barnes 
(2011) describes her UK primary care role as a member of a multidisciplinary 
team and meeting and overcoming initial resistance from consultant 
neurologists (Barnes, 2012). Observational studies provide evidence that 
pharmacists make interventions into patient care but do not offer an insight as 
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to how those interventions are presented, received, negotiated and actioned 
within a multidisciplinary setting. 
The identified literature has concentrated on analysing pharmacists’ clinical 
interventions. Table 1 (p.11) illustrates the different aspects of UK hospital 
pharmacy services of which clinical pharmacy is one facet. A priori I take the 
view that neurosciences pharmacists are involved directly or indirectly with 
several to many of these facets. Thus to concentrate on studying patient 
interventions does not progress an understanding of the pharmacist role in its 
entirety and how pharmacists reconcile the facets of the role to shape it. 
  
2.3 Literature examining roles in pharmacy and healthcare 
The results of the literature review in the previous section led me to reflect on 
what the true nature of my research question was. Evaluating interventions or 
the outcomes of interventions pharmacists make provides evidence for the 
pharmacists’ role (see section 3.2.1 (p.46) for a further discussion of evidence). 
Evidence provides the ‘what’ of the role, but it does not explain the ‘how’ or the 
‘why’. Focusing on clinical interventions has the potential to produce a unilateral 
‘outcomes’ analysis of the pharmacist role and does not answer the question of 
how a role for a specialist neurosciences pharmacist is defined. 
2.3.1 Search strategy 
 
After discussion with my supervisors I further explored the concept of the role 
more generally within the literature and how this might be defined. I undertook a 
literature review around role theory. I looked for literature concerning roles in 
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pharmacy and more widely, in the literature of nursing practice. I undertook a 
less structured and defined literature search to orientate me to this research 
area rather than to define a theoretical framework for exploring the concept of 
the role within the context of clinical pharmacy specialism in neurosciences. I 
also undertook a literature review to ensure I would not be duplicating existing 
research of clinical pharmacy practice in neuroscience.   
2.3.2 Role theory 
 
My initial attempts at identifying relevant citations around the concept role 
theory yielded limited success in terms of citation quantity and recent 
publications. I began with a definition of role theory provided by Biddle (1986 
p.67) as: 
It [role theory] explains roles by presuming that persons are members of 
social positions and hold expectations for their own behaviours and the 
behaviours of others. 
 
My literature searching for role theory and pharmacy identified very few citations 
and none in relation to pharmacy practice in neuroscience. Guirguis and 
Chewning (2005), citing Biddle (1986),  have provided an overview of role 
theory in its application to research of community pharmacist-patient interaction. 
They argued the potential for role theory in pharmacy research and a paucity of 
literature in this field. 
Biddle identified the prominence of expectations, formed through experience, in 
theories about roles. To me, role theory legitimises the investigation of the 
social or organisational construction of the pharmacist’s role, rather than 
empirical quantification of role outputs.  
42 
 
2.3.3 Professional role research in nursing 
 
I reviewed literature that examined advanced specialist and consultant nursing 
practice. I chose to examine this literature base because, like neuroscience 
pharmacists, specialist and consultant nursing roles are evolving ones practiced 
predominantly, although not exclusively, within hospitals. 
I observed a greater prominence of qualitative and mixed methods research 
amongst the literature examining nursing roles. A variety of findings were 
discovered. A recurrent finding throughout the literature was the prominence 
placed in defining these advanced nursing roles within an organisational context 
(Abbott, 2007 , McSherry et al., 2007 , Mullen et al., 2011 , Woodward et al., 
2006). 
 
2.4 Chapter summary 
 A varying body of literature was identified pertaining to pharmaceutical care in 
neurological disease which in the main studied the interventions of pharmacists 
within individual neurological disease states. The studies illustrate pharmacists 
can and do become involved in providing pharmaceutical care to patients with 
neurological disease. There are some methodological concerns about drawing 
inferential conclusions from the studies, notably controlling for confounders. 
While acknowledging myself as a pharmacist I would make some assumptions 
that the pharmaceutical care interventions were in the main beneficial to 
patients.  
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The literature search identified a lack of evidence for the involvement of 
specialist pharmacists in neuroscience. The identified studies could support the 
hypothesis that specialist pharmacists improve patient care but the complexity 
of multidisciplinary management of neurological illness in a specialist setting 
and the diversity of neurological illness present challenges to developing 
reliable and valid measurement techniques for testing of this hypothesis. 
A literature review examining the concept of the role suggests that lack of role 
clarity can be a barrier to effective clinical practice and developing theories of 
roles can better understand practice. The existing empirical literature for 
pharmaceutical care in neurological disease focuses primarily on the 
quantitative analysis of clinical interventions. No identified research has 
examined this specialist pharmacist role within a multidisciplinary context in the 
hospital setting of a neuroscience service through a sociologically informed 
analysis. The conundrum of defining and understanding the role for a specialist 
neurosciences pharmacist has potential to lend itself to a metaphysical 
interpretative analysis. 
 
2.5 Research questions for the study 
The setting of aims and objectives is not concordant with traditional approaches 
to qualitative research as it may serve to focus the research too narrowly, at the 
expense of collecting useful data (Creswell, 1994). Setting research questions 
is the more typical approach undertaken within qualitative research (Holloway 
and Brown, 2012); Miles and Huberman (1994 p.25) advocate that for even the 
most inductive research it is advisable to devise some research questions to 
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answer to “…make the implicit explicit without necessarily freezing or limiting 
your vision.” This viewpoint is still contentious in grounded theory research 
(Birks and Mills, 2011). 
While acknowledging these tensions I elected to set some research questions 
stemming from my initial reflections in section 1.1 (p.1), and refined by a 
literature search. I considered these questions to be sufficiently broad to allow 
flexibility in my data collection and analysis while at the same time not allowing 
me to lose sight of the fact that I was undertaking a piece of applied research to 
address the practice issues that had prompted the research. While 
understanding the inductive nature of grounded theory research I remained 
cognisant of the need for the research to retain relevance and resonance to the 
substantive research area of contemporary specialist clinical pharmacy practice 
in neurosciences. 
The research questions for the study are: 
1. How do neurosciences pharmacists perceive and define their role within 
a neurosciences service? 
2. How do pharmacists specialising in neurosciences develop their role and 
specialism?  
The rationale for the use of the grounded theory method to produce theoretical 
insights into these processes is presented in the next chapter, which outlines 
the methodology of the research. 
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3 Methodology 
 
3.1 Introduction 
This chapter will set out the methodological approach and methods used to 
answer the research questions of the study. In section 3.2 I will provide some 
context to the need to study the clinical pharmacist’s role (evidence based 
healthcare) and outline the formation of my philosophical underpinnings 
(ontology) to studying the pharmacist’s role, to illuminate the reasoning of my 
decision to undertake qualitative research.  
Section 3.2.3 provides a brief overview and critique of qualitative strategies of 
inquiry in relation to the research project, explaining my decision to use the 
grounded theory method. In section 3.2.4 I will outline the grounded theory 
method as a methodological approach, its various forms and the philosophical 
underpinnings of the method. I then set out my decision to use the constructivist 
grounded theory method, through the assumption of a subjective epistemology. 
Section 3.3 describes the methodological procedures and processes of data 
collection and analysis. Section 3.4 discusses the ethical considerations that 
were addressed to undertake the research. Section 3.5 provides a brief 
overview of the study participants before presenting the findings.  
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3.2 Choosing the methodological approach 
This section sets out the reasoning to undertake a qualitative research study 
using the constructivist grounded theory method 
3.2.1 Evidence based pharmacy practice 
 
The literature search I undertook in section 2.2 (p.25) examined the empirical 
evidence for the involvement of pharmacists in the care of patients with 
neurological disease and yielded relatively little appropriate research. In 
reflecting on my initial approach to the literature search strategy I concluded 
that my professional and educational background, shaped by a need for 
‘evidence’, informed my initial approach to the literature.  
My reflections have led me to further question, what is evidence? A lay, general 
definition of evidence is “the available body of facts or information indicating 
whether a belief or proposition is true or valid” (Oxford Dictionaries, 2013a). 
Such a definition aligns within a positivist paradigm, and as identified by 
Barbour (2000), can invoke a sense of objective measurement (empiricism) to 
validate or refute a held belief or proposition. 
The use of evidence within healthcare, now commonly termed ‘evidence based 
healthcare’, has emerged with increasing predominance since the 1970s 
(Aveyard, 2010).  Evidence based healthcare is built upon a doctrine of 
ensuring medical services and therapeutic interventions offered to people are 
effective, safe and increasingly, provide value for money. The Cochrane 
Collaboration (2013), an internationally recognized and respected body 
promoting and supporting evidence based healthcare, define it as, “… the 
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conscientious use of current best evidence in making decisions about the care 
of individual patients or the delivery of health services.”.  
Wiffen (2001) has highlighted the argument that evidence should support 
decision making in healthcare and not dictate it; the expertise of practitioners 
cannot be overlooked. However evidence based healthcare has been pivotal in 
informing UK healthcare policy since the early 1990s (Harrison and Checkland, 
2009).  
The use of evidence imbues the clinical and regulatory assessment of drug 
technologies. The randomised controlled trial is second only to the meta-
analysis in hierarchies of evidence in healthcare, a grading system of evidence 
quality, usually set against the criteria of evidence being the objective truth 
(Aveyard, 2010 p.62). Randomised controlled trials are largely a pre-requisite 
for the licencing of new health technologies by the regulatory agencies of 
Europe and North America. 
The randomised controlled clinical trial is underpinned by hypothetical deductive 
scientific reasoning, a concept defined by Karl Popper (see Bilton et al. (2002) 
for further discussion within the meaning of science). Through hypothetical 
deductive reasoning, a drug or intervention is postulated to cause a clinical 
effect in patients with a specific medical condition (the hypothesis) through pre-
clinical scientific work or observation of clinical practice. A controlled trial is 
devised with empirical recording of clinical outcomes or 
physiological/radiological measurements which are an operationalization, or 
surrogate markers of the perceived clinical effect. Statistical analyses of 
predominantly numerical data then occur, which may need to account for 
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confounding variables, to deduce if the results have occurred by chance or not 
and if the null hypothesis, that the drug or intervention does not cause an effect, 
can be rejected.   
My background as a pharmacist and biomedical scientific training has equipped 
me to be relatively comfortable with assessing quantitative empirical research in 
the form of randomised trials. This positivist cause and effect inference from 
analysis of (quantitative) empirical measurement is evident in my initial literature 
search strategy which attempted to identify studies where a pharmacist 
intervention (cause) led to a beneficial effect in defined patient populations with 
a neurological disease. 
The requirement for the evidence of effectiveness also underpins UK hospital 
clinical pharmacy practice, dating back to the 1986 Nuffield report into clinical 
pharmacy (Child et al., 2004).  Child et al. (2004) have previously assessed the 
quality of evidence for hospital (clinical) pharmacy and found it to be lacking 
against the tenets of quantitative research, of internal and external validity i.e. 
the results accurate reflect what happened in the study and can be applied to 
other settings. Yet despite these criticisms the accumulation of evidence which 
proves the value of clinical pharmacy has been pivotal in improving recognition 
of the contribution of clinical pharmacy within healthcare e.g. Child et al. (2004). 
If I turn the concept of evidence on to pharmacy practice within neuroscience: 
within a positivist paradigm, I might theorise that the involvement of a 
pharmacist within a neuroscience centre improves the quality of patient care. 
Taking the concept of quality healthcare I would then seek to operationalize that 
concept in to measurable outcomes which may be, for example, a particular 
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medical outcome, a patient experience measured by some form of 
questionnaire, or a reduced length of stay as other investigators have (cf. 
2.2.2.2, p.34). Assuming that a sensitive and validated outcome measure is 
identified or developed, I would then need to account for the input of other 
healthcare professionals i.e. confounding variables which, depending on the 
number and location of study sites, could be variable.  
In summary, as I have previously identified, undertaking an experimental or 
quasi-experimental analysis of the contribution of a pharmacist in a 
neuroscience centre, accounting for all the confounding variables, is an 
inherently complex undertaking. So a priori, I take the view that the overall role 
of the neurosciences pharmacist is too complex and multifaceted to 
operationalize into a list of measurable outcomes. Furthermore such an analysis 
would not capture the overall role of the pharmacist and, assuming that a 
discernible effect was noted, would not inform how the effect was achieved. 
Such a study would be of limited of limited benefit in supporting and developing 
practice.   
I shall once again acknowledge my reasons for studying the role of 
neuroscience pharmacists. I am a committee member of a professional body 
representing neuroscience pharmacists which has a broad aim of supporting 
and developing practice. A research project of this scale will consume not 
inconsiderable resources of my time, the time of potential participants and any 
material costs and educational costs to support the supervision of my research. 
Therefore rather than try to prove the value of neuroscience pharmacists’ roles I 
think it is a more appropriate use of resources to better understand current 
practice and how pharmacists develop within their roles. 
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A quantitative research study will enable ‘measurement’ of the effects or outputs 
of pharmacists but it will not enable a deeper understanding of their role and 
how it is performed within everyday practice. I therefore seek a mode of, or 
frame of reference for inquiry (paradigm) that can illuminate and understand 
(interpret) contemporary clinical pharmacy practice within the specialism of 
neuroscience, in an everyday naturalistic setting and with all the complexities of 
professional and social interactions that entails.   
My experiences and reflections as a practicing hospital pharmacist, of which the 
latter has been enhanced by the requirements of a professional doctorate, have 
informed the following viewpoint: good healthcare within an acute hospital 
setting for people with acute or long-term neurological conditions is a complex 
gestalt of the collaborative working of members of the multidisciplinary 
healthcare team, the patient, and the patients’ carers/family. In using the term 
good healthcare my intention is to encapsulate the concept of a positive human 
experience for the patient, their family and carers, as well as biomedical 
outcomes. 
Hence to undertake a study that specifically measures pharmacists’ unique 
contribution to the care of patients with neurological disease does not capture 
that contribution as part of a multidisciplinary team. In my opinion, such a 
focused analysis is not congruent with the prevailing ethos of co-ordinated care 
for treating patients with neurological diseases that can be chronic, fluctuant 
and progressive.  
My professional experiences, reflections, and engagement with research 
literature, particularly within nursing practice research, have led me to consider 
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a relativist ontological perspective towards studying the role of the neuroscience 
pharmacist. The pharmacist’s role is not something that can be simply 
measured; it is constructed, with multiple perceptions of it from the groups and 
individuals that interact with the role (cf. ‘multiple realities’, see Creswell (2013 
p. 21)). The construction of the pharmacist’s role takes place through the 
everyday activities of the pharmacists during their interactions with patients, 
healthcare professionals and other groups that take place within professional, 
organisational, and social contexts. Hence a more informative analysis of the 
pharmacist’s role in neuroscience might be produced by employing more 
sociologically informed, interpretative qualitative research methods.  
3.2.2 Choosing a qualitative research paradigm 
 
Quantitative and qualitative research approaches have been distinguished in 
the literature as differing ‘paradigms’ or sets of assumptions through which to 
see the empirical world e.g. Punch (2005). Holloway and Brown (2012) argue 
this distinction between quantitative and qualitative research can carry 
dichotomous connotations of research being purely one or the other; they prefer 
to consider research approaches lying on a continuum between quantitative and 
qualitative research in their purest forms. I am in agreement with this view and I 
will further explicate this viewpoint in my discussion of the grounded theory 
method (3.2.4). 
At this juncture of the research journey it seems appropriate to consider what 
the essence of qualitative research is, to evaluate if it is the most appropriate 
strategy of inquiry to answer the research questions for the study. Holloway and 
Brown (2012 p.15)  define qualitative research below. 
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Qualitative research will give you an insight into various perspectives on 
a phenomenon, on behaviours and feelings, and it allows a deep 
exploration of different experiences. Researchers study people in their 
natural surroundings and build up relationships so they can learn and 
see the world from the participants’ point of view, on the basis of a 
common humanity and sometimes a shared culture although they can 
never put themselves wholly in “other people’s shoes”. 
 
Through this definition I identify qualitative research as an approach that could 
enable the development of a rich descriptive reconstruction of everyday clinical 
pharmacy practice within neuroscience. Qualitative research studies of nursing 
practice have already illuminated this potential. 
Furthermore, qualitative research can help to develop an understanding of the 
meaning of everyday events and interactions and how they shape the 
pharmacist’s role in neuroscience. There is an acknowledgement that 
individuals’ (emic) perspective will never be truly re-created but qualitative 
research can enable a better understanding towards this.  
In her discussion of the place of qualitative research in forming an evidence 
base for clinical practice, Barbour (2000 p.157) further defines its value.  
Qualitative research is suited to the study of process - how outcomes are 
achieved, the mechanisms involved, how situations or changes unfold in 
the short- or long-term. It can document difficulties and obstacles 
encountered, how these are perceived and dealt with and can provide 
insights into why particular interventions and attempts at implementation 
are successful or unsuccessful.  
 
I infer Barbour’s advocacy of qualitative research towards examining clinical 
interventions in healthcare. However the potential for the discovery of 
processes and identification for facilitators and obstacles to process suggest to 
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me that qualitative research is a potentially useful strategy to study the process 
of pharmacists developing into their role. 
3.2.3 The strategy of inquiry 
 
Qualitative research generally entails the generation of a detailed or ‘thick’ 
description of everyday events to reconstruct them and develop an 
understanding of the phenomenon (Babbie, 2010). While I have stated that I 
wish to develop an emic understanding of pharmacists’ role, the research 
questions of the study and the context of the study drive the analysis to uncover 
the processes that are occurring throughout it. Applied qualitative research is 
intended to produce findings that can answer specific information needs (Ritchie 
and Spencer, 1994). The intention of this research is to understand the 
processes that clinical pharmacists practicing in neuroscience go through to 
develop and define their role, to develop appropriate professional support. 
The phenomenon of interest for this research project, the professional role and 
its development, is placed within a substantive context, clinical pharmacy 
practice in neuroscience. One may term this a ‘bounded system’, in order to 
form the basis of a case study research (Creswell, 2003). A nomothetic 
approach using multiple cases (pharmacists) could identify issues of 
commonality and variation within the practice. Creswell (2003) has highlighted 
differing opinions on the case study as either definition of what or who to study, 
or a methodological approach.  Case studies enable a rich description of 
phenomenon and this method has been used to study of other healthcare roles, 
for example, nurse consultants (Graham, 2007). I prefer at this point to consider 
a case study, of multiple pharmacists, as defining the focus of the study. I 
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believe the grounded theory method is the best methodological procedure for 
analysing the case studies and answering the research questions for the study. 
I will explain this decision in the next section. 
3.2.4 The grounded theory method 
 
The grounded theory method was developed by the sociologists Barney Glaser 
and Anselm Strauss and presented in their seminal text ‘The Discovery of 
Grounded Theory’ (1967), which from hereon, is referred to as Discovery.  
The grounded theory method is a methodological approach that develops a 
theory grounded in the empirical data i.e. it is an inductive research process that 
generates new or evolved explanations about phenomena rather than testing 
hypotheses (Lingard et al., 2008 , Mills et al., 2006). The grounded theory 
method is suitable for studying processes (Elliott and Lazenbett, 2004 , 
Holloway, 2012), and topics with little previous empirical research (Holloway, 
2012). Trying to understand the development of specialist pharmacy practice is 
a process analysis and the literature search had identified that very little is 
known about this specific area of pharmacy practice. The substantive focus for 
this study therefore appears to fulfil the criteria to make a suitable grounded 
theory method study.  
Grounded theory method is unique in qualitative research in that is produces an 
explanatory analysis rather than a descriptive one (Holloway and Brown, 2012). 
Theory provides the ‘why’ to the ‘what’ description analysis of phenomenon 
(Babbie, 2010) to facilitate a conceptual understanding of everyday phenomena 
that can otherwise be difficult to explain (Reeves et al., 2008). Rovers (2011 p. 
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1) in his discussion of social theory in pharmacy practice asserts “Theory 
provides a base upon which practice change can occur”.  This study is intended 
as a piece of applied qualitative research to answer some specific questions 
about everyday pharmacy practice in neuroscience and the grounded theory 
method is suited to answering those questions. 
It is important to be clear that the grounded theory method is the methodological 
approach which results in the generation of a grounded theory. For consistency 
I shall refer to the grounded theory method when discussing the methodological 
approach to the study and a grounded theory when discussing the analytical 
findings of the study. Two forms of grounded theory can be produced: formal 
theory which has more widespread relevance and fit across a number of 
substantive areas, and substantive theory which is workable in explaining 
phenomenon and has fit to a specific area of empirical investigation (Glaser and 
Strauss, 1967). The aim of this study is to produce a substantive theory of 
clinical pharmacy practice in neuroscience that answers the research questions 
to this study. 
One of the strengths of the grounded theory method in relation to the planned 
research is the tenet of ‘grounding’ the analysis within the data. I have already 
identified my axiological position in relation to the research in that I have a 
professional attachment to the substantive area and I am not merely 
undertaking neutral observation and analysis of the empirical data. Babbie 
(2010) identifies that ultimately, all social science is a human construct while 
Punch (2005) states that much applied social science research takes place 
within professional practice and researchers are closely connected to it.  
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I acknowledge that my professional and personal background cannot be 
completely bracketed from the research process. As a neophyte researcher, my 
concern is to undertake data collection and analysis completely fed by 
conscious or subconscious, a priori assumptions, about the role. I am drawn to 
grounded theory method because of its inbuilt methodological checks through 
the constant comparative method, abductive logic, and memo writing. These 
processes do not absolve these factors, but acknowledge them and build them 
into the research process (Holloway, 2012). These processes place emphasis 
on findings emerging from, and hence grounded within the data.   
Appendix 7 provides my defence of the rigour of this study through the 
responses to an evaluative quality framework for qualitative research, 
developed by Spencer et al. (2003). There has been scepticism over ‘checklists’ 
for assessing qualitative research (Barbour, 2001). However as an 
inexperienced researcher this evaluation seemed an appropriate undertaking.  
3.2.4.1 The different forms of grounded theory method 
 
Since its development in the 1960s, grounded theory method development has 
followed divergent paths with Glaser, and Strauss (latterly in collaboration with 
Juliet Corbin) developing their own particular stances on the method. Kathy 
Charmaz, a student of Glaser and Strauss subsequently proposed constructivist 
grounded theory (Charmaz, 2006). Within the extant methodology literature, 
these three forms of grounded theory predominate within the field under a 
common vernacular of Classic or Glaserian grounded theory method; 
Straussian grounded theory method and Charmaz’s constructivist grounded 
theory method. 
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Birks and Mills (2011) provide a more comprehensive historical account of the 
development and evolution of the grounded theory method. In current research 
practice, Bryant and Charmaz (2007) consider the grounded theory method as 
a family of approaches while Mills et al. (2006) have referred to the different 
versions of grounded theory method as points along a methodological spiral 
indicating overlap between the approaches. 
With divergent forms of grounded theory method available to choose from there 
are multiple views on what constitutes the essence of grounded theory as 
illustrated in the introduction to ‘The SAGE Handbook of Grounded Theory’ 
(Bryant and Charmaz, 2007). This choice of approaches further raises issues 
about whether grounded theory constitutes a set of prescriptive rules to be 
followed or a set of guidelines to be used flexibly according to the research 
situation. Birks and Mills (2011), Bryant and Charmaz (2007) and Charmaz 
(2006) advocate the latter methodological approach. Birks and Mills (2011) 
provide one of the most comprehensive itineraries for essential procedural 
methods within a grounded theory method study which is shown in Figure 2. 
Having undertaken extensive reading of the grounded theory methods literature, 
I have chosen this list as the basis for my methodological approach and 
describe how these processes were undertaken within the study in section 3.3. 
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Figure 2. Elements of the grounded theory method. 
 
3.2.4.2 The case for constructivist grounded theory method 
 
In deciding which version of the grounded theory method to undertake, one 
needs to consider what is meant by theory. One also needs to consider their 
ontological and epistemological perspective towards the study to ensure it is 
aligned to the methodological approach and methods, to ensure what Birks and 
Mills (2011 p.36) term “methodological congruence”.  
Discovery listed the ‘jobs’ of theory specifically within sociology, which included 
the need to “enable prediction and explanation of behaviour”, “to be useful in 
theoretical advance of sociology” and “be usable in practical applications” 
(Glaser and Strauss, 1967 p.3). Strauss and Corbin (1998) define theory as:  
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A set of well defined concepts related through statements of relationship, 
which together constitute an integrated framework that can be used to 
explain or predict phenomena. 
 
Glaser and Strauss (1967) were clear in Discovery that a grounded theory does 
not provide a perfect description of the substantive area but can account for 
much of the relevant behaviour, or actions. However the use of terms such as 
“statements of relationship” (Glaser and Strauss, 1967 p.30), and descriptions 
of explanatory or predictor power invoke a positivist sense towards research. 
Indeed grounded theory method has been described as occupying the middle 
ground between positivist and post-positivist approaches (Suddaby, 2006). One 
of the criticisms placed on Glaser and Strauss has been their lack of 
explicitness about their philosophical underpinnings (Birks and Mills, 2011), 
although Annells (1996) has attempted to define these. 
The grounded theory method was developed in the 1960s as a response to the 
prevailing sociological research practice at that time which was to Glaser and 
Strauss’ view, centred on empirical verification of grand theories via the use of 
quantitative methods (Suddaby, 2006). The grounded theory method is 
theoretically underpinned by Strauss’ background in symbolic interactionism 
(Annells, 1996 , Milliken and Schreiber, 2012) but combines with Glaser’s 
background of quantitative research, to incorporate rigorous data analysis 
(Charmaz, 2006). The theoretical premise of symbolic interactionism is that the 
self, society and reality are constructed through interaction to ascribe meanings 
and actions that are inter-dependent (Annells, 1996 , Bryant and Charmaz, 
2007 , Charmaz, 2006).   
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Glaser’s version of grounded theory has remained largely true to the original 
method within Discovery, with strong emphasis on theory emerging from the 
data, independent of the objective researcher by avoidance of initial literature 
searching and entering the research tabula rasa (with a blank mind i.e. without 
preconceived notions). 
Strauss’ iterations of grounded theory method have come to further 
acknowledge the role of the researcher as a research tool with modified coding 
strategies and more tolerance of earlier engagement with literature relevant to a 
study. 
Charmaz’s constructivist version of grounded theory method further builds on its 
symbolic interactionism foundations, placing grounded theory within the 
constructivist paradigm with emphasis on understanding rather than 
explanation. Charmaz also acknowledges the contribution of the researcher in 
the construction of a theory. I have already stated my assumptions and 
closeness to the substantive area. I believe in doing so, I align myself to 
Charmaz’s constructivist grounded theory.  
Within the alignment to Charmaz I acknowledge that the theory produced from 
the study will be a co-constructed interpretive analysis between me as the 
researcher and my professional peers as study participants. My epistemological 
stance towards the knowledge generated from this study is a subjective one. By 
adhering to the methodological processes of the grounded theory method, my 
intention is to produce a study that stands up robustly to the scrutiny of rigour; 
ultimately, the result of the study will provide one depiction of reality, out of 
many co-existent ones.  
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3.3 Methods 
The methods are divided below as data generation methods and data analysis 
methods. For ease of reading the two sections are presented sequentially. 
However grounded theory method is iterative and non-linear (Birks and Mills, 
2011) and the processes were interwoven and overlapped throughout the study. 
Concurrent data generation and analysis is a key feature of the grounded theory 
method (see Figure 2 on p.58). It should also be noted that the research design 
of a grounded theory method study is iterative and often needs to incorporate 
flexibility to address the changing focus of the research as developing concepts 
emerge from data analysis (Elliott and Lazenbett, 2004).  
3.3.1 Data generation methods 
 
I have used the term data generation rather than data collection to indicate a 
process which involves the researcher engaging with sources of data to 
produce materials for analysis rather than a process of passive acquisition 
(Birks and Mills, 2011 p. 74). In this study, data were generated from interview 
conversations with pharmacists and the data codes were then generated from 
my analysis and interpretations of the interview transcripts.  
Standard data collection methods for qualitative research include individual 
interviews, focus groups (group interviews), observation of participants within 
the substantive setting and documentary analysis (Holloway and Wheeler, 2010 
, Punch, 2005 , Silverman, 2010). The design of the research project must 
address what is the optimal method to extract or generate data, balancing what 
is theoretically desirable from a methodological perspective against what is 
practically achievable within the time and resources allocated to the project. 
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Recorded, unstructured telephone interviews were chosen as the main data 
collection method. The data were also supplemented by documentary analysis, 
relevant literature and the experience and beliefs that I, as the researcher, 
brought to the research project. I will discuss my involvement as a data source 
within section 3.3.2.3. 
The inclusion criterion for participation in telephone interviews was pharmacists 
practicing partly or fully within the clinical specialism of neurosciences. There is 
no formally held list of specialist neuroscience pharmacists in the NHS. I 
therefore undertook a manual search of NHS Trusts to identify clinical 
pharmacist posts within neuroscience services. I also used a ‘snowballing’ 
strategy by enquiring amongst neuroscience pharmacists that I was acquainted 
with to identify further posts and potential participants. 
Individual interviews provide a forum for interaction with participants to discuss 
and explore issues relevant to them within the context of the research. 
According to Bowling (2002 p.378), unstructured in-depth interviews: 
…aim to delve deep below the surface of superficial responses to obtain 
true meanings that individuals assign to events, and the complexities of 
their attitudes, behaviours and experiences. 
 
The flexibility of loosely or semi-structured interviews is particularly appropriate 
to grounded theory studies where further exploration of responses can attain 
rich data. I exploited this property to develop theoretical sampling by altering my 
research interview questions as the study proceeded; I discuss this strategy 
further in section 3.3.2.2 
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Co-ordinating focus groups, by inviting groups of pharmacists to one location to 
participate in a group discussion, would have been an efficient way to generate 
data for the study. Furthermore it is recognised that the dynamics of focus 
groups can enable topics to be generated and explored further by group 
discussion (Bowling, 2002). There are several reasons why I chose not to 
pursue focus groups. From a practical perspective, my knowledge of the study 
population and experience in previously trying to arrange meetings indicated 
that co-ordinating a mutually suitable venue and time for participants would be 
challenging.  
From a methodological perspective the rapid data generation that focus groups 
can achieve does not seem to fit with the grounded theory method and its 
iterative cycles of data generation and analysis driving theoretical sampling, as 
described in section 3.3.2.2. Methodological incongruence between the use of 
focus groups and the grounded theory method has been observed by Webb 
and Kevern (2001) while others, such as Birks and Mills (2011) have advocated 
a potential role for focus groups. The final deciding factor not to utilise focus 
groups was my limited experience as a researcher, with little experience of 
facilitating group events. I felt that data generation needed to be controlled by 
me to allow sufficient time for familiarisation and analysis, while heuristically 
developing interview skills. 
One of the practical considerations of the project was how to access 
participants for individual interviews. An initial search for clinical pharmacist 
posts in neuroscience revealed that there were relatively few practitioners and 
that the posts are often relatively geographically dispersed and isolated. 
Undertaking face to face interviews with the pharmacists would have involved 
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extensive travel around the UK. Figure 3 below summarises recruitment of 
pharmacists into the study. 
 
 
Figure 3. Summary of participant recruitment. 
 
Recorded telephone interviews were undertaken instead of face to face 
interviews. The decision to undertake telephone interviews was a pragmatic 
one, based on the logistical and financial challenges of travelling to meet 
pharmacists to undertake interviews. While there are a number of video 
conferencing packages freely available I did not consider them necessarily to be 
readily available (to the potential participants) and sufficiently reliable to record 
interviews. 
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There are limitations to interviews. The accounts provided by participants are 
frequently historical ones subjected to interpretative renderings through time 
and subsequent experiences (Creswell, 2003). The relationship between 
interviewer and interviewee, and the context and way in which questions are 
asked can all affect the conversation and the data collected (Charmaz, 2006 , 
Kvale, 2007). 
Telephone interviews presented challenges, not least the ability to make 
participants sufficiently at ease to disclose experiences and opinions of their 
professional role. Data collection in qualitative research involves a co-operation 
between the researcher and participant (Graneheim and Lundman, 2004). 
Morse (2007) asserts that establishment of trust from the participant early on in 
the interview is needed to gain relevant information from the interview. Without 
initial face to face contact the initial establishment of a rapport and trust can be 
a challenge. Furthermore telephone interviewing does not allow the researcher 
to detect non-verbal clues from the participants, such as facial expressions, 
body gestures (Birks and Mills, 2011).  
I also considered that my dual role as a researcher and yet at the same time a 
professional peer to the research participants, could be a potential issue in 
gaining useful data. I perceived the issue could unfold in two ways. Firstly, 
participants, seeing me as a professional peer, might disclose and attempt to 
draw me into discussions about very specific aspects of their practice, for 
example the use of a specific drug therapy, which would potentially be of little 
value to the research project. Secondly, participants might be reticent to talk 
openly about their practice to a possibly judgemental peer.  
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I undertook the following measures to mitigate the issues associated with 
telephone interviews and my dual role as a researcher and pharmacist. 
 Providing a written information leaflet about the research (Appendix 4) 
and taking formal written consent (Appendix 5) before research 
interviews to provide assurance of confidentiality. 
 Establishing congenial, yet professional e-mail contact with the 
participants when trying to arrange a date and time for an interview. 
 Discussing what the interview entailed with the participant immediately 
before it. In later interviews I asked the participants to consider it more of 
a chat or conversation than an interview (Kotchokova, 2013, Pers. 
Comm., 27th July). 
 Noting all pauses, sighs or intonations of the participant within the 
interview transcripts. 
 Emphasising my role as a researcher rather than a pharmacist in the 
information leaflet and again verbally prior to each interview. 
In reflecting on the interview process, from the notes I made about the interview 
process after each interview; Appendix 6 (p.274) includes some memo extracts 
from my journals. I do not believe my role as a pharmacist was unduly 
detrimental to the flow of the conversations. Within a number of the interviews 
participants did attempt to engage me over specific clinical and professional 
issues in practice. I explained within the interview that I would be happy to 
discuss those issues immediately after the interview. That approach was 
satisfactory in all cases.  
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Telephone interviews were recorded using a digital voice recorder with an 
additional ear piece microphone to record the interviewee. Interviews were then 
transcribed verbatim by me using Dragon Naturally Speaking voice recognition 
software (Premium version 11.5, Nuance Communications Inc.). After initial 
transcription the interview was then played through again and compared to the 
transcript to allow correction of any initial transcribing errors. The use of voice 
recognition software approximately halved the time to transcribe each interview 
compared to manual typing. I had to manually type one interview transcript 
when experiencing a problem with the Dragon software. 
Personal transcription of the interviews allowed opportunities for further 
familiarisation with the data and I made a number of notes and observations as 
the transcript text appeared before me for the first time on the computer 
monitor. By personally generating the transcripts I avoided the costs of a 
professional typist and avoided issues of confidentiality by not passing audio 
recordings to a third party.  
It was not possible to pre-determine the number of interviews that would be 
required. A grounded theory study continues until theoretical saturation is 
achieved (see section 3.3.2.4). A total of fourteen individual research interviews 
were undertaken and transcribed for coding. 
3.3.2 Data analysis 
 
3.3.2.1 Coding 
 
Coding is essentially a process to label and index varying forms of qualitative 
data for analysis, comparison, and identification of recurring events within the 
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data (Coffey and Atkinson, 1996).  The processes of coding within grounded 
theory method vary depending on the version used – see Holton (2007), 
Strauss and Corbin (1998), and Charmaz (2006) respectively for guidance on 
coding in Glaserian, Straussian and constructivist grounded theory method.  
A common feature of all coding approaches in grounded theory method is that 
coding moves from initially remaining very close to the data towards a higher 
level of abstraction as conceptual ideas about the data, and its theoretical 
integration to the central phenomenon, emerge from the study (Birks and Mills, 
2011). I interpreted the ethos of using grounded theory method as a set of 
flexible rather than prescriptive guidelines and I chose to adopt an approach of 
moving from initial focused coding to higher level coding rather than consciously 
aligning myself to a particular coding strategy.   
I coded my initial interview transcripts by undertaking a line by line analysis. My 
initial coding strategy was to remain close to the data and identify processes 
(Charmaz, 2006). I utilised significant in vivo coding and gerunds. I reviewed my 
initial coded transcripts with my supervisors. Appendix 6 (p.272) includes an 
example of coding from an early interview. 
I assigned a further label for my codes in the format of x.y with x representing 
the interview number and y the line number of the code within the transcript. 
This labelling system enabled me to locate the corresponding text when I was 
undertaking data analysis and the constant comparative method by comparing 
findings from different interviews. 
I listed all my codes initially within an Excel spreadsheet with their locational 
labels. I iteratively grouped my codes representing the same phenomenon. As 
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interviews proceeded I started to place my grouped codes within the 
worksheets of Microsoft OneNote and analyse them diagrammatically. I was 
able to move the codes around and maintain an electronic copy of the coding 
diagrams as they developed and an audit trail of my emerging analysis. By 
using Microsoft OneNote I could hyperlink my sheets to notes, memos and 
appropriate internet-based references to aid my developing analysis.    
I maintained a researcher journal throughout the study both electronically in 
Microsoft OneNote and I maintained a paper notebook for ideas that would 
come to me on my daily train journey to and from work. I iteratively moved 
between my spreadsheets, coding diagrams, journal and memos throughout the 
research to review and progress my analysis and thoughts. 
3.3.2.2 Theoretical sampling 
 
Theoretical sampling is a key strategy for developing grounded theory (Birks 
and Mills, 2011). Draucker et al. (2007) have observed how theoretical sampling 
is differently undertaken within grounded theory method research studies. My 
interpretation of theoretical sampling was that as ideas and concepts emerged 
from the interview data I sought to explore and develop them further in 
subsequent research interviews. As there are relatively few neuroscience 
pharmacists and my research was focused within a defined substantive setting I 
did not have a large participant pool to sample from. Theoretical sampling was 
undertaken by modification of my interview questions. However I also retained 
an opening general question of asking people to describe their roles.   
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3.3.2.3 Higher level coding to develop the theory 
 
As I began to group codes together through the comparison of the data I 
iteratively began to explore higher level concepts that began to emerge from the 
data. I found this process to be a fine balance between the identity that I held to 
some of the data by virtue of being a neuroscience pharmacist, and employing 
abductive logic to consider all possibilities for the data.  
Birks and Mills (2011 p.59) concisely define theoretical sensitivity as “… the 
ability to recognize and extract from the data elements that have relevance to 
your emerging theory”. My concern was that I would only identify things in the 
data that resonated with my own practice. I acknowledge that my professional 
experiences aided in the construction of the theory but I did not intend for them 
to stifle that process and overlook other relevant data. Writing memos, 
constantly questioning my codes, and returning to the data were strategies that 
I employed to address these concerns and improve my theoretical sensitivity. 
Appendix 6 contains examples of memos and reflections that I made around the 
emerging concept of being a clinical generalist and specialist (5.5, p.115) and 
how I altered my interview questioning strategy in response to these reflections. 
I was also attuned to the roots of constructivist grounded theory within symbolic 
interactionism and the use of language to construct reality. In this phase of 
higher level coding I regularly consulted dictionaries to check the definitions of 
codes or gerunds that I had labelled to data or concepts to verify the fit and 
relevance of those labels. I also wanted to retain the primacy of the participants’ 
experiences within the theory and a number of in vivo codes are retained within 
the presented theory because I believe them to convey the constructed 
71 
 
phenomena. Examples include ‘Policing the formulary’ (6.3.1, p.149), and 
‘Classis CPD’ (5.2.3, p.86).  
I also turned to the literature around emerging concepts. I did not necessarily 
read the literature in great detail at this point but it sometimes highlighted 
different ways for me to think about my data. 
3.3.2.4 Achieving theoretical saturation 
 
Theoretical saturation is a contested concept with grounded theory method 
research, as to whether it represents the point where no new data codes occur 
or the theory is not able to be further developed. After interview twelve I did not 
feel that any new categories were emerging from interview data; I discuss the 
potential for observational data to develop the theory further in the limitations of 
the study (9.3, p.232). I undertook two further interviews which helped to 
generate useful data extracts that could illuminate the theory but did not serve 
to alter the concepts I had constructed. I therefore concluded the data 
generation phase of the study after fourteen interviews.    
 
3.4 Ethical considerations 
This section details the ethical considerations towards the participants of the 
research project and the research process itself. I will also outline the ethical 
and research permissions that were gained to conduct the study.  
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3.4.1 Ethical  considerations towards the research 
 
 The ethical obligation to the research process is underpinned by a prior 
assessment of the value of the research i.e. the legitimate necessity to 
undertake it, and the utilisation of a robust methodology. 
There was a legitimate need to undertake this research to address the gap 
within the pharmacy practice research literature, and to understand and support 
professional practice. A methodological description of the study, and its 
adherence to the principles of the grounded theory method, has already been 
provided in section 3.3. The rest of this section deals with addressing the ethical 
considerations towards the participants. 
The use of interviews as the main data collection method entails direct 
involvement between the researcher and participants; a degree of trust from the 
participant towards the researcher needs to be built to enable honest disclosure 
of views and experiences and thus gain useful data (Orb et al., 2001). 
Underpinning the principle of trust is the concept of informed consent to 
participate in the research, so that participants understand why the research is 
being undertaken (Orb et al., 2001 , Richards and Schwartz, 2001 , Sture, 
2010). Information leaflets were provided to potential participants to detail the 
reasons for undertaking the study and what was involved (see Appendix 4). 
Signed informed consent was obtained from participants willing to be involved 
before the research interviews were conducted (see Appendix 5). 
Adopting a reflexive approach to the research harboured a reflective 
assessment of my performance as a researcher as well as analysis of the data, 
when analysing interviews. The iterative nature of the grounded theory method 
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allowed me to develop my interview technique. Appendix 6 contains memos 
and reflections on my interview technique. There is also an example of how I 
felt I may have been forcing data generation and altered my interview questions 
accordingly.  
A further consideration of my dual role was what action to take in the event of a 
participant disclosing professional practice that was illegal or a gross breach of 
their professional ethical code. My researcher obligation of maintaining 
participant confidentiality and anonymity conflicts with my professional code of 
ethics as a pharmacist to report illegal or unethical practice (General 
Pharmaceutical Council, 2010). Johnson and Long (2010) assert that 
confidentiality cannot be maintained if the researcher is made aware of a 
serious issue and my professional code of ethics led me to concur with that 
assertion. Although I perceived it very unlikely to happen, given that the project 
did not seek to deliberately explore highly contentious or litigious areas of 
professional practice, the project information leaflet did include a statement of 
my professional obligation to report any unethical or illegal practice that was 
disclosed during research interviews. I re-emphasised this obligation at the 
beginning of each interview. I entered the study with a strategy to be cognisant 
to steer conversations away from topic areas if I felt there was a risk of such a 
disclosure being made. Such a scenario did not arise during the interviews. 
3.4.2 Ethical and NHS permissions for the research  
 
Independent ethical review is important to ensure research is appropriate to be 
undertaken. The Biomedical, Natural and Physical Sciences Research Ethics 
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Panel at the University of Bradford reviewed and approved the Project on 24 th 
August 2012 (see Appendix 3). 
Research governance approval for the project was granted by the research 
department of Sheffield Teaching Hospitals NHS Foundation Trust (see 
Appendix 3). The participants of the study were NHS staff and under guidance 
from the NHS Health Research Authority the project did not require review by a 
NHS research ethics committee (Department of Health, 2011a). Before formally 
approaching and consenting each participant, I was required to obtain 
permission from their NHS Trust research department to conduct the research 
interviews. To maintain the confidentiality of the participants I have not included 
within the appendices, research permissions from the individual Trusts.  
There was considerable variation in the requirements from each Trust’s 
research department. These requirements ranged from providing just a covering 
letter outlining the intended research, to the need for an ‘Integrated Research 
Application System’ account and the need for a site-specific co-investigator. I 
had not anticipated the need for such a high level of detail. I learnt that if I 
intend to conduct further research with pharmacists across the NHS, not to 
underestimate the research permission process. 
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3.5 Study participants 
To maintain their anonymity each participating pharmacist has been assigned a 
pseudonym. A brief and non-specific overview of each pharmacist is provided to 
assist the reader in placing the interview quotes in context of the pharmacist’s 
professional experiences. Given the relatively small number of neuroscience 
pharmacists I have not specifically detailed the duration of professional 
qualification of each pharmacist, to maintain anonymity. Instead I have 
characterised them by being experienced (5 to 10 years of professional 
qualification) or very experienced (greater than 10 years of professional 
qualification). 
I have chosen to assign pseudonyms to each participant rather than a study 
number because I wish to convey the study findings as those of human 
professional experiences. 
(1) Michael: Michael is a very experienced senior pharmacist with a 
lead pharmacist role within a large teaching hospital 
Trust.  
(2) Kate: Kate is a very experienced senior pharmacist with a lead 
pharmacist role for neuroscience in a large teaching 
hospital Trust. 
(3) Belinda: Belinda is a very experienced clinical pharmacist with a 
lead pharmacist role for neurology within a large tertiary 
neuroscience service. 
(4) Beth: Beth is an experienced pharmacist working within a 
neuroscience rotational role in a large teaching hospital 
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Trust.  
(5) Natalie: Natalie is a very experienced pharmacist working in a 
mid-sized NHS Trust. Part of her role comprises a lead 
clinical role for the neurology service. 
(6) Laura: Laura is a very experienced clinical pharmacist working 
as part of a pharmacy team within a large tertiary 
neuroscience service. 
(7) Lisa: Lisa is a very experienced senior clinical pharmacist with 
a lead pharmacist role within a large tertiary 
neuroscience service. 
(8) Billy: Billy is a very experienced clinical pharmacist with a lead 
pharmacist role within the neuroscience service of a 
large teaching hospital Trust. 
(9) Patti: Patti is a very experienced pharmacist with a lead 
pharmacist role in the neurology service of a teaching 
hospital Trust. 
(10) Polly: Polly is a very experienced pharmacist in a large 
teaching hospital Trust who has previously worked in a 
clinical role within the neuroscience service of that 
organisation. 
(11) Lauren: Lauren is a very experienced pharmacist who has a lead 
role for a tertiary neuroscience service within a large 
teaching hospital Trust. 
(12) Megan: Megan is an experienced pharmacist working as part of 
a pharmacy team within a large tertiary neuroscience 
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service. 
(13) Sally: Sally is a very experienced pharmacist working within a 
mid-sized NHS Trust. She is assigned pharmacy 
responsibility for a neurology service.   
(14) Sophie: Sophie is a very experienced pharmacist working as part 
of a pharmacy team in a large tertiary neuroscience 
service. 
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4 Introducing the grounded theory 
 
The processes of data generation and analysis, as described in the previous 
chapter, resulted in the identification of three conceptual processes within 
specialist clinical pharmacy practice in neuroscience. These processes are:  
(1) Acquiring and utilising knowledge.  
(2) Gatekeeping access to drugs. 
(3) Integrating into the neuroscience service.   
Theoretical abstraction of the data resulted in the identification of the basic 
social process for clinical pharmacy practice in neuroscience of ‘Maintaining an 
overview of drug therapy for patients with neurological disease’.  
The three conceptual categories are presented sequentially within the next 
three chapters. The core category of maintaining an overview is set out in 
chapter 8. The theory is presented firstly in their own right (chapters 5 to 8) with 
extracts of interview data to illuminate the analysis. By presenting the theory 
first I have followed the recommendations of  Charmaz (2006) and Birks and 
Mills (2011) to facilitate the reader in judging the merit of the theory without 
having to unpick it from discussion. 
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5 Acquiring and utilising knowledge 
 
5.1 Introduction 
This research study set out to explore how pharmacists in neuroscience 
develop within their role, to understand what differentiates their practice as 
assumed specialists in their clinical field from the non-specialist pharmacist. A 
strongly emergent conceptual process from the interviews with the pharmacists 
is a two stage process of acquiring knowledge and then utilising it in their 
clinical practice. 
Clinical pharmacy practice in neuroscience is focused on drug use for 
neurological disease. The knowledge base that pharmacists develop to support 
clinical pharmacy practice centres on two aspects: 
(1) Knowledge of neurological disease 
a. The clinical manifestations of neurological disease  
b. The pathological processes of neurological disease to:  
i. Rationalise the mechanism of action (pharmacology) of 
drug treatments. 
ii. Understand the prognostic implications of the disease 
i.e. the risks of morbidity and mortality.  
(2) Knowledge of drug therapy for neurological disease 
a. The clinical application of drugs to treat neurological disease 
with: 
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i. The expectant benefits of drug therapy. 
ii. The expectant risks of drug therapy.  
b. The organisational rules around drug use: 
i. In what circumstances drug therapies can be used and 
how to give them. 
ii. What needs to be undertaken to authorise drug use i.e. 
gatekeeping issues. 
 
The drug knowledge types listed in 2b help pharmacists to navigate around the 
issues of gatekeeping access to specialist drug therapies for neurological 
diseases. This knowledge type and the process of gatekeeping access to drug 
therapy are presented in chapter 6. This chapter focuses on the other aspects 
of knowledge that are outlined above. 
Lay definitions of knowledge place emphasis on the experiential or educational 
acquisition of facts and information (Oxford Dictionaries, 2014). These 
processes are evident among the data generated from this study. More 
fundamental discussions around knowledge identify it as a basic commodity 
that humans require to make sense of the world around us (Beijerse, 1999). 
This study data identified three forms of knowledge that neuroscience 
pharmacists utilise, and how these serve as reference points to make sense of 
and guide their clinical practice. Figure 4 summarises the three identified clinical 
knowledge types; sections 5.2 to 5.4 present and discuss these sequentially. 
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Figure 4. Acquisition of knowledge types. 
 
The study data also illuminate a tension within professional practice of 
balancing developing specialist knowledge in neuroscience whilst maintaining 
the broader clinical knowledge base. Running concomitantly to the knowledge 
acquisition processes of Figure 4 is the need for knowledge to support general 
clinical practice in other areas outside of neuroscience. Section 5.5 outlines this 
tension, and how pharmacists respond to that. 
Section 5.6 presents a process of how the relative utilisation of different forms 
of clinical knowledge changes as clinical practice in neuroscience develops. 
Through exploring the processes of knowledge acquisition, the data also 
indicated perceived barriers and facilitators to these processes. These findings 
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have important implications for supporting professional practice that which are 
discussed further in section 9.2.1 (p.214). 
 
5.2 Learning theoretical knowledge 
5.2.1 Navigating early practice 
 
Most of the pharmacists interviewed entered into a clinical post in neuroscience 
with little previous professional exposure to, or knowledge of neurological 
disease. Reasons for taking up a clinical role in neuroscience were varied, but 
commonly the job vacancy arose at the right time for that person and 
neuroscience seemed an attractive proposition as a clinical pharmacy 
specialism.  
I came to the end of my diploma and started looking for what was at the 
time, the D grade jobs, and they got funding within the hospital I was 
working in at the time and the neurology job came up and it just seemed 
perfect. So I kind of a didn't really have any experience so it wasn't that 
we had, that I'd done a rotation and really loved it or anything. But there 
is a lot to get your teeth into it neurology so it just seemed a good choice 
really. 
Belinda [3.115] 
 
…it [neurology role] was offered to me – “do you want to do it?” And I 
thought, yes why not, I’ve never done it before, why not do it (laughs). So 
that's how I kind of fell into it really, more by accident (laughs). 
Sophie [14.54] 
 
 
Laura alludes to a more widespread lack of knowledge of neurological disease 
in pharmacy practice, beyond the most prevalent disorders. The identification of 
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this knowledge deficit arises through observations of her rotational pharmacist 
colleagues as they enter a period of practice within her neuroscience unit. 
Generally, I think there's a lot deficit in neurology knowledge in general. I 
mean what you normally know [of neurology] as a band 7 [pharmacist] is 
the basic Parkinson's [disease] and a little bit about epilepsy. Anything 
that comes outside is new and different… 
Laura [6.265] 
 
Laura describes receiving a high volume of enquiries initially from junior 
pharmacists as they enter the neuroscience rotation to verify the 
appropriateness of unfamiliar drug treatments they encounter.  
A similar observation of general pharmacy practice is made by Lauren in that 
she identifies a general lack of pharmacists’ exposure to neurological disease. 
Lauren also identifies a diversity of neurological disease through an extent of 
disease sub-types. 
One thing you mentioned there was that they [junior pharmacists] 
said it [neurology] was different. I just wondered what they meant 
by that? 
I think sometimes they haven't done neurology before and I think it is 
also because it's very specialised, and it’s neurology. But then you've got 
this very specialist areas within that you know what I mean. So you've 
got your MS [multiple sclerosis] and then you've got neuromyelitis optica 
and “Oh what's that?” And then the next thing is NF2 [neurofibromatosis 
type 2] and they've never heard of that before. 
Lauren [11.309] 
 
The neuroscience pharmacists identify initial deficits in their clinical knowledge 
of neurological disease and its treatment and seek to address these deficits in 
knowledge by learning about neurological disease. I have termed this form of 
learnt knowledge as theoretical knowledge; it is knowledge that is consciously 
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gained outside of everyday practice. It is the knowledge that is used to make 
sense of clinical practice. 
Theoretical knowledge assumes a prominence in the early stages of clinical 
pharmacy practice in neuroscience. As the pharmacists enter unchartered 
areas of specialist clinical practice they seek to make sense of the new 
diseases and forms of drug use they encounter and to establish the conformity 
of these phenomena to normal practice. The theoretical knowledge the 
pharmacists learn provide points of reference to make judgements about the 
normality and acceptability of the new clinical practice they encounter. In these 
early days of specialist practice and in the absence of experiential knowledge, 
which is developed over time through clinical practice and experience (section 
5.3), the pharmacists otherwise lack points of reference to make sense of the 
new clinical scenarios they practice within. 
5.2.2 Making sense of new practice in specialism isolation 
 
The initial need to find theoretical knowledge, references for drug use, is 
prominent amongst although not confined to the pharmacists who practice in 
speciality isolation i.e. as the only specialist neuroscience pharmacist within 
their organisation. When pharmacists practice in specialism isolation they 
cannot easily compare their practice with peers, who serve as another point of 
reference in their learning. This feeling of professional isolation was offered by 
several of the pharmacists often when debriefing towards the end of the 
research interviews.  
Belinda disclosed her feelings of isolation after I had felt it necessary in the 
interview to interject and reassure her that an aspect of her practice which she 
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had just disclosed was similar to that of other pharmacists. She wonders about 
how her practice compares to her neuroscience pharmacist peers and in the 
absence of that knowledge, this brings feelings of uncertainty about the 
competency of her practice. 
Oh good (laughs). You just you know feel very much isolated because 
you're the only one [neuroscience pharmacist] in one hospital. I sort of sit 
here and think oh God all the other people [neuroscience pharmacists] 
across the country they’ve probably in their post for years and years and 
years. That's probably a bit of a warped idea and they know loads more 
than I do. They wouldn't have done originally.  
Belinda [9.469] 
 
Lisa also disclosed how hearing the experiences of other neuroscience 
pharmacists provided some reassurance that the practice she encountered was 
normal, in that it conforms to practice in other centres. 
What was interesting, you know the pharmacy conference last year and I 
came to you5 and there were things that you said then which made me 
think oh actually I’m not alone in this because it is quite different to a lot 
of other specialities. I've not had much opportunity to network with other 
people that work in neuro so that, even that little thing where you 
mentioned other things it's quite interesting to hear okay, maybe that's 
normal for neuro[logy]. 
Lisa [7.680] 
  
Polly recalls the challenges of trying to make sense of previously unmet drug 
therapies and how she would look to other neuroscience centres as sources of 
theoretical knowledge to make comparisons with the drug use she is exposed to 
in practice. She acknowledges these experiences in a time before the formation 
of a professional (UKCPA) network for neuroscience pharmacists. 
                                                             
5
 I had delivered an educational talk about epilepsy and headache at a pharmacy conference which the 
participant had attended. She approached me afterwards to discuss some aspects of my presentation.  
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I found there wasn't a huge amount of support out there at that point. It 
was just at the point where the UKCPA [neuroscience] group was 
beginning to take off, even a little bit before it really. So it didn't feel that 
there was a huge amount of resource to go to find out why somebody 
would be on something bizarre and had anybody used it before. So we’d 
do things like call at the pharmacy in [Specialist Hospital] and get some 
idea of whether they'd used it before and if they had any protocols or 
guidelines that they would be happy to share. 
Polly [10.215] 
 
The benefit of the UKCPA network is highlighted by Beth when we were 
discussing the progression of her career. Beth acknowledges the benefit of the 
network for gaining insight into the practice of her peers. By putting practice 
issues and queries onto the network she will not only gain knowledge for the 
specific issue but be able to judge how the practice she encounters compares 
to that of peers. 
I think it's a great opportunity to not just network but to see what's going 
on and get an insight into other people's practice. To make connections 
and know that you can always you can always put something on there 
without, I don't know what the proper word is, but without prejudice. You 
can write on there and you know you’ll get a response. It will either be an 
answer or at least advice.  
Beth [4.499] 
 
These data reveal how practicing in specialism isolation can heighten the 
difficulties pharmacists experience in finding reference points for comparison of 
their clinical practice to the normal.  
5.2.3 ‘Classic CPD’ – strategies for learning theoretical knowledge 
 
Having identified gaps in their knowledge base from encountering new practice, 
the pharmacists seek to address those gaps through learning about 
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neurological disease and its treatment. Undertaking continual professional 
development (CPD) was a common answer provided when the pharmacists 
were asked how they sought to develop their clinical knowledge in 
neuroscience. An interpretation of CPD provided by Polly, and also similarly 
provided by Billy, is to identify and fill gaps in their knowledge base. 
… I suppose it was classic CPD but it wasn't really recorded in such a 
way at that time. It was just like you would come across something, I 
wouldn’t know much about it. I would then go and try and find out more 
about the disease and how the drugs work within the disease. 
Polly [10.362] 
 
The pharmacists identified various strategies for developing their clinical 
knowledge in neuroscience; these are summarised in Figure 5. 
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Figure 5. Strategies for learning the theoretical knowledge of neurological 
disease. 
 
The effectiveness of CPD strategies is variably perceived. Self-directed study, 
reading around the subject, was a commonly employed strategy to develop 
theoretical knowledge. A lack of pharmacy specific educational material and 
events was noted. One of the common strategies for learning about 
neuroscience was to attend the in house teaching provided for medical staff. 
Pharmacy specific educational material about neurological disease was 
identified in general pharmacy journals such as the Pharmaceutical Journal and 
Clinical Pharmacist. It was sometimes perceived however that general 
pharmacy educational material was not of a sufficient level of detail to support 
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specialist practice. Conversely review articles in medical journals or textbooks 
could be overly technical and esoteric to provide a rudimentary introduction into 
a specific neurological disease, or not concentrate sufficiently on the drug 
therapy. Some pharmacists, like Sophie, feel there are limitations to this form of 
learning. 
I just did my own research, my own reading. It was quite difficult because 
you can only learn so much from textbooks, theoretical things. 
Sophie [14.72] 
 
As pharmacists become established into their post the demands of the role and 
maintaining a work - home life balance mean that initial intentions of learning 
about neurological disease can fall by the wayside. Pharmacists made efforts to 
gather educational material but did not always get around to studying it as their 
time became limited. 
…I've not had chance to, I've got files full of articles  that I have never 
just got to the bottom of reading which I would like to have done but you 
know I haven't managed to. So really it's just been sort of learning on the 
job really as I've gone along. You know anything unusual I've looked up 
but not really in any depth which is incredibly frustrating. I was hoping 
that one day I will be able to but it never quite arrives (laughs). 
Belinda [9.298] 
 
…all the other demands of my role just didn't allow time for that 
[spending time with clinical nurse specialists]. So I just had to do some 
reading and I attended talks and that kind of thing when I got a chance. 
Lisa [7.101] 
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And again I've got a few CPPE packs that are on my coffee table at 
home (laughs), but they are there, I do physically have them, and a 
couple of books and stuff but it's really difficult to [find time to read 
them]… 
Megan [12.563] 
 
Pharmacists also become less reliant on theoretical knowledge as their 
experiential knowledge base develops (see Figure 7, p.130). 
5.2.4 Signposting to clinical guidelines 
 
The interview data evince pharmacists’ affinity towards clinical guidelines as 
theoretical knowledge sources. Clinical guidelines seek to standardise practice; 
in the practice of neuroscience, clinical guidelines cover the treatment of a 
specific neurological condition or condition groups, or the use of a specific drug 
treatment.  
Clinical guidelines are concentrated sources of information that can bring 
together multiple information and evidence sources to guide the practice of how 
to use a drug or treat a specific neurological disease. Clinical guidelines may 
define the conditions in which a drug may or may not be used, the dose or dose 
range to be used, the exact method of administering the drug and the specific 
monitoring required to assessing therapeutic and adverse effects. Within the 
interview data policy and protocol were mentioned as coterminous descriptors 
to guideline. While these synonyms might be construed differently in their 
prescriptive intent, they convey the same concept of a guiding framework for 
drug use; for consistency I have used the term clinical guideline except where 
its synonyms are presented within the interview data. Neuroscience 
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pharmacists encounter clinical guidelines with scope at varying organisational 
levels, as summarised in Table 3 below. 
Table 3. The organisational levels of clinical guidelines. 
Organisational level Examples 
Micro-level Unit / departmental guideline 
Meso-level NHS Trust guideline 
Macro-level National guideline e.g. NICE guidance, NHS England 
 
Where the pharmacists are responsible for inducting or mentoring junior or 
rotational pharmacist colleagues, they often signpost the available guidelines to 
their colleagues as part of the induction process.  
… we have our standard training tools. Obviously we go through [with 
pharmacists] all the policies and protocols and things… 
Kate [2.359] 
 
The affinity that pharmacists can hold to guidelines is illustrated by the response 
Natalie gave when I asked her how she might define specialist pharmacy 
practice in neuroscience. 
Being able to know the NICE guidelines like the back of your hand and 
quote things like that. I suppose it's being able to quote your trials which 
sometimes you just can't just because there’s that many (laughs).  
Natalie [5.436] 
 
This response infers that practice can be standardised based on evidence, then 
learnt, understood and followed. Natalie’s response refers to standard reference 
points (guidelines, evidence base) that practice can be compared for 
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confirmation of conformity to these standards. This opinion of clinical practice in 
neuroscience however is not universally held; this disparity with other 
practitioners’ viewpoints is explicated in the next section.  
5.2.5 Encountering the weird and wonderful of neurology  
 
Ten of the fourteen pharmacists practice in tertiary neuroscience centres. 
Practice within tertiary centres is often described as involving exposure to 
challenging or difficult clinical cases or rare conditions that could not be 
managed in local hospitals. Where clinical guidelines or standardized therapies 
do exist they have invariably already been tried and were not successful.  
 
Michael, Beth, Laura, Billy, Polly, and Megan, who all work in regional 
neurosciences centres described, unprompted, the “weird and wonderful” of 
neurology. This term is a reference to often rare neurological conditions with 
uncommonly used drugs or drug usage outside of the parameters of what might 
be considered routine practice. Laura describes the British National Formulary 
(BNF), the standard drug monograph compendium reference in UK clinical 
practice, not giving much away. This alludes to indications for drugs, doses 
prescribed and indeed the drugs being used being outside of routine clinical 
practice in the UK. Table 4 overleaf presents a typology of the weird and 
wonderful drug use in neuroscience as identified from the interview data. 
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Table 4. A typology for the 'weird and wonderful': non-routine forms of drug use. 
Conditions of drug use Examples from the data 
Off-licence drug use:  
Use of a drug outside of the indications 
permitted by the drug licensing 
authorities. 
 
Rituximab for neuromyelitis 
optica (Devic’s disease). 
Deviation from the licensing authorities 
dosing recommendations for drugs by: 
 
Exceeding maximum 
recommended dose. 
Indometacin for headache 
syndromes. 
The recommended dose titration 
schedule. 
 
Rapid dose titration of anti-
epileptic drugs. 
Unlicensed drug use:  
Use of a drug that does not have a 
marketing authorisation (licence) – a 
pharmaceutical special. 
 
3,4-diaminopyridine for 
Lambert-Eaton myasthenic 
syndrome. 
Intrathecal baclofen for 
spasticity. 
Buccal midazolam for 
epilepsy. 
 
Use of an imported drug that is not 
licensed and marketed in the UK. 
 
Sulthiame for epilepsy. 
Use of substances not classified a 
medicinal product for a therapeutic 
purpose. 
Co-enzyme Q10 (uniquinone) 
for myopathies. 
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The nature of clinical practice in tertiary neuroscience centres, often involving 
difficult or rare cases of neurological disease, leads to more nuanced drug 
therapies and therefore practice does not necessarily lend itself to the formation 
of standardised clinical guidelines. Billy feels that working often without 
guidelines is the main difference from his previous role in a medical speciality. 
Megan who practices in a large tertiary centre identifies how a paucity of 
guidelines can be a challenge for junior pharmacist entering a rotation in 
neuroscience under her supervision, particularly when they have been used to 
clinical guidelines in other appears of practice. 
We do think they [junior pharmacist] struggle… they come from where 
they’ve been in cardiology, respiratory where there is a NICE guideline 
for everything. A NICE flowchart and a step-by-step how to introduce 
bisoprolol and you don’t get that here, you don’t even hardly get any 
Trust guidelines…      
Megan [12.606] 
   
The majority of pharmacists describe being involved in the development of 
clinical guidelines. The interview data highlighted differences amongst 
neuroscience centres in the prevailing culture of the acceptance of clinical 
guidelines. Michael devises protocols for new medicines which he perceives to 
be helpfully received by the consultant staff he works with suggesting a culture 
that was embracing of guidelines.  
There was [sic] a lot of things we had to do around that [drug] patient 
information leaflets and policies and procedures and supportive 
therapies, protocolising things and standard drug charts for it etc. etc. 
etc. So that stuff was all just ‘Thank God you're here Michael because we 
[medical staff] wouldn't have known what to do without you…  
Michael [1.139] 
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In contrast, Megan has encountered resistance to the development of 
guidelines within her practice. 
… they’re [medical staff are] much less policy driven, much less guideline 
driven than… Probably because of the nature of the conditions we deal 
with. You know some of them are so niche you don't have a general 
guideline for them but they just don't have general guidelines and 
policies… They're coming round to that but it's still a bit (pause), you 
know, “we’ve always done it this way and why are we having to do this 
now?” 
Megan [12.113] 
5.2.6 Summary 
 
As pharmacists enter into clinical practice in neuroscience they encounter new 
disease states and forms of drug use. Pharmacists seek to learn theoretical 
knowledge about neurological disease and its treatment, and seek to locate 
appropriate clinical guidelines. These forms of theoretical knowledge serve as 
points of reference to enable the pharmacists to assess the conformity of the 
clinical practice they encounter towards a normal practice. Within neuroscience 
the pharmacists identify difficulties in accessing appropriate learning materials 
and a relative lack of clinical guidelines and standardisation of practice. The 
deficiency of relevant theoretical knowledge sources can make initial practice in 
neuroscience challenging for pharmacists as they struggle to make sense of the 
practice they encounter. 
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5.3 Developing experiential knowledge 
Experiential knowledge is knowledge gained through the experience of direct 
professional exposure to neurological disease and its treatment i.e. seeing real 
life patients and directly observing the effects of drug treatments.  
Experiential knowledge can help to consolidate theoretical knowledge. However 
in everyday clinical work, pharmacists can encounter practices that may differ 
from the theory they have learnt or, what they have previously understood to be 
the normal acceptable practice. Through the development of experiential 
knowledge, pharmacists begin to alter their points of reference for the 
parameters of acceptable practice. 
Experiential knowledge does not purely define clinical knowledge but 
encompasses ways or working, processes and prevailing cultures within 
neuroscience units which is encapsulated by Natalie. 
I’ve got a lot more knowledge about particular diseases that just comes 
with time and working on the ward and knowing what nursing practices 
are and how it all gels together really.  
Natalie [5.86] 
 
5.3.1 Resetting the reference points for the parameters of drug use 
 
In the clinical specialism of neuroscience, pharmacists can encounter new 
practices of drug usage that do not conform to what they have previously learnt 
or been exposed to. Forms and examples of non-routine drug use have been 
provided in Table 4 (p.93). The parameters for drug use, for example the 
disease that a drug is used to treat, or the doses at which drugs are prescribed, 
do not match the pharmacists’ reference points for acceptable drug use at that 
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stage of their practice experience. Pharmacists may be exposed to completely 
new drugs or neurological diseases not previously encountered. In these 
situations the pharmacists may have no, or very faint, reference points to 
assess and make sense of the clinical situation. Over time the pharmacists can 
reconcile the differences in drug use between what they have previously learnt 
(the theoretical knowledge) and what they see in practice (experiential 
knowledge) to alter their parameters for acceptable drug use that accommodate 
these newly encountered drug practices. 
Patti’s account of her practice exemplifies this process: she changes the 
acceptable dose parameters for the non-steroidal anti-inflammatory drug 
indometacin from what she has previously learnt from the licencing guidelines, 
to a dose that is commonly prescribed by a consultant neurologist she works 
with. 
I guess I'm sort of open to these bizarre things because I'm still learning 
about it all, not seeing it all. It's like seeing very high doses of 
indomethacin6 prescribed that I've had to query with the consultant they 
are unlicensed [doses] that he does use. 
Patti [9.288]  
 
In Lisa’s neuroscience unit neurological sub-specialities tend to be grouped 
together on specific wards. The organisation of the wards increases the 
exposure to similar clinical conditions and scenarios for the pharmacists visiting 
the same ward each day. Lisa’s observation of this pattern of working illustrates 
how time and repeated exposure to practices that are initially perceived to be 
                                                             
6
 Indometacin and indomethacin are names for the same drug. Indometacin is the approved name for 
this drug under the current nomenclature; indomethacin is the name under the previous drug 
nomenclature system. 
98 
 
unusual helps to reset the reference points for acceptable drug use which can 
be incorporated into the specific practices within the unit: the unusual becomes 
the normal.     
We’ve got another one [ward] which is a neuro oncology ward. I suppose 
within that, on the wards they’re [pharmacists are] seeing a bit more of 
the same thing and a bit more of the unusual stuff together than they 
might be when they were covering one of five wards  and patients were 
spread all over the place. So that probably helps a bit because the more 
you see it, the more quickly I suppose you get used… Yes it's an unusual 
thing in general but this is what's normally done here. 
Lisa [7.434] 
 
Pharmacists do not necessarily alter the reference points for the parameters of 
acceptable drug use immediately. They do not take on face value that different 
forms of drug use are acceptable. Through answering my question of how she 
would define an expert neurology pharmacist, Patti explicates the reconciliation 
process further by explaining how professional exposure to drug treatments 
provides assurance of having seen them given without adverse consequences. 
(nervous laugh) I think I'd struggle to agree that I was that person [an 
expert pharmacist]. Just because (sighs) I don't feel I've got the 
experience to be the expert. 
So you feel experience is an important thing? 
Yeah. Because you see so many bizarre things [drug treatments] don't 
you that don't appear to be written down anywhere very clearly. So it’s 
experience of coming across those things and seeing them being given 
without any problem.  
Patti [9.438] 
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5.3.2 Getting professional exposure to neurological disease 
 
Experiential knowledge is by its nature of clinical exposure, a reinforcing 
knowledge type. The importance of getting sufficient exposure to neurological 
disease was raised by a number of pharmacists. Natalie identifies the 
importance of daily working for maintaining her to-hand knowledge base. 
Is there anything you think that’s really helped you to develop your 
role? 
Err (pause) definitely the day-to-day on the ward helps because there 
was a short time when I was moved off the neurology ward and had to 
cover different specialities. And I think you do lose that, you do not 
knowing what happens on a day-to-day, at ground level sometimes. 
Can you give sorts of examples of things that you mean by that? 
Just for example if somebody came in fitting and knowing that they 
weren't on any epilepsy medication, what we use, this is what we use in 
a stroke patient so it's… Yeah. So it's things like that, knowing things like 
that off the top of your head which if you didn’t work, you know, if you 
were looking after a respiratory ward [instead] you sometimes lose, you 
know, what happens. 
Natalie [5.344] 
 
At the end of the previous subsection, Patti identified the importance of actually 
seeing drug treatments given and therefore the tangible assurance that the 
bizarre treatments she encounters are given without problem. Sophie identifies 
a concern that she does not have the experience of seeing the therapeutic and 
adverse effects of drugs on patients once they have left the hospital in order to 
help her generate a tangible repository of real life cases. 
Because often we just give out loads of drugs here but we never see the 
patient again so you don't have that, I guess the other side of it saying 
well the patient came back a few weeks later or the patient came that 
because had this side-effect. You never really get to see that side of it 
because you don't follow them up in clinic or anything. 
Sophie [14.579] 
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Similarly Polly was not always able to follow through the patient journey of 
complex clinical cases she was involved in, as the patients care could be 
transferred to more specialist centres. 
Like the really, really complex patients get shipped down to [specialist 
centre] to be reviewed and so you kind of got bypassed and actually 
didn’t find out what they were doing to be able to follow the patient up 
carefully and completely. 
Polly [10.272] 
There can be a wider issue in clinical practice of attaining sufficient professional 
exposure to neurological disease. Lisa perceives this as a challenge in 
neurology, the medical treatment of neurological disease. In Lisa’s 
neuroscience centre patients with neurological conditions are not in the main 
treated as inpatients by neurologists, yet Lisa’s clinical practice takes place 
predominantly in this setting.  
… in [other specialities], a lot of the clinical stuff you're expected to know 
about  you would actually see day-to-day on the wards because you 
have patients with [common diseases] coming into the wards regularly. 
 Where as in neurology, yes some of the patients with neurological 
diseases do come in but to a much lesser extent and the bulk of it seems 
to be managed in outpatients so I didn't have that sort of automatic 
connection with them to get those bits of knowledge with everything.   
Lisa [7.82] 
 
The perception of not gaining sufficient professional exposure can arise from 
comparison to other clinical practitioners – medical staff and clinical nursing 
specialists in particular, clinicians who are at the forefront of patient 
management. 
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There's [sic] quite a lot of clinics that they [clinical nurse specialists] hold 
so sometimes if they’re at the forefront of managing the patient…   
Natalie [5.130] 
 
Getting sufficient exposure to neurological disease to develop experiential 
knowledge is a perceived challenge of clinical pharmacy practice in 
neuroscience. 
5.3.3 Getting a feel for neuroscience and dealing with the unknown 
 
As pharmacists encounter more clinical practice in neurology they develop their 
knowledge base. Through clinical experience, pharmacists form a tangible feel 
for the diseases and drug use they are encountering. They reconcile the 
theoretical knowledge they have learnt about neurological disease with the 
experiential knowledge they have gained through their practice of seeing 
patients with neurological diseases being treated with drugs. This process is 
best described by Laura, a very experienced pharmacist in neuroscience.    
So when you're getting these obscure, niche things [drug therapies] 
how do you decide whether they’re appropriate? 
I think that is [many] years of experience (laughs). I don't underestimate 
experience. You do get a feel for…  You have got a big knowledge about 
all these conditions after a time and so I think when I first started and I 
came up across all these new conditions I actually had to sit down and 
read up so when people come with certain requests I either have come 
across them previously or I know where to look to see what's happening.  
Laura [6.185] 
 
The diversity of neurological disease encompassing a range of rare and orphan 
diseases means that even experienced neuroscience pharmacists can be 
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confronted with previously unmet conditions and situations; Laura  describes 
the “…conditions you might come across once every 10 years”. Experiential 
knowledge is identified as an important tool to deal with these situations as 
identified by Billy below. 
You have to deal with using your knowledge that you gained and 
experience that you gain to help out with a scenario that there is no 
evidence or no guideline.  
Billy [8.307] 
 
Laura recalls a specific neurological condition of copper deficiency and how she 
kept notes and references from the first time she encountered this and how that 
helped her with subsequent cases. 
We've had patients with copper deficiencies where we were looking for 
oral copper preparations years ago in somebody who was copper 
deficient and then about 10 or 12 years later somebody else asked and I 
remember that I did huge calculations of what copper content was in 
different sources and I luckily found all of the old papers I had. So 
sometimes you know things come back and you know where to look 
basically. You might not retain all the information that if you come across 
certain things you know where to look, you know where you are most 
likely to get a good answer. 
Laura [6.373] 
     
Similarly, through the practice of encountering neurological disease, Polly has 
developed a folder of notes and theoretical knowledge sources, references for 
the weird and wonderful. This repository serves as signposts to guide 
colleagues who have followed in her footsteps walking through clinical practice 
in neuroscience. 
And we give them some background but we’ve got quite a lot of files in 
our clinical information on our intranet that the pharmacy section gives 
them a lot of information for the weird and wonderful things that go on. 
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So the routine ones they would never come across. It's one of those 
things that you are specialists in an area and they see it all the time, 
nobody else gets to see it at all and then when somebody goes into it 
new they've never come across but it's something that is done on a 
regular basis. So things like that we try to keep information about so that 
there is [sic] now files and records and references for them to refer to. 
Polly [10.300] 
 
5.3.4 Summary  
 
Experiential knowledge is knowledge gained of neuroscience from tangible 
experiences in clinical practice of seeing neurological disease and drug 
treatments being given. As pharmacists encounter unusual practice experiential 
knowledge helps them to reset the reference points for the parameters of usual 
and acceptable practice. This reconciliation process is a gradual one, reliant on 
professional exposure to the clinical practice which provides pharmacists with 
reassurance. The diversity of neurological disease and rarity of some of its 
forms, and the breadth of pharmacists’ roles can dilute their professional 
exposure to neurological disease to develop experiential knowledge. This 
dilution of exposure can be perceived as a challenge in clinical practice. 
Pharmacists can recognise the importance of turning their experiential 
knowledge into theoretical knowledge by making notes and keeping reference 
material they have collated in dealing with rare or complicated cases of 
neurological disease.  
 
5.4 Acquiring situational knowledge 
Situational knowledge is collateral information that is patient or situation 
specific, gained for judgement and decision making. Situational knowledge 
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provides context with which to assess the appropriateness of drug therapies 
and treatments for the individual patient. Sophie identifies the importance of 
situational knowledge: she identifies a cautionary tale of how individual patient 
factors, in this case the patient not being able to swallow a capsule, can 
override all other considerations in prescribing a drug therapy. 
So you always get this – we want to use this drug and it's all like this but 
then nobody has thought can the patient actually take it. For whatever 
reason, they can't swallow and we can't crush the capsule. So medically 
they [doctors] spent a lot of time and effort looking at these things and 
then forget that the patient has to take it and they can't take it. So 
where's the thought process in that? 
Sophie [14.210] 
 
5.4.1 Scratching the surface to find situational knowledge 
 
Situational knowledge needs to be actively gained. Scratching the surface is an 
in vivo code described by Billy for gathering patient specific information. In 
Billy’s metaphor of scratching the surface, the patient drug chart serves as the 
metaphorical surface to be scratched through. The drug chart is an electronic or 
paper order list of drug prescriptions for the patient, which also serves as a 
record of drug administration. Billy alludes to the basic activities in clinical ward 
pharmacy of reviewing a patient’s drug chart, which can be done remotely 
without seeing the patient. Information about a patient’s ability to take drug 
therapy, such as issues with cognition, dexterity and vision, cannot necessarily 
be gleaned from the drug chart. 
I think it’s about (pause) from experience you can easily, pharmacy can 
be very closed and you can do your own job, make sure the charts are 
safe etc., supplies of medicines and walk off. But if you scratch the 
surface and find out things that the patient can’t… has got eyesight 
problems or dexterity problems or cognition… [says nothing further] 
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So you sort of mention there that people just go on, do the basics if 
you like (interrupted)… 
And yes the medicines will be safe, they will be correct  hopefully but 
they may not be aware the patient’s got hemianopia, or can’t manage… 
or certainly the social aspects, what happens at home – do they have 
support at home, that sort of thing. 
Billy [8.73] 
 
Billy’s observation of pharmacist colleagues being rather “closed” suggests an 
inter-individual variation in each pharmacist’s inherent ability and motivation to 
pro-actively scratch the surface, to look beyond the drug chart. Polly makes a 
similar observation, in that her junior colleagues focus on the drugs in isolation, 
rather than linking the drugs to the patient, citing lack of experience as a factor 
for this.   
…they don't know what they don't know. They can miss lots without even 
having a clue that they're missing stuff. They’re almost doing a patient 
safety check for the medicines but not actually looking into what the 
patients on why there on it, why the patient’s sodium might not be right. 
They're just not really picking up on some of those things. 
And why do you think that is? 
I think it's just experience and it's an awareness that they just don't get to 
see specialist patients in the same way.  
Polly [10.312] 
 
Lisa identifies a variation in the ability of the junior pharmacists she supervises 
to ‘look at the bigger picture’ and contextualise the drug therapy to the patient. 
… I was thinking about the way they [junior pharmacists] make their 
assessment of the patients, the drug therapy, the patient. Are there 
any differences you’ve picked up on at all? 
It depends where they’re at some ways in their diploma I think. Some of 
them who are more into the diploma will approach it in a bit more of a 
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structured way.  I think some of the ones who are a bit more newly 
qualified, it depends very much where they were trained as to what 
approach they take. And some of them seem to be able to pick out quite 
quickly what the important things are. And some of them seem to 
struggle a bit more and will find one small thing that is wrong and get 
hung up on that and not really look at the bigger picture. 
Lisa [7.405] 
The data illuminate that the ability to acquire situational knowledge is a skill that 
is possessed by more senior pharmacists through experience. The next section 
identifies the processes through which situational knowledge is acquired. 
5.4.2 Strategies for the acquisition of situational knowledge 
 
5.4.2.1 Working with the ward-based multidisciplinary team 
 
Neuroscience pharmacists interact with a range of healthcare professionals 
aside from the medical and nursing staff they encounter in the course of their 
clinical pharmacy practice at a ward level. They utilise the expertise of these 
healthcare professionals to elicit specific information about patients that enables 
them to make judgements about drug therapy and pharmaceutical interventions. 
When asked about the healthcare professionals they work with on the ward, 
many of the pharmacists describe working with speech and language 
therapists. Dysphagia is an impairment in swallowing and is a relatively 
common sequela of a number of neurological diseases (Leslie et al., 2003). 
Dysphagia may be temporary or permanent, dependent on the nature of the 
pathological cause and can impair the ability of a patient to swallow safely with 
the risk that oral intake may enter into the lungs. Patients may require a 
temporary or permanent enteral feeding tube to enable safe administration of 
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nutrition and oral drug therapy. Conventional oral drug formulations of tablets 
and capsules cannot be administered via this route.  
I was unable to find any published empirical evidence of the incidence and 
prevalence of dysphagia amongst neurological inpatients. However the relative 
frequency with which pharmacists describe liaison with speech and language 
therapists over patients with dysphagia, suggests dysphagia is a relatively 
common condition encountered in neurological patients.  
The pharmacists work with the speech and language therapists, utilising their 
expertise to ascertain the extent and time course of swallowing difficulties in 
patients. This information is utilised by the pharmacists to advise a suitable 
formulation of drug for a patient, or to consider an alternative drug if necessary.  
Beth describes this process in her practice, highlighting a reciprocal sharing of 
knowledge and expertise between herself and the speech and language 
therapist, which focuses collaboratively on optimising the suitability of oral drug 
therapy for that specific patient.     
…and SALT [speech and language therapists], especially obviously with 
the neurosciences patients, we have to work quite closely with them in 
order for their regimes when they're switching from soft to pure to normal 
so we work together on the [drug] formulations and what they feel is 
appropriate for the patient and what can I do to change [drug] 
formulations to make that appropriate for that patient. 
Beth [4.218] 
 
Pharmacists also liaise with physiotherapists to assess the effects of drug 
therapies prescribed for pain and spasticity, and with dieticians to manage 
interactions between drugs and enteral feed regimes.  
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So we work with those quite closely and with the physios for spasticity 
and things like that; they could be quite useful for respiratory weaning of 
nebs and things like that you need to be working with the physios. 
Kate [2.171] 
 
5.4.2.2 Working with clinical nurses specialists 
 
Pharmacists regard clinical nurse specialists as a source of patient specific 
knowledge. Billy identifies this when describing how he works with clinical nurse 
specialists. 
…but also I can find out what's happening with a particular patient. 
Because they see them in the clinic potentially and if they've been 
admitted as an inpatient or a day patient they have that knowledge, the 
nurses have that knowledge of what's gone on previously so I could 
suggest ‘x’ particular drug to help with this symptom or control if we're 
talking about Parkinson. But the nurses say well we've already tried that 
or it didn’t work or… 
Billy [8.239] 
 
Billy’s perception of clinical nurse specialists having greater individual 
knowledge is held by other pharmacists. Kate makes a similar observation of 
the oncology nurse specialists she practices with. Furthermore she identifies 
how this collaboration facilitates acquisition of situational knowledge by 
facilitating a holistic overview of patients.  
… so I work quite closely with them [nurse specialists] in terms of you 
often find that they know the patients a lot better and have contact with 
them once they're discharged which is where we would normally lose 
contact so it's quite useful to be able to follow through on their drugs and 
they'll kind of send e-mails to say they’re now on this what do we do next 
and things like that. Yeah quite useful from that point of view but very 
kind of drug specific but it just somehow allows you to look at the whole 
patient. 
Kate [2.206] 
 
109 
 
Like Billy, Kate identifies that clinical nurse specialists gain this unique patient-
specific knowledge through their chronic interaction with patients and follow up 
through outpatient clinics. None of the pharmacists interviewed work in an 
outpatient clinic setting; their direct patient contact and clinical practice occurs 
predominantly in the inpatient setting. Patti identifies that the nature of her role 
will not allow her to develop the level of unique patient knowledge in 
comparison to specialist nurses. 
And they know the patients because they see them regularly. You know 
they must get to know, they perhaps don't remember specifics and they 
read their notes and get reminders. You know they know what the patient 
has tried and what side-effects they've had and they’ve built up a rapport 
with the patients which you just can't do flying around a ward every day 
(nervous laugh). 
Patti [9.352] 
 
Belinda identifies the wider usefulness of nurse specialists, by referring her 
pharmacist colleagues to nurse specialists if they encounter a patient with a 
neurological condition in a non-neurological clinical area. She also believes that 
her junior colleagues have less awareness of the specialist nursing role. Section 
7.5.2 (p.192) explores how working relationships are formed over time. Junior 
pharmacists undertaking relatively short term rotations in neuroscience may not 
be afforded the time to form these professional links to exploit nurse specialist 
as sources of situational knowledge. 
I would have thought they [specialist nurses] were a really useful 
resource and that if I had been a junior pharmacist, and you know what I 
mean, covering on a ward then I would have been more than happy to go 
up-can I have your opinion on this patient you know they've gone nil by 
mouth or whatever. I think I would have been quite happy to but they 
[junior pharmacists] don't seem to be quite as aware maybe. 
Belinda [3.196] 
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Pharmacists identify how the chronicity of clinical nurse specialists’ interaction 
with the patient enables development of patient-specific knowledge. However 
when encountering patients in an inpatient hospital setting Megan identified a 
clinical case where her continuity of being on the ward and seeing a patient 
every day, which the senior medical staff did not do, enabled her to attain 
situational knowledge about a patient with epilepsy and detect non-compliance 
with the taking of anti-epileptic drugs. 
I think they're [doctors are] starting to realise that sometimes you are the 
continuity of the ward, you're the only person who sees every patient 
every day.   
So yesterday I was able to say of a telemetry7 patient who came in on 
the Monday, she walked in, she was TCI [to come in] – looked fine. By 
Thursday she was [vomiting], she had a headache; she looked like a sick 
person and it was because, as I said yesterday to him [consultant], do 
you think she's non-compliant with drugs with all these high doses of the 
[anti-] epileptics?  
The answer was yes so they cut them all down. They don't have that 
continuity because they don't see them every day. So I think they're 
coming round to the- oh actually, it would be quite useful on this round. 
Megan [12.226] 
 
5.4.2.3 Participating in multidisciplinary ward rounds 
 
Billy attributes his participation in ward rounds as pivotal in the acquisition of 
situational knowledge to understand prescribing decisions. 
So you can influence [prescribing] and also there’s a learning thing from 
pharmacy staff that you can learn why a particular prescriber’s decided to 
do that at the time which may not always be documented. And also 
you’re able to sort of reason, to discuss why, with the person there. 
Billy [8.180] 
  
                                                             
7
 Telemetry is a diagnostic technique for epilepsy requiring admission to hospital for simultaneous video 
monitoring of the patient with physiological monitoring of electrical activity of the brain. 
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Megan also identifies the importance of attending ward rounds as an efficient 
strategy of gathering situational information and unwritten considerations 
underpinning prescribing decisions. Ward round participation facilitates getting a 
feel for a case, implying an attainment of comprehension of the issues and 
mitigating factors within a clinical case beyond that which can be attained from 
reading of the medical notes. 
…you don't have to trawl through X number of case notes, you sort of 
know what to expect… so we got a couple patients who have, they've 
been in the seven months one of them and she's going home and the 
epilepsy specialist wants the same generic manufactured drugs, you 
know that whole can of worms (laughs), but in her I can see why he does 
because she's been on ITU for months this girl. So it's sort of teeing that 
all up for when she goes home the next day. So it [attending ward 
rounds] is useful yes.  
Megan [12.268] 
 
Eight of the fourteen pharmacists stated they participate in ward rounds. Of the 
four pharmacists that explicitly stated they did not participate in ward rounds, 
three stated lack of time or time pressures as the main reason for not doing so. 
Ward rounds vary in their characteristics; Table 5 (p.114) summarises how the 
properties of ward rounds affect the ability of pharmacists to attend and their 
usefulness in acquiring situational knowledge.  
Ward rounds, particularly neurosurgical ward rounds, may also take place very 
quickly with limited time and opportunity to elicit situational knowledge. The 
focus of the ward round may be very medically or surgically orientated with 
limited opportunity for pharmaceutical input. Lauren describes the time pressure 
that her junior colleagues are under to collate situational knowledge, “what’s 
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happened to the patient”, from which to make pharmaceutical interventions 
beyond assurance that the drug treatments are safe. 
So you've got to very quickly go through, try and work out what's 
happened to that patient so that they can maybe have meaningful input 
from a pharmacist colleague. 
Lauren [11.320] 
 
Despite the challenges of attending the surgical ward round, Lauren still 
perceives participation as important to understanding the daily plan and patient 
movement in and out of the neurosurgical unit. Participation in the ward rounds 
involves one of her team beginning the working day at 7.30am, outside of the 
core pharmacy working hours. Hence pharmacist involvement in ward rounds 
involves some co-ordination of staff to ensure that the attending pharmacist 
does not work above their contracted hours whilst the overall pharmacy service 
is still maintained. Kate also starts work “at a ridiculous time in the morning” to 
undertake her pre-surgical rounds. Some of the pharmacists interviewed have 
less personal or job flexibility to accommodate such changes to working 
patterns.  
Larger tertiary neuroscience units employ a large number of consultant medical 
staff, resulting in multiple medical teams of junior doctors assigned to a group of 
consultants. Ward rounds can therefore occur concurrently, creating a dilemma 
of which ward round to attend for the pharmacist. Sophie identifies that the ward 
round she attends will enable her to see as many patients as possible and with 
the highest likelihood of providing successful interventions into patient care.  
Where neurological services are provided through a ‘hub-and-spoke’ model, 
consultant medical staff split their time between the tertiary neuroscience centre 
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and the local base hospital they provide their outreach service to. In these 
circumstances consultant medical staff may only undertake a ward round when 
they have patients under their care as inpatients. The ad hoc nature of these 
ward rounds makes it difficult for pharmacists to participate, as they may not 
know they have taken place or do not have sufficient flexibility within their role to 
attend impromptu ward rounds. Despite Beth’s strong involvement with 
neurosurgical ward rounds, she does not attend neurology ward rounds partly 
because of their unpredictability.  
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Table 5. Properties of ward rounds for pharmacist participation and acquisition of situational knowledge. 
Property Dimension Implications for acquiring situational knowledge 
Scope and focus of the 
ward round. 
Medical / surgical overview of the patient 
Sub-speciality ward round e.g. epilepsy, microbiology 
Full multidisciplinary involvement – SALT, 
occupational therapy, physiotherapy, specialist 
nurses, pharmacy. 
 
Lack of focus on medicines or focus only on the medical 
condition under review in the ward round. 
 
Holistic overview of patient with considerations for drug therapy: 
swallowing ability, cognition, dexterity, patient beliefs and 
preferences over drug therapy. 
 
Location / proximity of ward 
round to patient. 
Remote from patient e.g. within ward office. 
Patient bedside. 
Combination of remote and bedside. 
  
Drug chart not present to focus analysis on drugs (mitigated 
with electronic prescribing systems). 
Facilitates end of bed assessment of patient and patient 
involvement with drug therapy decisions. 
 
Duration of ward round. Short (minutes) to long (half a day). Ward round too short to acquire useful information.  
Long duration is prohibitive to attending due to time pressures. 
 
Scheduling and timing of 
the ward round in relation to 
pharmacists’ working hours. 
Scheduled to the same time. 
Occur spontaneously or are ad hoc. 
 
Within or outside of core pharmacy working hours. 
Pharmacist role is full time or part time. 
Ward rounds scheduled into working week. 
Ward rounds not attended as cannot be scheduled. 
 
Working hours amended to attend or may not be possible due 
to personal/family circumstances, personal preference not to do 
so. 
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5.5 Balancing specialist and general clinical knowledge  
In clinical practice neuroscience pharmacists experience tension in balancing 
the extent of their specialist clinical knowledge in neuroscience and their 
general clinical knowledge. This process is summarised by Figure 6 below by a 
metaphorical comparison to the filling of a cone with two immiscible liquids.  
 
Figure 6. Balancing specialist and general knowledge in clinical practice. 
 
General clinical knowledge conveys a broader, less detailed knowledge base 
that supports a competent level of general clinical pharmacy practice in areas of 
general and specialist medicine. Clinical knowledge is reinforced and 
maintained by exposure to clinical situations that require use of that knowledge. 
General knowledge is depicted in Figure 6 by the lighter shading in the top 
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section of the cone. The top section of the cone, relative to the lower section, is 
shallower and broader; these properties convey those of general knowledge. 
Specialist knowledge, the dark liquid at the bottom of the cone, is gained 
through clinical practice. As specialist knowledge enters pharmacists’ 
knowledge base (is poured into the cone) it sinks to the bottom of the cone. The 
bottom of a cone is narrower and deeper, conveying the properties of specialist 
knowledge that is focused on neurological disease.  
Pharmacists identify that they have a finite capacity for usable clinical 
knowledge – the metaphorical cone has a defined maximum volume. Any 
additional fluid added to the cone merely flows out of the top of it. As specialist 
knowledge is poured into the cone, being denser, it displaces general 
knowledge through the top of the cone as it sinks to the bottom. The tension the 
pharmacists experience in practice is balancing how much of their knowledge 
base (the cone) comprises specialist knowledge (is filled with dark liquid) and 
how much of it comprises general knowledge (is filled with light liquid). 
5.5.1 Identifying the diversity of neuroscience as a clinical specialism  
 
While carrying an identity as practitioners within a specialist clinical field of 
neuroscience, pharmacists can also perceive they are generalists within 
neuroscience through identifying neuroscience as a broad and diverse clinical 
specialism. Belinda identifies the scope for clinical pharmacy involvement.  
…there is a lot to get your teeth into in neurology.  
Belinda [3.118] 
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There is variation amongst the pharmacists in the breadth of practice exposure 
to neuroscience which is predominantly determined by the size and service 
profile of the unit that they practice within i.e. what neurological conditions are 
treated within the unit and therefore what pharmacists are exposed to. Belinda, 
Natalie, Patti and Sally practice within a medical neurology service; the other 
pharmacists practice in neuroscience centres offering neurology and 
neurosurgical services. Practice exposure is also determined by the extent of 
pharmacists’ clinical or direct patient facing involvement, primarily within an 
inpatient ward setting, within their role. 
The diversity of neuroscience is partly identified through observation of the 
extent of subspecialisation amongst the medical and nursing staff that they work 
with. Most pharmacists frequently work with condition-specific specialist nurses, 
most commonly in epilepsy, multiple sclerosis and Parkinson’s disease, but also 
stroke, motor neurone disease, headache and other neurological conditions. 
Billy commented on working with disease-specific specialist nurses in 
neuroscience, something he had not encountered in his previous roles.  
Clinical nursing specialism is identified as an established clinical service 
preceding the introduction of clinical pharmacy services. The role for the clinical 
nurse specialist in neurological disease is recognised in health policy by NICE 
clinical guidance (see section 1.5.2.1, p.17) and through other forms of policy 
review e.g. All Party Parliamentary Group on Epilepsy (2007), All Party 
Parliamentary Group for Parkinson’s Disease (2009). 
When making comparisons to nurse specialists, pharmacist can perceive their 
neuroscience expertise to be less extensive and more generalised.  
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…One of the things I'm interested to know is how pharmacists work 
with those groups of specialist nurses – if you’ve had any 
involvement with those. 
No not really… You know, just pharmacy related queries more so than 
advice particularly on… Because I still class them as knowing more than 
I do about even the combinations of drugs that are used and what would 
particularly in epilepsy, you know they would stop one and start another 
one. You know I'm not the point yet where they asked me questions. 
And why do you feel they know more? 
Because they've got the experience… You know looking at those drugs 
because that would be their specialist area and that's what they do 
specifically, you know day in day out. Whereas I’ve got to worry about all 
this specialities across neurology so I can't possibly know it in as depth 
as they do their areas.  
Patti [9.337] 
 
Patti’s response to my questioning of how she works with nurse specialists 
identifies a pressure of her role to maintain a broader overview of neurological 
disease. She is responsible for overseeing a clinical directorate rather than a 
service for a specific condition. She also places an importance in experiential 
knowledge underpinning expertise which is analysed further within this chapter.  
5.5.2 Identifying the strength of the generalist amongst the specialists  
 
While also acknowledging that their disease specific knowledge may not be as 
extensive as that of their specialist nursing colleagues, other pharmacists 
recognise that clinical sub specialism can be limiting to effective clinical 
pharmacy practice. This is evident in the pharmacists’ belief that their broader 
clinical knowledge base, within neurological disease and also more generally, 
makes an important clinical contribution to patients under the care of 
neuroscience services. An initial data code of broad knowledge was identified 
from a spontaneous contribution made by Michael in the first research interview. 
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Sometimes the value of what we bring, say clinically, is the fact that 
there’s a diabetic on the ward and nobody knows about the management 
of diabetes or hypertension or something. Now we kind of have that 
broad overview whereas a lot of the doctors get niched and kind of lose 
track of some of the broader views.  
Michael [1.160] 
 
Also unprompted, when describing a lack of engagement from neurosurgical 
medical staff over drug-related issues, Megan identified limits to their drug 
knowledge and her role as a pharmacist to stop inappropriate prescribing in 
areas outside of the expertise of those medical staff. 
You don't think it's [drugs are] on their agenda? 
No. Drugs aren’t are they, they have their own little pool, depending on 
what their specialty is, they have probably about eight drugs that they 
use if that all the time and that's it. And anything else just bamboozles 
them and they do silly things and you have to stop them.  
Megan [12.396] 
 
Beth makes similar observations of the knowledge base of neurosurgeons. 
… I guess when you become a specialist as they are-surgeons, they 
don't think about normal medical practice. They can't understand how to 
restart people’s warfarin and bits and bobs…  
Beth [4.393] 
 
Michael’s viewpoint that a broad knowledge base is a strength of the 
pharmacist, was offered to Kate for her thoughts and it evoked a general 
concurrence. 
One of the things that has come up previously was about 
specialism and pharmacy and one of the strengths being that 
pharmacists know quite a lot about quite a lot rather than an awful 
lot about a few things. How do you feel about that statement? 
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I think it probably is and I think it's why we're in a good position with that 
in that the specialist nurses know a lot about their little area but we've 
got, or we should have if we keep our knowledge up-to-date, a much 
broader understanding of medicines for everything not just for the little 
condition we’re trying to treat. So we do tend to take everything into 
consideration… And I don't really know where that comes from because I 
mean I've done neuro for six and a half years so my exposure is very 
similar to a specialist in any other profession but I don't know… 
Kate [2.558] 
  
Like Michael, Laura identifies that a key role for the contribution of pharmacists 
is to consider all the medical conditions a patient has. Laura also identifies that 
her broader knowledge outside of neuroscience is acknowledged within the 
wider clinical team through her contributions within that team, and by her being 
consulted for advice on patients’ general drug therapy. 
…Say that you've got a patient in with you and they are in for some 
neurological issue but they also happen to have asthma or 
diabetes. How do your teams get on with managing the other 
conditions? 
I think that's one of the key roles of pharmacy because your consultant 
and your nurses will not be so aware of what's going on otherwise. So it 
is actually down to the pharmacy to pick up other issues like steroids in 
diabetic patients. So this is one of the areas where we actually intervene 
mostly or where we get asked for advice as well. 
Laura [6.309] 
 
Maintaining broad clinical knowledge is necessary to undertake a holistic 
analysis of patients’ drug therapy which is considered to be an essential 
element of clinical pharmacy practice. This belief is underpinned by an imbued 
sense that the role of the pharmacist is to analyse a patient’s medicine chart in 
its entirety for all drugs prescribed, checking for their suitability and compatibility 
for the patient in combination with other drugs and other co-morbidities. The 
121 
 
response above from Laura is illustrative of this consideration in this case, 
considering the effect that steroids can have on glycaemic control in people with 
diabetes. Kate could not initially define why she maintained a broader 
knowledge base but she did subsequently identify the requirement to clinically 
assess (screen) the appropriateness of a patient’s entire medication regime 
prescribed on a drug chart. 
…I just think because we screen a whole patient chart rather than just 
the bit they're in for. I think that's just inbred in us whereas a specialist 
nurse will just look at the bit that is relevant to them.  
Kate [2.569] 
 
Laura justifies the process of screening an entire patient drug chart, by 
identifying the need to assess or judge the appropriateness of an individual drug 
in combination with other drugs that the patient may be taking.  
…as a pharmacist even when you take in a prescription of course you 
need to ask what else they are taking so you come across a whole range 
of medications. And so you might have to be broader because if you 
don't know what the other things do you can't make a judgement.  
Laura [6.340] 
 
While still identifying herself as a specialist practitioner, Lisa provided similar 
justification of the need as a pharmacist, to asses a patient’s entire medication 
regime as an integral part of the pharmacist role. 
… even as a specialist pharmacist, yes you might be a bit more clued up 
on the neurology, neurosurgery things in my case but that doesn't 
mean… You know I see my role on the wards as well as being a 
specialist for that, to very much be the one that looks at all the other 
drugs and doesn't just ignore them as… you know, ‘that’s a just pile of 
stuff’ where as normally, it’s a key part of what we’re looking at every 
day. 
Lisa [7.331]  
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Belinda [3.317] and Natalie [5.427] believe the ability to clinically check a drug 
chart to a standard is a basic clinical pharmacy skill that equips a pharmacist 
with the competency to practice on neurosciences wards. When asked how 
they would distinguish specialist clinical pharmacy practice from that of junior 
colleagues neither could readily identify any perceivable difference. Belinda 
cites completion of a clinical diploma, a general rather than neuroscience 
specific clinical pharmacy qualification, as the criteria for competent practice. A 
similar observation is made by Lauren of her junior colleagues. 
They [junior pharmacists] tend to… The diploma, especially when they 
start doing the diploma they tend to be quite good by then. They have 
done many other rotations - they have done renal, things like oncology, 
gastro so they tend to pick things up medically. 
Lauren [11.338] 
 
Lisa identifies the ethos of clinical diploma training that she has been involved 
with, to consider the patient holistically. 
Maybe it is just the training. Because we’re very much trained to look at 
the person and the prescription as a whole; not just focusing on ‘they’re 
in with Parkinson's’ or whatever so what do I need to do about this? We 
are very much expected to interlink it all. Certainly the diplomas I’ve been 
involved in have very much had a focus about not just dealing with one 
specific problem but interlinking all the different drugs, and conditions 
and patient factors together. 
Lisa [7.320] 
 
These data support the viewpoint that a rounded clinical knowledge and 
experience base, as well as the ability to screen a drug chart, can support a 
competent level of clinical pharmacy practice within the neuroscience unit. 
Several pharmacists describe how the requirement of their role to work in other 
clinical areas or within other areas of the pharmacy department aside from 
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neuroscience broadens their clinical exposure and professional exposure to 
drug therapies. The broader scope of their practice requires them to maintain, 
and also facilitates, development of a broad knowledge base to practice 
proficiently within those areas. 
…from the way the department is set up there's no way in our 
department that you could get away from being, from keeping up your 
general knowledge because we still have to do on calls, and things like 
that for the whole hospital so we can still be getting calls about TPN [total 
parenteral nutrition] patients or, do you know what I mean?  
Belinda [3.380] 
 
We do, obviously our weekend service I don't get to just cover 
neuro[logy]. We get to cover everything. We do post take ward rounds 
and bits and bobs so I still need to maintain a baseline clinical 
knowledge…  
Beth [4.404] 
 
Belinda’s response conveys a requirement of and expectation from the 
pharmacy department to maintain a broad knowledge and skill base. She 
further acknowledged the requirement of working in the pharmacy department 
to remain somewhat of a generalist. 
Even when you’re a specialist pharmacist you still have to work within the 
[pharmacy] department and it’s a general department.  
Belinda [3.390] 
 
The study data reveal an identity of being a pharmacist, and that despite 
practicing within a clinical specialism, of belonging within a general pharmacy 
department. In her description above of pharmacy services Beth makes use of 
we as the subject personal pronoun in statements about the pharmacy 
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department, invoking a sense of collective belonging; similar patterns in the use 
of personal pronouns were found in the transcripts of other interviews.  
Neuroscience pharmacists acknowledge the expertise of their pharmacist peers 
within other clinical specialities and pharmacy departments being relatively 
close-knit departments of practitioners within different specialisms. Kate 
describes a culture of collaborative learning within pharmacy through events 
such as lunchtime teaching sessions led by pharmacists.  
Neuroscience pharmacists identify limits to their general clinical knowledge and 
they cannot keep up to date with clinical and drug advances in other medical 
specialities. 
…one of the strengths of pharmacy is that we know quite a lot 
about a lot of things and I don’t know what you feel about that. 
Yeah we do I think but the thing is that it’s like a fast moving market so I 
think it’s quite hard to keep up to date with everything so say with the 
diabetes, type 2  diabetes there’s so many new drugs on the market…  
…I think it’s really hard to keep up to date with everything; I don’t think 
you can.  But I think you’re right in that we do have a more general 
overview of things or kind of like the bread and butter things you’ll know. 
Medics when they’re in their speciality will only concentrate really on in 
that area; they’re not interested really in anything else. 
Sophie [14.657] 
 
Clinical pharmacists within other medical specialities are used as sources of 
knowledge or advice when feeling unsure or not confident of a clinical issue or 
situation.  
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… you know I'm part of pharmacy; we have regular meetings where we 
present to each other on that kind of thing. That really does help me to 
keep up to date with all the other different specialities. But more than that 
as well it means if something comes in and I'm not too up-to-date on it or 
I’ve forgotten then there's a specialist as part of my own department I can 
just ring up and ask for informal advice. 
Lisa [7.310] 
 
The affiliation to the pharmacy department and identification of pharmacist 
colleagues as resources for information and advice can be maintained when 
pharmacists have work bases outside of the pharmacy department, or practice 
within units that are geographically separated from the main pharmacy 
department of their Trust. 
If it's something we are not familiar with-we get a complicated patient on 
anti-retrovirals we actually probably refer back to our colleagues over at 
[neighbouring Trust] and ask for advice if we can't make that sort of 
decision.  
Laura [6.316] 
 
Pharmacists’ affinity to the pharmacy department, and the underlying sense of 
generalised practice, creates a tension as their roles develop and specialise. 
Michael and Belinda acknowledged that as their roles became more senior and 
specialist they spend less time within the pharmacy department, to the 
detriment of the maintenance and further development of their general 
knowledge base; both were concerned about this. The response of Michael 
again illustrates an inherent need in the role of the pharmacist to maintain a 
broad clinical knowledge base to practice, and how a loss of a broad knowledge 
could detract from his role and clinical input as a pharmacist. His use of the 
term touch base implies a need to interact professionally within the pharmacy 
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department to continue a broad range of clinical exposure and maintain a broad 
knowledge base. 
And it's kind of interesting how you alluded to earlier about… one of the 
strengths of pharmacist seems to be that breadth of knowledge… 
[interrupted] 
Yes that's one of the things that’s being eroded. These days I'm seldom 
in a dispensary and that’s actually kind of worrying that I’m kind of losing 
that broad skill base as a senior pharmacist… we are losing some of the 
core skills. 
What’s your feeling on that? 
I think we need to be able to touch base and know what things are 
because if you’re only ever working in your area you start to lose the 
benefit you bring of being the kind of pharmacist that yeah you know the 
stuff in your area you know also how to manage like what the latest 
guidelines on hypertension are or the latest whatever else. You need to 
see patients from other areas and be confronted with this clinical 
checking in a dispensary or something to keep yourself up-to-date with 
things that are going on.  
Michael [1.370] 
 
Patti, who is relatively new within her post, identifies her level of expertise by 
positioning it within the pharmacy department; her response again illuminates 
an identity of belonging in a pharmacy department and the influence which that 
exerts on her perception of her role and expertise. 
But you know I’ve had this conversation with my line manager in many a 
one-to-one meeting and they sort of, quite rightly I think, said well you’re 
not an expert above a consultant.  You’re really… you know my role as 
the pharmacist in the pharmacy department here is to guide fellow 
pharmacists in neurology. So I’m an expert amongst them about 
neurology but not necessarily on the ward with the consultants. 
Patti [9.453] 
 
The tension between generalised and specialised practice is not universally 
held. By contrast, Billy is concerned his specialist practice is being 
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compromised by service reconfiguration and the requirement of his role as a 
lead pharmacist to provide cover for gaps in the service. These factors detract 
from his ability to provide a specialist role; he perceives generalisation in the 
sense of covering the neuroscience directorate. 
I see the 8a’s role is… it seems to be, whether this is intentional or not, it 
seems to become more generalised, I’m losing the specialist. Because of 
the way circumstances are this could be a [local] thing I don’t know but I 
really want to be, I think that’s a primary role – we need to be there 
having contact with the clinicians and the other MDT members .  
So generalised in the sense of neurology generalised or… 
[interrupted] 
Generally, as an overall the way things are working we’ve now got within 
certain neurosciences, because historically there used to be neurology 
and stroke was separate, and neurosurgery was separate… So I’m 
having to deal with sort of things that are not traditionally, sort of 
neurosurgery side of things which takes me away. 
From? 
Neurology and stroke which is overall a good thing for the patient and the 
staff that they’ve got someone, they’ve got access to a clinical 
pharmacist on the ward through the normal working hours… But the 
worry I feel is we could be taken away from the specialist, not being able 
to devote enough time to that. 
Billy [8.140] 
 
The data reveal a tension that can exist in the practice of neuroscience 
pharmacists between developing a specialised knowledge base and 
maintaining a broad clinical knowledge base that allows the pharmacists to 
maintain an overview of a patient and their drug therapy. An affiliation towards 
maintaining a broad knowledge base is evident, although not universally held. 
This affiliation towards maintaining a broad practice and knowledge base is 
influenced by a deep sense that, as a pharmacist, to be able to assess a 
patient’s drug therapy in its entirety; belonging to a hospital pharmacy 
128 
 
department with role commitments in other clinical and pharmacy areas; an 
identification that an ability to holistically assess a patient in the context of 
concomitant morbidities and drug therapy is a strength which the pharmacist, 
who has more of a generalist drug overview of the patient, brings to patient care 
in neuroscience services. 
 
5.6 Utilising knowledge in clinical practice 
5.6.1 The pharmacist as the dispenser of drug knowledge 
 
Neuroscience pharmacists find credence in the currency of their clinical 
knowledge as a marker of the wealth of their expertise. The importance of 
knowledge in clinical pharmacy practice is exemplified by the efforts which 
pharmacists place in acquiring this knowledge, as has been presented so far in 
this chapter. 
5.6.1.1 Being the drug advisor 
 
The interview data illustrate at numerous points how pharmacists serve as 
providers of information or advice about drugs. Lisa describes from day one of 
her job how she had a pile of information queries waiting for her.  
…the e-mails and letters with requests for advice and that kind of thing 
started pretty immediately. I had a pile waiting for me the day I started 
(laughs), with the handover from the previous person. 
Lisa [7.150] 
 
Some pharmacists, like Natalie, identify their strength in acquiring knowledge in 
the form of information – medicines information. Being approached for advice 
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on medicines is a marker of expertise. When pharmacists are more remotely 
removed from the clinical case, their knowledge of drugs is required to support 
a clinical decision making process but the pharmacists are not necessarily 
involved in the final decision. 
Do they [neurologists] ever ask for an opinion on something, you 
know do you think this is a suitable drug to use, or course of 
action? 
Definitely that's not their approach they know, they know (laughs). 
They're the experts and they don't ask me my opinion on something. 
They'll ask me more factual questions you know like are there 
interactions or are there supply problems? They wouldn’t ask me my 
opinion. 
And how do you feel about that? 
I don't generally feel too perturbed. 
Sally [13.434] 
 
  
5.6.2 Using knowledge for clinical decision making 
 
Figure 7 (p.130) is a schematic representation using a Venn diagram to 
represent the interplay between theoretical, experiential and situational 
knowledge in the clinical practice of pharmacists.  
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Figure 7. Utilisation of knowledge types in clinical practice. 
 
The enlarging of the shaded circles symbolizes the acquisition and expansion of 
experiential (section 5.3) and situational knowledge (section 5.4) through clinical 
practice and experience. There is variability in how extensively pharmacists 
acquire these knowledge forms due to the heterogeneity of clinical practice. As 
theoretical and situational knowledge become more prominent they facilitate the 
pharmacist’s clinical analysis and practice to focus on the individual patient. 
Ensuring drug therapy is safe is an inherent gatekeeping process imbued in 
clinical pharmacy practice in neuroscience; its significance is discussed in 
section 6.3.3 (p.157). 
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Clinical practice does not progress in the sense of moving steadily in a 
unidirectional motion from left to right; pharmacy practice may move in either 
direction along this continuum.  
Sophie, a very experienced pharmacist working in a large tertiary neuroscience 
service, encountering rare and refractory neurological disease, exemplifies 
practice towards the right of Figure 7 in her discussion of expert practice. 
I think anybody can write a guideline but you’re not really an expert in it 
unless you can (sigh), I suppose apply the guideline to the patient 
individually or know what the guideline doesn't fit the patient and what do 
you do then. 
Sophie [14.633] 
 
I acknowledge that portrayal of a process through diagramming is to an extent a 
pejorative depiction of professional practice. The study data did identify other 
factors that can influence where practice is situated along the continuum of 
Figure 7 on the previous page.  
5.6.2.1 Becoming a pharmacist prescriber 
 
Two of the pharmacists interviewed were independent pharmacist prescribers. 
One pharmacist was in the process of completing their qualification as a 
pharmacist prescriber. 
Billy and Lauren both describe how undertaking a prescribing qualification 
shifted their clinical focus to considering the patient holistically, moving their 
practice towards the right of Figure 7. Lauren who practices predominantly 
within a critical care setting considers the patient more holistically in a 
physiological sense. 
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I think it has reinforced looking at the patient globally rather than just 
focusing on the therapy, drug, sort of medical issues because when you 
do that course, when I did that I'd have to ‘I'm doing that from an ICU 
perspective’ but then have to go through all the organ systems… 
Lauren [11.240] 
 
Billy practices in less acute, general ward settings. He identifies how 
multidisciplinary learning with nurses on a prescribing course revealed a 
different way of looking at a patient, aside from identifying drug issues. 
I was shown again when I did prescribing course that we [pharmacists] 
can potentially have a blinkered, we focus in on what's the problem with 
the meds, “right, we’ll sort out by prescribing this or stopping that”. 
Whereas the nurses come from a more holistic way of looking at how the 
patient is generally. 
Billy [8.243] 
 
The differing skill sets that nurses and pharmacists bring to pharmacist 
prescribing has been identified in other clinical areas such as oncology 
(Williamson et al., 2010). 
 
5.7 Chapter summary 
Pharmacists practicing in neuroscience identify the need for knowledge to make 
sense of their clinical practice. They also recognise that the possession of 
knowledge, particularly about drugs, is part of their professional identity as a 
pharmacist. Three forms of knowledge are identified to support clinical practice 
in neuroscience – theoretical knowledge, experiential knowledge and situational 
knowledge.  
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Learnt or taught theoretical knowledge is a prominent knowledge type in the 
early stages of clinical practice, as pharmacists seek to make sense of the new 
practice they encounter. There is a particular reliance on clinical guidelines 
which serve as a reference points for comparison of this previously unmet 
practice.  
As clinical practice develops there is a realization, especially in more 
specialised tertiary neuroscience centres dealing with difficult or very rare forms 
of neurological disease, that clinical practice can be nuanced and less 
standardised in relation to other areas of medicine. Pharmacists develop an 
experiential knowledge base of tangible experiences of neurological disease 
and drug treatments. An experiential knowledge base helps to create new 
reference points for clinical practice and may move the reference points for 
comparison of practice that were created from experiential knowledge. 
A third form of knowledge is situational knowledge, background and collateral 
information around individual clinical cases. Situational knowledge helps to 
focus clinical decision making on the individual patient, and has less emphasis 
on compliance with clinical guidelines. Pharmacists learn to acquire situational 
knowledge through their ward working and integration within the 
multidisciplinary team. Acquiring situational knowledge can be time consuming 
and there can be challenges in practice to being able to acquire this form of 
knowledge. 
As clinical practice in neuroscience progresses, pharmacists have less reliance 
on theoretical knowledge as they develop their experiential knowledge base and 
learn how to acquire situational knowledge. This change in knowledge focus 
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facilitates practice that is more orientated to the individual patient. While still 
striving for the standardisation of practice through the development of 
guidelines, pharmacists are able to become more tolerant of clinical practice 
that deviates from guidelines. 
The ability to gain and use knowledge to underpin clinical decision making and 
making clinical sense of the drug therapies which pharmacists encounter, is an 
important consideration in another emergent conceptual process gatekeeping 
access to drug therapies. The involvement of pharmacists in gatekeeping 
access to drug therapy will be presented in the next chapter.  
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6 Gatekeeping access to drug therapies 
 
6.1 Introduction 
Gatekeeping is a well described phenomenon in many fields; it is concerned 
with the regulation of processes. In the substantive theory of clinical pharmacy 
practice within neuroscience, gatekeeping is the process of regulating access to 
drug therapies for patients being treated by neuroscience services.  
Gatekeeping issues may arise within individual patient cases or more widely, for 
example, if a new drug or new use (indication) for a drug is introduced into 
clinical practice. Gatekeeping processes affect both patients being directly 
treated within a neuroscience hospital unit, and patients receiving ongoing 
specialist drug treatments for neurological diseases on an outpatient basis.   
Neuroscience pharmacists, through their intermediary role, act as the link 
between the clinical teams in neuroscience who wish to prescribe drug 
therapies for patients, and the pharmacy department which is the major 
repository for drugs within the hospital (cf. section 7.1, p.176). The study data 
identify how pharmacists frequently serve as the conduit through which 
requests to use drugs are channelled. Section 6.2 sets out the professional and 
organisational antecedents for gatekeeping by exploring the conditions of 
pharmacy practice that bring about pharmacists’ exposure to, and involvement 
with gatekeeping processes. 
Within neuroscience, gatekeeping assumes a certain prominence in clinical 
pharmacy practice. Neuroscience pharmacists can serve as a gatekeeper to 
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drug access; they also, at times, serve as the metaphorical key to help unlock 
and open the gate, and facilitate access to drug therapies. 
This prominence of gatekeeping arises from the pharmacists’ perception that 
neurological diseases, and by association their drug treatments, are at times 
relatively rare and complex. The nature of clinical practice in neuroscience can 
result in the use of specialist drugs which I will define as those that are 
prescribed only by neurologists or neurosurgeons. These specialist drug 
treatments may also be expensive, or prescribed outside of the parameters of 
what the pharmacists consider to be routine practice (cf. ‘weird and wonderful’ 
of drug usage: 5.2.5, p.92).  
Section 6.3 sets out the gatekeeping issues recognised by pharmacists in their 
clinical practice, through consideration of:  
 Adherence to organisational policies around drug usage (6.3.1).  
 The financial implications of drug usage (6.3.2).  
 Ensuring the safe use of drugs (6.3.3). 
 
Section 6.4 sets out the processes of how pharmacists deal with and analyse 
the implications of identified gatekeeping issues. Section 6.5 illuminates how 
pharmacists work with the clinical teams to resolve gatekeeping issues. These 
sequential stages are summarised in Figure 8. 
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Figure 8. Stages of gatekeeping access to drug therapies. 
 
6.2 Professional and organisational antecedents to gatekeeping 
Charmaz (2006) acknowledges that grounded theories serve as contemporary 
analyses of phenomenon that are contextualised within a time and place. A brief 
overview of how drugs within NHS hospitals are supplied and funded is 
provided in this section. An outline of these processes, provided within sections 
6.2.1 to 6.2.3, sketches an organisational framework for drug use that the 
pharmacists practice within. The purpose for providing this information is to 
enable the contextualisation of the processes and interview data presented. 
138 
 
6.2.1  Drug supply processes within hospitals 
 
Pharmacy departments, in the main, are the point of entry (procurement) for 
drugs into, and distribution (supply) throughout hospitals. These two functions 
remain a significant facet of hospital pharmacy services (see Table 1, p.11). 
In clinical and ward areas of NHS hospitals, although the exact mechanisms 
may vary, the standard practice for managing medicines is to maintain a profile 
of stock drugs that are routinely used or may be urgently required within that 
area. A supply of these stock drugs is stored within the clinical area. As part of 
their role, pharmacists visiting a ward or clinical area initiate the supply of, or 
authorise the supply of non-stock individual drugs required for patients. This 
process runs alongside the pharmacists’ clinical check of patients’ drug 
regimes. In applying a clinical check, the pharmacist is indicating that the 
prescribed drug is appropriate for the patient and if necessary, supplies can be 
made i.e. the drug can be dispensed. 
The pharmacists provide accounts of being involved in the ongoing supply of 
specialist drug treatments for patients, outside of the hospital. There has been 
an increasing trend within the NHS for hospitals to outsource the supply, of 
often high cost or specialist drugs that cannot or will not be routinely prescribed 
by non-specialist clinicians, to external pharmacy companies. These companies 
dispense drugs and delivery them directly to patients within their homes. This 
mechanism of drug supply is known as homecare. In response to growing 
concerns over the regulation of homecare drug supply, a report was published 
by the Department of Health (Hackett, 2011). One of the recommendations of 
this report was greater involvement of pharmacy within the homecare process.  
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6.2.2 Drug funding processes within hospitals 
 
All the pharmacists interviewed for this study practice within secondary and 
tertiary neuroscience services of acute NHS Trusts. Within the NHS, acute 
Trusts function as care providers (cf. 1.3, p.3). A care provider Trust receives 
income in the form of a tariff for each episode of patient care provided. This 
tariff charge provides reimbursement for the cost of providing all aspects of the 
care and treatment for that patient, including the drug therapy. This activity-
based tariff system is known as Payment by Results (PbR) and it was gradually 
introduced into the NHS from 2003 (Appleby et al., 2012). 
There is recognition within the PbR system that certain aspects of care are too 
expensive to be included within standard tariffs.  Amongst those exclusions is 
an extensive list of certain high-cost drug therapies. It has been estimated, by 
cost, that up to 60% of drugs prescribed by hospital clinicians are excluded from 
the PbR tariffs (Howard, 2012) i.e. they are high cost, specialised drugs.  
For some of these high-cost drug therapies commissioning policies exist and 
the drug treatments provided by the provider Trust will be automatically 
recompensed for providing the treatment. Commissioning policies will stipulate 
the clinical circumstances in which use of a specific drug therapy is acceptable 
and will be funded. A number of high cost drug treatments for neurological 
diseases fall into this category; examples of high cost drugs, identified by 
pharmacists in the interview data, are summarised in Table 6 on the following 
page. 
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Table 6. Examples of high-cost drug therapies for neurological disease. 
Drug name (Branded name) Therapeutic indication 
 
Fingolimod (Gilenya®) 
 
      Multiple sclerosis. 
Natalizumab (Tysabri®)  
  
Intravenous Immunoglobulin (IVIg) 
 
Various auto-immune neurological 
diseases. 
 
Botulinum toxin Spasticity; Dystonia; Prevention of 
migraine headaches. 
     
For drugs where a commissioning policy does not exist or there is an intention 
to use a drug outside of the commissioning criteria, provider Trusts seek a 
funding approval through a process termed ‘individual funding requests’ (IFRs). 
Failure to seek funding approval before use of a high cost drug can result in the 
Trust ultimately paying for the treatment.  
Having presented the organisational mechanism around drug use in the NHS 
the next section presents data that identify pharmacists’ participation within 
these processes, and the construction of their role as the drug supplier. 
6.2.3 The pharmacist as the drug supplier 
 
Involvement in, or acknowledgement of drug supply processes, was a recurrent 
theme throughout the interview data. This section describes how the drug 
supply role of pharmacists is perceived in practice. 
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6.2.3.1 Practicing pharmacy beyond the dispensing role 
 
In pharmacy practice, dispensing is the task or process of preparing a drug for 
administration to the patient either directly by a patient or more commonly in 
hospital for a nurse or other suitably qualified healthcare professional to 
administer to the patient. The dispensing of drugs is undertaken against the 
orders of a drug prescription. 
The drug dispensing function is the historical antecedent of the modern clinical 
pharmacist role (cf. 1.4.2, p.6). There is an acknowledgement of that 
professional heritage from Laura, a very experienced pharmacist. Laura also 
recognises the evolution of the clinical role and in the passage below, she 
places a certain distancing from the past dispensing role of the pharmacist. 
Laura’s observation of past practices also alludes to a more balancing change 
in the power relationship between the doctor as drug prescriber, and pharmacist 
as drug supplier. Laura describes how the historical dispensing role assumed 
subservience to the doctor’s prescribing orders. 
I come from the time when pharmacists dispensed basically (laughs). 
When the doctor ordered and the pharmacist dispensed. The broad work 
was basically make sure that everything [drugs] is there labelled up 
correctly and in a timely manner. We become [sic] a lot more clinical over 
the years which actually reflects a lot more in what, (pause) well, what 
responsibilities we get as well. 
Laura [6.83] 
 
There were three interviews where the term ‘dispense’ or its derivatives were 
mentioned; apart from Laura’s historical reference to pharmacists as 
dispensers, no reference to dispensing was made in the context of the 
pharmacist being directly involved in that process. These findings corroborate 
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Laura’s perception that the dispensing role of the pharmacist is a historical one, 
and the pharmacists do not associate their clinical role with the mechanical task 
of dispensing drugs. 
6.2.3.2 Seeing the pharmacist as the drug supplier 
 
Despite the pharmacists distancing themselves from a historical dispensing 
role, within current pharmacy practice the data identify within the 
multidisciplinary neuroscience clinical teams, the pharmacist as the conduit 
through which access to drug therapy can be secured, and their role is 
associated with supplying drugs.  
This perception of pharmacists as suppliers of drugs is not necessarily held 
explicitly by the pharmacists themselves. Only Kate and Billy make reference to 
the supply of drugs in response to the standard opening question of each 
interview of how the pharmacists would describe their role. Billy identifies the 
drug supply function of the pharmacy service although he does not explicitly 
state that he, as a pharmacist, supplies drugs. 
…[the role is] obviously [ensuring] safe and appropriate supply, 
prescribing, administration of medicines. 
Billy [8.8] 
 
Kate’s description of her involvement with specialist drug treatments 
(fingolimod, natalizumab, IVIg) is one of co-ordinating their supply. Kate does 
not imply that she is necessarily involved in the physical process of supplying 
that drug, but rather she oversees and co-ordinates it. 
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I provide support for PIU, so our programmed investigation unit, with all 
our regular IVIg and Tysabri [natalizumab], sort out the fingolimod 
service. That's my day-to-day job. 
Okay so when you say sort out fingolimod etc. what do you mean 
by sorting out? 
So organise supplies. We brought the MS nurse back from the 
community to do this kind of practical side of the fingolimod service and 
then I just oversee it from a more structural, financial… (did not complete 
sentence). 
Kate [2.39] 
 
Billy holds an opinion that the basics of ward-based pharmacy practice in 
reviewing patients’ drug therapy, aside to ensuring safety, is to ensure the 
supply of drugs. Billy then continued to discuss how pharmacists can become 
more directly involved in patient care, implying that supplying drugs is a more 
traditional, core activity of pharmacy practice on hospital wards. 
… you can do your own job, make sure the charts are safe etc., supplies 
of medicines and walk off [the ward]… 
Billy [8.75] 
 
Although the pharmacists do not necessarily describe their role as a supplier of 
drugs, they identify that perception of the role from other healthcare 
professionals that they work with. Notably, the pharmacists recognised that 
ward-based nurses identify them as suppliers of drugs. 
…that's probably where the nurses come in as well - they see us as the 
discharger of patients and the supplier of drugs… 
Michael [1.114] 
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Section 6.5.2 (p.171) further illuminates the identity of the pharmacist as the 
drug supplier on hospital wards. Pharmacists have an acceptance of this role 
function through the identification of their contribution to patient care by 
expediting access to drug therapies. Megan however expresses some 
frustration at how being perceived as the drug supplier (as well as safety net for 
drugs cf. 6.3.3), by medical staff, because it detracts from her role as a clinical 
practitioner.  
What do you think their [consultants’] perception of the pharmacist 
role is then? 
I still think, here, they think it's predominantly a safety and supply of just 
cost effective medicines but I don't think they get that we have... I think 
they think we have less clinical knowledge than we actually do if that 
makes sense? 
Megan [12.206] 
 
The standard practice within hospitals is for nurses to administer drugs to 
patients. The ability of nurses to administer drugs to patients is dependent on 
the drugs being available. Section 6.5.2 illuminates a common interface 
between nurses and pharmacists to be issues of drug supply. This gives rise, as 
identified above by Michael, to the perception of pharmacists as drug suppliers.   
Clinical nurse specialists also identify the function of supplying drugs within the 
role of the pharmacists. Pharmacists describe being approached by specialist 
nurses when there is an issue in relation to the supply of a particular drug.  
What sort of things does she [Parkinson’s disease nurse] tend to 
come to you [about]? 
She's recently taken up post so she came to us about supply of 
apomorphine [drug for Parkinson’s disease]…  
145 
 
…She works with us very much coordinating [drug supplies], making 
sure we’ve got the stock in; asking us questions about where to get the 
lines from. She's more principally about that… 
Sally [13.336] 
 
One of the things I'm interested to know is how pharmacists work 
with those groups of specialist nurses, if you’ve had any 
involvement with those. 
No not really. Just the odd question about: “is such a drug out of stock 
because we’ve got a patient here who says they can't get any of it in 
community”. You know, just pharmacy related queries more so than 
advice particularly. 
Patti [9.337] 
 
…they [nurse specialists] do see me as a port of call when they've got 
queries with medication and shortages, and you know, where to get hold 
of unlicensed [drug] products and things like that. 
Natalie [5.124] 
 
Through coming to the pharmacist, the nurses make an identification of the 
pharmacist as the drug supplier and somebody who can resolve issues with the 
supply of drugs. 
6.2.3.3 Delegating the drug supply role to pharmacy technicians 
 
Some pharmacists discussed and acknowledged the role of ward-based 
pharmacy technicians, sometimes referred to as medicines management 
technicians (MMTs), to supply drugs. Three pharmacists explicitly described 
working alongside a MMT; In Polly’s Trust, the MMTs now undertake the 
processes of co-ordinating the preparation of drugs for patient discharges. 
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In Lauren’s practice, traditional supply roles have been delegated to her 
medicines management technician colleague. Clinical staff within the 
neuroscience unit can distinguish between the role of the pharmacist, as the 
clinical practitioner, and the technician by approaching the latter for the supply 
of a drug.  
Yes because now we've got more people [pharmacy staff] around more, 
our drug charts, I don't think they ever go to pharmacy during working 
hours and they [ward staff] know who our medicines management 
technician is [to go to] if it's a simple supply issue. 
Lauren [11.391] 
 
The provision of medicines management technicians to work alongside the 
neuroscience pharmacists is variable amongst neuroscience units. While some 
pharmacists like Lauren work alongside dedicated technicians, Patti shares the 
MMT she works alongside with other wards in the hospital.  
I have a medicines management technician. He spends some of his day 
on the [neurology] ward. He is responsible for three wards in total. He’s 
spread rather thinly (laughs). 
Patti [9.17] 
  
Michael and Sophie do not work alongside MMTs in their Trusts. They both, 
unprompted, declared this information within their interviews. Michael identifies 
the potential advantages of MMTs to free up pharmacist time and assist in 
patient discharge. Sophie’s description of her ward-based activities places 
emphasis on doing “all the ward work”, which involves the ordering of drugs and 
an acknowledgement that those functions of the role could and perhaps should 
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be undertaken by a MMT to release time for the pharmacist to undertake other 
roles. 
…we don't have any ward-based technicians here so all the ward work is 
done by pharmacists. So it involves everything. So you go to the ward…   
And then ordering medication so just like inpatient ordering sheets, doing 
TTA's [to take away (discharge) prescriptions], checking discharge 
prescriptions... 
Sophie [14.177] 
Pharmacists are able to make a distinction for the drug supply role that can be 
undertaken by MMTs. MMTs are not a ubiquitous presence within pharmacy 
teams in neuroscience services however their presence can shift the focus of 
the drug supply role away from the pharmacist. 
6.2.4 Summary 
 
Within the clinical specialism of neuroscience the heritage of the pharmacy 
profession, as the suppliers of drugs, still permeates through the contemporary 
perception of the pharmacist from members of the neuroscience clinical teams. 
In the main, pharmacists do not explicitly identify their role with supplying drugs. 
The perceptions of pharmacists held by their multidisciplinary colleagues, 
notably nurses, aid in the construction of the drug supply role of the pharmacist. 
The identity of the pharmacist as the drug supplier can be diminished where 
pharmacists have the support of medicines management technicians to 
relinquish the traditional drug supply functions.  However the mechanisms of 
medicines management within hospitals posit the pharmacist as the conduit to 
drug access for the neuroscience services, through their ability to clinically 
check prescriptions and authorise supplies of drugs. 
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The next section presents the analytical processes, aside of their clinical 
assessment (cf. 5.6.2, p.129), the pharmacists apply in their routine daily 
activities of assessing drug therapies.  
 
6.3 Identifying gatekeeping issues 
From the data analysis, there are three processes through which the 
pharmacists identify gatekeeping issues in clinical practice; these are presented 
in Figure 9. More than one gatekeeping issue may arise from the use of a drug.  
 
 
Figure 9. Processes in clinical practice for identifying drug gatekeeping issues. 
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This section explicates the individual gatekeeping processes, through the 
pharmacists’ interpretation of clinical practice.  
6.3.1 Policing the formulary 
 
Pharmacists identify how they regulate or are perceived to regulate prescribing 
access to drug therapies by policing the formulary. The purpose of a hospital or 
NHS Trust formulary is outlined in Table 1 (p.11). To provide a brief re-
orientation, a drug formulary is a list of drugs and drug products which may be 
prescribed within an organisation, and a mechanism to control the prescribing of 
drugs. 
The concept of the formulary operates for specialised and expensive drug 
therapies at a macro (national) level through the remit of NICE technology 
appraisals (cf. 1.5.2.1, p.17), and NHS commissioning policies (cf. 6.2.2) 
authorising drugs to be used within the NHS. These policies may also dictate in 
what specific clinical circumstances the drugs may be used.   
Policing the formulary is an in vivo code for the action of how pharmacists seek 
to maintain adherence to the rules of drug use dictated by hospital formularies 
or national guidelines. The initial code of ‘policemen of the formulary’ arose from 
the interview with Belinda when we were discussing her relationship with 
medical consultants. 
Some of them [consultants] do tend to be a bit old-fashioned in their 
ideas but not just about whether pharmacy can help them clinically but 
also regarding you know, pharmacist being the policeman of the 
formulary, and I've had like comments… 
Is that how you've been described then?  
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Well not so much they've never described me like that but that's certainly 
how I feel. I have had consultants say “tell your director of pharmacy” 
and then something about a budgetary thing.  
Belinda [3.61] 
 
Policing serves as a useful metaphorical analogy to the action of pharmacists 
regulating access to drug therapies. The rest of this section sets out the 
processes of policing the formulary.  
6.3.1.1 Adhering to organisational rules for drug usage  
 
Pharmacists describe having to work through organisational rules to help 
clinicians gain access to the use certain drugs. Commissioning or organisational 
policies may stipulate extra requirements in order to access drug therapies. In 
the analogy to gatekeeping these rules create barriers to accessing drug 
treatments that can require implementation of changes in practice. 
Ten of the fourteen pharmacists cited their involvement in the provision of IVIg 
therapy. This treatment was not an included topic in any of the interview 
question guides. IVIg is a high-cost treatment used to treat a wide range of 
conditions in different medical specialities but, specifically within neurology, for 
a number of relatively rare auto-immune diseases. There is a national 
commissioning policy for the use of IVIg which requires submission of clinical 
data around each treatment use (Department of Health, 2008a). A common 
challenge in professional practice is ensuring neurology services comply with 
the requirements of the commissioning policy. 
….with regards to the [national IVIg] database, the processes that we 
had within the Trust, they weren't tight enough basically. So it's a case of 
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getting all the consultants on board the fact that this database is 
[emphasised] going to be filled in; we’re not going to miss data off. 
Megan [12.56] 
 
At a more local level, Belinda describes setting up a new system for supplying 
botulinum toxin (Botox®) to a neurology clinic that captured details of all the 
patients that receive treatment. She identifies an external driver, a change in the 
level of information required by commissioners, the body that ultimately pays for 
the drug and clinical service, as the need for this system change. 
Sort of one of my pieces of work is regarding Botox and the sort of 
ordering of supplies…  
…But, with obviously commissioning sort of changing and it's all a bit 
unknown we felt that a point was gonna [sic] come where the CCGs were 
going to be asking for proper patient details as to who’d had it, because 
of the [high cost] spend on it. 
Belinda [9.121] 
 
Sally is also dealing with an organisational requirement for the use of botulinum 
toxin, where a policy change within her Trust has also stipulated extra recording 
requirements (in a register) for its use. 
… botulinum toxin is one of my issues where I do have a (slight pause) 
not a disagreement with the consultant. So for example, we have a policy 
in our Trust where botulinum toxin is managed as a controlled drug… 
…our neurology consultant [who] uses it for spasticity flatly refuses to do 
that. 
Sally [13.409] 
Pharmacists encounter a range of organisational rules for drugs to be used. 
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6.3.1.2 Undertaking surveillance of prescribing  
 
Eight of the fourteen pharmacists identified at the outset of the interview, from 
the opening question of describing their role, that they were involved in 
monitoring and reporting on the usage of drugs within the neuroscience clinical 
service. I interpret the early mention of monitoring drug usage within the 
interviews to assign some prominence of this activity to those pharmacists 
within their individual roles.  
The requirement to monitor and report on the usage of drugs can be set by the 
pharmacy department. Several of the pharmacists describe how within their 
Trust, monitoring of drug expenditure and usage to be compliant with the 
formulary is an established aspect of the directorate pharmacist role.  
 
We’ve [pharmacy have] always been quite proactive within the Trust 
about the formulary and sticking to formulary choices and things. 
Belinda [3.92] 
 
We [pharmacy] look at their usage reports in terms of the kind of 
prescribing they're doing through outpatients and we pick up any 
anomalies or strange prescribing habits. 
Sally [13.28] 
 
You mentioned financial reports, was one of the things that you do. 
What things are you doing there? 
Well that's a bit driven from within the pharmacy department. We have 
historically always produced directorate reports. So we look at [drug] 
spend, the top 50 [most expensive drugs] spend for each quarter…  
Patti [9.166] 
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The surveillance role, monitoring the usage and expenditure of drugs, can 
permeate everyday perceptions of practice. An example is Sally who makes a 
favourable assessment of the neurologists she works with, by the criterion of 
their compliance with prescribing drugs within the Trust formulary. 
And we also write twice yearly annual reports for them [neurology 
directorate], which is picking up their prescribing, issues we might have 
picked up on. They're pretty good though in neurology, they pretty much 
stick to the formulary. 
Sally [13.35] 
 
An exploration with Laura of everyday working on the ward identifies how she is 
cognisant of the formulary as she undertakes her review of prescription charts, 
identifying drug prescribing not within the formulary. 
… do you think you can sort of talk me through what that entails in 
terms of when you are on the ward what you are actually doing? 
Okay. I am attending ward rounds. I review every prescription on a daily 
basis. I look at formulary issues… 
Laura [6.39] 
 
6.3.2 Being the accountant 
 
There is a widespread acknowledgement amongst the pharmacists of the 
financial pressures the NHS is currently facing and the pressures that creates in 
practice to contain drug expenditure. 
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6.3.2.1 Being the reluctant accountant 
 
There is a general resigned acceptance amongst the pharmacists that financial 
gatekeeping, monitoring and regulating drug prescribing on the basis of cost, is 
part of their professional role.  
So you're sitting in a meeting, they [managers] want to balance their 
books but as far as you're concerned everything is spent appropriately so 
that can be a bit frustrating thinking, if I want to be an accountant 
(laughs), but I chose to be a pharmacist. But I think it's kind of something 
that comes with the role. 
Lauren [11.442] 
 
Lisa similarly identifies the need to consider the financial implications of drug 
usage as a fact of professional life. 
You can't get away from funding unfortunately. Much as you would like it 
always be about is it [clinically] effective, you can't ignore the cost issue 
where the money is going to come from. 
Lisa [7.621] 
 
Kate identifies financial processes as a means to an end in securing access to 
drug therapy. 
I guess yes I prefer the kind of clinical hands-on and stuff and some of 
the other stuff yeah can be a bit… the finance stuff and the kind of trying 
to get things through ridiculous committees sometimes can be a bit 
frustrating but I guess it all needs to be done. 
Kate [2.157] 
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Like Lauren, Patti is also frustrated by a perceived incessant need to save 
money but also identifies this function as an intrinsic element of the 
pharmacist’s role. 
What do you feel about the financial aspect of saving money in 
terms of your role? 
I understand that that's a big portion of why we’re here doing the job, to 
find, to make sure it's cost-effective prescribing. But I think that it's almost 
been done to death. It's been going on for years, trying to come up with 
money-saving initiatives that really aren’t there anymore. The ones that 
were there, we've done and tackled. There aren't, as far as I can see, 
there's not much left, anything left to do. 
Patti [9.202] 
 
6.3.2.2 Acknowledging the need to spend money wisely 
 
Both Belinda and Natalie’s observation of cost being more of a historical issue 
alludes to a time when consultants experienced more freedom in their 
prescribing of drug therapies. Natalie identifies a change in the prevailing 
culture of her neurology service, and a wider acknowledgement, outside of 
pharmacy, of the current requirement to find financial savings within the NHS. 
This change in attitudes has helped to relieve the tension in financially 
gatekeeping access to drug therapies. 
Is there ever any tension when you talk about financial things to 
clinicians, problems there? 
I suppose not in the last year or two because I think everybody 
understands the reasons why costs are… you know in today's day and 
age that everything is financially based at the moment.  Maybe three or 
four years ago probably people were a bit "oh you only want this because 
it's the cheapest one" or whatever.  
So I think people (sigh and pause), I think everybody is on the same 
wavelength at the moment because everybody knows there are cost 
savings that need to be made… 
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…it's not just pharmacy being funny sort of thing you know it's a bit of a 
wider problem now (laughs). 
Natalie [5.291] 
 
In contrast, Belinda’s experience with the medical staff she works alongside is 
that they do not fully understand the implications of the current financial 
situation on their ability to prescribe drugs without financial consideration. 
They don't seem to have grasped necessarily the way that the NHS is 
going. Do you know what I mean?  They seem to think that pharmacy, 
we have a pharmacy [drug] budget and we don't. We have a directorate 
budget. It’s their budget, we don’t have money for drugs that we only let 
them have a bit of but they still seem to think that. 
Belinda [3.68] 
 
Laura similarly recognises that the clinicians she works with do not necessarily 
identify or acknowledge the prevailing financial climate. She provides an 
admonition that the current financial climate within the NHS requires judicious 
use of drugs.  
I get very angry with CCG's and NHS England but on the other hand I 
think people here need to wake up to reality. There isn't enough money 
around for everybody so we need to choose wisely. 
Laura [6.554] 
 
Laura identifies how one of the aspects of her role is to explain to medical staff 
the concept of a formulary and that there is not complete autonomy within the 
NHS to prescribe any drug that they deem clinically appropriate for their 
patients. 
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[some consultants] don't quite understand how the NHS works so we 
sometimes actually have to educate people on that. Consultants who 
prescribe something and have no concept of a formulary at all… 
Laura [6.206] 
 
There is a widespread acknowledgement amongst the pharmacists that the 
need to save money on the expenditure of drugs, and provide evidence of doing 
so, is a de facto professional activity. This requirement to save money is not 
identified to be a new aspect of the pharmacist role. Through the pharmacists’ 
acknowledgement of the financial climate within the NHS and their involvement 
with a number of high-cost drug therapies they assume a certain prominence to 
financial gatekeeping within the role.  
The extent to which the current financial pressures facing the NHS are more 
widely identified and acknowledged by other clinicians is variably perceived. 
Where there is wider acknowledgement of the financial pressures of the NHS, 
financial gatekeeping by pharmacists can be more acceptably received.   
6.3.3 Being the safety net for drugs 
 
A recurring theme through the data is a doctrine within practice of ensuring that 
drug therapy is safe, and used safely. Several of the pharmacists identify how 
ensuring safety around drug usage is a perceived key characteristic of the 
pharmacist role within neurological clinical services.   
I think they’re [clinical members if the neurology team] aware that I'm 
there as a safety check for the prescription, so I hope that they have 
confidence that I’m doing a good job there. 
Belinda [9.217] 
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…but the most important factor for them [senior clinical staff] is our 
involvement in discharge and ensuring medicines safety on the ward. 
Beth [4.179] 
 
There are two ways that pharmacists identify safety issues around the use of 
drugs.  
6.3.3.1 Ensuring the drug is safe 
 
Section 5.6 (p.128) identified how the default position for pharmacists, in their 
interpretation of treatment strategies and clinical reasoning, is to ensure that 
drug therapy does no harm to patients (see Figure 7, p.130). The notion of safe 
is free from the risk of adverse effects and the neuroscience pharmacists 
actualise safe as doing no harm. 
6.3.3.2 Ensuring procedures for drug use are safe  
 
The pharmacists identify that in supplying drugs they have a responsibility to 
ensure the drugs are used safely. 
We do a lot of work with theatres the gliolans and gliadels, intrathecal 
pumps and things like that. Making sure they [neurosurgeons] get what 
they need, and they’re safe down there. 
Kate [2.65] 
 
Megan similarly has concerns about the safe use of intrathecal drugs that are 
supplied to a clinic. 
It's [the use of intrathecal drugs] just an untapped area [from pharmacy] 
and we just want to be a bit more informed. It might be perfect but 
(laughs) we need to be safe in the knowledge that these drugs we’re just 
churning out on a monthly basis are being utilised safely. 
Megan [12.356] 
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6.3.4 Summary 
 
Pharmacists consider a range of factors when assessing the appropriateness of 
drug therapies for patients with neurological diseases. These considerations, 
which guide daily practice, are inbuilt into their constructed professional identity 
of the pharmacist within neuroscience services. The identity of the pharmacists 
is further discussed in section 7.3.2 (p.183). The next section describes the 
processes of analysing gatekeeping situations. 
 
6.4 Analysing the implications of gatekeeping 
Section 6.3 identifies that neuroscience pharmacists consider a heterogeneous 
mix of issues that regulate access to drug use. These considerations take place 
with individual clinical cases, as well as for more widespread service 
implications for drug use.  Having identified a gatekeeping issue with the 
intended use of a drug, the pharmacists are required to make a decision of how 
to proceed with one of several outcomes: 
 Proposed drug use is acceptable and may proceed. 
 Proposed drug use is not acceptable and needs to be challenged. 
Where a gatekeeping issue arises in respect of a formulary or cost issue, the 
pharmacists do not necessarily have the autonomy within their organisation to 
authorise treatment. In these cases resolution often proceeds through 
mechanisms such as individual funding requests or applications to formulary 
committees, as set out in section 6.2.2. Some pharmacists in more senior posts 
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are afforded a greater degree of autonomy within their role to make 
deliberations on authorising drug use. 
Gatekeeping situations which require greater involvement from the pharmacists 
arise from the non-routine clinical use of a drug, requiring a judgement about its 
therapeutic appropriateness, or ensuring local compliance of drug use with 
organisational or national policies. Two factors were identified that influence the 
pharmacists’ analytical process and are subsequently discussed. 
 Understanding local and individual needs.  
 Clinical experience in neuroscience.  
6.4.1 Understanding local and individual needs   
 
Neuroscience pharmacists can experience a tension in these gatekeeping 
situations because they are aware of policies and guidelines but can also have 
insight into individual clinical cases or the running of local services. As a 
consequence the pharmacists have an appreciation of the impact gatekeeping 
decisions can have. They can be sympathetic to the local and individual needs. 
Section 6.3.1.2 highlighted an issue within Sally’s practice of extra recording 
requirements for a drug and a neurologist’s refusal to do that. Sally has 
empathy and sympathy to the recalcitrance of the neurologist because she 
understands the implications for his practice. Consequently she has not forced 
the required changes in practice and is seeking a compromise. 
But I partly don't agree with what’s being proposed from the governance 
side of things so I'm a bit stuck really. I’m kind of more on the [laughs] 
neurologist’s side than the governance side…  
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…I understand exactly where he's coming from and I can see the 
difficulties that he has. The amount of recording that they’re asking him 
to do in addition to the routine recording that he has to do anyway as part 
of seeing the patient. 
Sally [13.416] 
 
Belinda was involved in gatekeeping access to IVIg for a patient who did not 
meet the national criteria for its use. She has empathy to the patient concerned 
but ultimately acknowledges the need to comply with national policy. 
…you kind of feel a bit torn really because if it was your relative you 
would want them to have the treatment wouldn’t you, straightaway. But 
you kind of have to step back from that and you know that’s the policy, 
that's what we have to follow. 
Belinda [9.422] 
 
6.4.2 Clinical experience in neuroscience 
 
When encountered with a previously unmet proposed drug treatment that they 
are unfamiliar with and does not fit within any recognised guidelines, 
pharmacists will intuitively seek empirical evidence to make an assessment of 
the potential benefits and risks for the patient. 
…you just have to weigh up effectiveness and cost and potential side 
effects and all that kind of thing. 
Lisa [7.588] 
 
Experiential and situational knowledge are important in supporting decision 
making and the pharmacists approach to these situations mirrors the clinical 
reasoning set out in Figure 7 (p.130). 
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Gathering evidence for drug use provides reassurance for the pharmacists. 
When evidence for drug use is not available the pharmacists can feel anxiety. 
Billy describes neurology as often being ‘at the cutting edge’, qualifying that 
statement through a recognition of working without established guidelines. Billy 
recalls feelings of anxiety when being involved in treatments with little evidence 
base behind their use. 
… you do get the flashbacks when you’re sat at home or watching the TV 
and you suddenly think oh my word what are we doing here? 
Billy [8.319] 
 
Similarly Polly recollects feelings of anxiety and vulnerability from her 
involvement in clinical cases where treatments with a limited evidence base 
have been provided. Those feelings appear to emanate from a perceived 
involvement with, but lack of control, over a treatment decision.   
They [neurologists] would have a few random papers but not really huge 
amounts of evidence. So it's sort of, like critiquing those papers as well 
and looking at it. But sometimes they wouldn’t give you huge amounts of 
information or huge confidence or it might be that it has worked in some 
patients or anecdotal information-some Professor somewhere had tried 
something and they thought they would give it a go as well. So at that 
point it seemed to be not very controlled. It made me feel quite 
vulnerable, being involved in that process too. 
In what respect? 
Professionally-knowing that you will be involved within a process that 
you're not entirely sure that its meeting standard of care for the patient 
really. 
Polly [10.240] 
 
Through the acquisition of theoretical and experiential knowledge in clinical 
practice, and as they learn about neurological disease, pharmacists start to 
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reconcile limited evidence bases for drug treatments with the rarity of the 
conditions being treated.  They also have a greater knowledge of the treatment 
alternatives, or lack of them, and consider the implications for the patient of not 
providing the treatment. 
Lisa, who is relatively more experienced in neuroscience, has learnt to become 
more comfortable with a less robust evidence base for proposed drug 
treatments. She is more sanguine in dealing with drug therapies supported by a 
limited evidence base, although she does still look to locate evidence to support 
the use of a treatment. She acknowledges a need for the patient to be treated in 
the absence of other suitably tested treatments. 
Because sometimes there are just things [proposed drug treatments] that 
we’ll say no to straight off because the evidence just isn't good enough, 
or we don't think the cost effectiveness is right, or it's just not safe or 
something. 
Right so is the evidence one of the primary things for assessing it? 
Yeah. Certainly I’d want to see something that endorses the use of it. I 
think sometimes with neurology it’s literally just a case study, you know a 
series of case studies published and not much more than that, 
particularly if it's a fairly rare disease. So again I think you kind of get 
used to that sort of thing.  
The first time I saw one I thought ‘there doesn’t seem to be much 
evidence base for this at all’. But you get a bit more used to the fact that 
some of the diseases are very rare and there isn't anything else out 
there, and where there isn’t a lot of evidence, and you have to accept 
sometimes that it might not be unreasonable to use something that's got 
poor quality evidence because at least it’s something to try. 
Lisa [7.575] 
  
Sophie is also an experienced pharmacist in neurology. Like Lisa, Sophie 
acknowledges a lingering professional tension with clinical cases where there is 
a paucity of evidence to guide therapeutic decision making. But again, like Lisa, 
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Sophie can reconcile limited evidence for use of a drug with the limited 
treatment options available, and by adopting an honest and transparent 
acknowledgement of that situation. 
And as a pharmacist how does that feel to be in a position where, 
sort of, it's a bit of the unknown isn't it? 
I think you have to be upfront about it and say to somebody if you don't 
know you don't know and say the data isn’t there. There’s no clinical, like 
trial data or whatever but these are the options really, and these are the 
risks and benefits of… Well it's not an easy thing to do at all but I think 
you have to be upfront about it. 
Sophie [14.611] 
 
The ability of the pharmacist to locate evidence is identified by the medical 
neurology staff and where that recognition takes place it can lead to the 
pharmacist being proactively approached to assist in implementing a new drug 
therapy. 
They [consultants] will find out that they want to use a new drug in a 
particular way, or an unlicensed version and they want more evidence, or 
want us to do some research, how can they get that drug to the patient, 
sort of support with drug and therapeutics etc. 
 Billy [8.122] 
 
 
6.5 Resolving gatekeeping issues in drug therapy 
If after analysis of the situation, the initially identified gatekeeping issue is not 
upheld the pharmacist may decide that the drug can be supplied and authorise 
its supply. Where after analysis of the situation the gatekeeping issue is upheld 
the pharmacist will work to resolve the issue. The outcomes of resolving 
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gatekeeping issues are that the treatment is not authorised or the prescriber is 
directed to another route to gain permission for drug use.  
6.5.1 Engaging the clinical team 
 
Pharmacists employ varying strategies to engage with the clinical teams to 
resolve gatekeeping issues in drug therapy. The approaches identified within 
the interview data are listed below. 
 Leaving notes (post its) on the drug chart. 
 Writing in the medical notes. 
 Approaching the medical team directly in person. 
 Bleeping (telephone paging) a member of the clinical team. 
 Liaising with third parties e.g. microbiologists, senior clinicians, 
management staff. 
Approaches undertaken by the pharmacists depend on the perceived urgency 
and complexity of the drug issue to resolve. Other factors include the time that 
the pharmacist has to spend on the ward, accessibility of the medical teams, 
and the normal cultural and working practices within the clinical environments. 
Lisa recognises the need for a balance between resolving issues and 
overburdening medical staff. 
I mean sometimes if it's a TTO then it might not be the most important 
thing in the world but if the patients out there waiting to go then you need 
to sort it sooner rather than later. So again we struggle with bleep 
policies here about not disturbing doctors too much over unimportant 
things but you've just got to have the balance haven’t you and make sure 
the patients coming out all right at the end of it. 
Lisa [7.212] 
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Pharmacists tend not to challenge prescribing decisions with medical staff. They 
take a less confrontational approach of questioning the reasons for prescribing 
decisions as illustrated by Sally. This stance is also taken because the 
pharmacists do not necessarily identify a black and white answer to the 
situation. 
I think if I came across something that I thought was incorrect or 
inappropriate. So like actually, thinking about teriflunomide, I did 
challenge him, not challenge him. He was pretty much saying that 
everybody who was appropriate, new presentation relapsing remitting 
MS, he was going to pretty much move towards teriflunomide and I just 
questioned that a little bit with him because of all the monitoring and 
queries that go with it… 
Sally [13.244] 
 
The organisational culture within neuroscience services can also affect the way 
in which pharmacists approach medical staff over an issue of drug prescribing, 
as illustrated by Megan.  
And I come from an environment [previous job]… where I used to just 
(laughs) boss them [medical staff] about with the drug chart, you know 
you'd be able to be candid and say, that's stupid don't do that, do this. 
Over here (with emphasis), if you did that, you would not go down well. 
Megan [12.180] 
 
6.5.1.1 Escalating through the medical team and service teams 
 
Pharmacists recognise within the medical teams a hierarchy of clinical decision 
making. Prescribing decisions in relation to the treatment of neurological illness 
are taken at a senior level, usually by a registrar or consultant, within the 
medical team. The pharmacists also identify that for complex specialist cases, 
junior medical staff do not possess sufficient comprehension of the issue being 
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raised. Consequently the pharmacists veer towards interacting more directly 
with senior medical staff over a drug prescribing issue. This process is 
exemplified by Polly’s recollection of practice. 
But the registrar would be on the ward, like senior registrars would be on 
the ward quite a lot. So they were the people that we ended up actually 
having discussions with because the juniors… It wasn’t like F1 
[foundation doctors] equivalents, so they were all SHO's or junior 
registrars. But it was the senior registrars we ended up talking to directly 
because the juniors would always say I don't know I need to speak to my 
senior. So we almost ended up bypassing them. 
Polly [10.103] 
 
Similarly, Billy will bypass the junior members of the medical team if he 
perceives an unsatisfactory recognition and response from them in relation to 
his intervention. 
…if the staff on the ward, the medical staff, are unaware or not much of a 
help with that, then I've always gone direct to the consultant, either 
ringing them through switchboard or whatever. 
Billy [8.195] 
 
Sophie identifies that often trying to resolve clinical issues through the junior 
medical staff as in effect, third parties, is often unsatisfactory. Direct 
communication with consultants enables her to communicate the exact issue 
and results in a more receptive response. 
…normally when you end up speaking to the consultants yourself they’re 
usually a lot more reasonable if you have a valid point to put forward. 
Whereas I think if you try to approach it through the junior doctor, if 
you're not going to be there on the [ward] round, your message never 
really gets across. You’re always told “Oh that's what they [the 
consultant] wanted to do” (spoken with slight exasperation). 
Sophie [14.237]  
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In her response above, Sophie acknowledges the ward round and the 
challenges of retrospectively challenging prescribing decisions. Billy recognises 
that participation in ward rounds enables him to influence prescribing decisions 
at the point of them being made. 
…do you feel they’re [ward rounds are] important to be on them as 
a pharmacist? 
Yep. 
Can you expand on that? 
To be there at the point of prescribing certainly…  
…So you can influence… 
…And also you’re able to sort of reason, to discuss why, with the person 
[prescriber] there. 
Billy [8.175]   
 
Where there are recurrent issues in relation to a drug, or an issue that has more 
widespread implications, pharmacists can identify limitations in their ability to 
influence these processes. In these situations, a number of pharmacists 
described escalating to senior clinical and managerial staff within the 
neuroscience services to resolve issues.  
Megan escalated the national requirements for IVIg use to senior managers to 
get compliance from the medical staff. 
So we discussed it at that meeting and it's reached the point where we 
escalated it to be honest to the divisional managers; as soon as the cost 
implications were discussed… 
Megan [12.74] 
 
169 
 
Kate has a very good professional relationship with a senior consultant; their 
involvement exerts the required influence to ensure comply with the necessary 
requirements for drug use.     
If your lead consultant will have a go at them [registrars] every time it 
goes wrong it soon gets sorted out quite quickly. 
Kate [2.118] 
 
6.5.1.2 Delineating the boundaries of clinical responsibility 
 
As gatekeeping emerged as a theoretical concept within the study I sought to 
explore the parameters of the pharmacists control over these processes. I 
asked the pharmacists about situations where there had been a difference of 
opinion over a therapeutic decision or if they had ever refused to supply or 
authorise the supply of a drug. Most pharmacists could not readily identify 
situations where that had occurred. Issues relating to drug formularies are 
usually dealt with through the relevant organisational mechanisms as already 
described in section 6.4.  
Where gatekeeping issues arise in relation to the use of a drug that require 
more of a clinical judgement, pharmacists often describe acquiescing to the 
prescribing wishes of the medical team. The proviso to this course of action is 
that the patients will not come to any real harm. Underpinning this action is the 
perception that the clinical responsibility for the care of the patient ultimately lies 
with the medical team caring for the patient. 
If it's [therapeutic issue is] something where it’s a bit more, maybe a 
matter of opinion, or, you know, we don't think the most rational thing to 
do but it's not going to do the patient too much harm or hopefully any 
harm. In the end you sometimes have to accept that it's their patient… 
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…And if we're happy it wasn’t completely unsafe what they were doing 
we would probably leave it at that. 
Lisa [7.237] 
 
Other pharmacists identified how they could advise on drug therapies but the 
therapeutic decision was ultimately taken by the medical staff. However the 
pharmacists will document discussions or recommendations with the medical 
teams. This action infers that although pharmacists identify the ultimate clinical 
responsibility to be with the medical team, it does not absolve their 
accountability as healthcare professionals. 
And in terms of getting them [antibiotics] stopped then, who steps 
in to speak to the neurosurgeons? Is it a joint thing? 
It is a joint thing. We both write in the notes… So the nurses then alert 
the doctors that this has been stopped and what they're supposed to do 
is to check if they want to continue or need to continue, or stop it 
completely. 
Okay. But ultimately it's the surgeons decision? 
Yeah [it’s] the surgeons decision. If microbiology does not agree with 
certain antibiotic treatments all they do is write in the notes… There is 
the occasional disagreement where surgeons want to proceed and 
there's nothing to stop them. So (pause), you document everything in the 
notes. 
Laura [6.127] 
 
 
… [if] you notice a prescribing or drug issue how do those get 
resolved normally on the ward? 
Depending on the severity-you know if it was a serious one I’d go to one 
at the registrars, try and work out which registrar was responsible for that 
patient you know which consultant they were under. I'd go and speak to 
them directly about it, or at least get their opinion on why they have done 
what they've done, and give my opinion on why I don't agree with it. 
And what happens then? 
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If it was a mistake they will correct it. If they're adamant that that’s what 
they want then I would probably endorse on the prescription that I've 
confirmed those, or whatever it may be, with the prescriber and then 
document that. 
Belinda [9.264] 
 
6.5.2 Expediting drug supplies 
 
As a result of working on hospital wards and closely with clinical teams the 
pharmacist develops a perceptible understanding of the importance of timely 
drug supply for the benefit of the patients and for the operational running of 
clinical services.  
6.5.2.1 Ensuring the patient gets the drug 
 
When working on neurology wards Lisa analyses the administration section of 
drug charts to ensure that drugs have been administered to patients. She 
identifies specifically patients with Parkinson’s disease and myasthenia gravis: 
the drug therapies for these conditions largely provide symptomatic relief and 
treatment regimens can be individualised. The omission of drug dose doses in 
Parkinson’s disease and myasthenia gravis can be uncomfortable and 
distressing for patients with potentially significant medical consequences. 
Some of the things [activities she undertakes on the ward] are very 
specific neuro wise-things like Parkinson's [disease] and myasthenia 
[gravis] - trying to make sure that things are prescribed at the right time, 
people aren't missing doses and keeping an eye out generally about 
missed doses. 
Lisa [7.198] 
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6.5.2.2 Being the discharge pioneer  
 
A common theme that arose from discussions of daily ward practice was the 
increasing turnover of patients in hospital wards. There was a perceptible 
emphasis on prioritising patient discharge. Beth perceives that the nurses she 
works alongside on a neurosurgical ward view pharmacists as ‘discharge 
pioneers’, a reference to facilitating patient discharges through the timely supply 
of drugs. Her practice appears to conform to the nurses’ viewpoint through her 
attempts to pre-emptively order drugs for patients in lieu of their expected 
discharge. 
… then that particular ward is quite high turnover as you can imagine so 
my priority then is to do the discharges. So, I don't know if you do in your 
Trust but we do drug lists here so we try and pre-empt and transcribe 
medicines onto the discharge letter and get them dispensed in order to 
speed up discharge before the doctor then adds their bit on and check 
the prescription that nothing else needs to be added. 
Beth [4.32] 
 
Similarly when discussing with ward-based nurses, Natalie identifies a 
perception that pharmacists need to be able to facilitate timely patient discharge 
and that the pressure to do so is becoming more pronounced due to a reduction 
in the average length of an inpatient admission to hospital. Like Beth, Natalie 
describes her practice at ward level focusing on patient discharge through 
timely supply of drugs and thus also conforming to the status of the discharge 
pioneer. Through working on the wards Natalie identifies a tangible pressure 
that the discharge process creates for her nursing colleagues and how her role 
in facilitating the timely supply of drugs helps to relieve that pressure. 
[Working] at ward level obviously [with] the nursing staff, just making sure 
that the medication is there ready to give them in the right form and the 
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right dosage…  Facilitating discharges really-just helping with them, 
making sure we can ease their pressure and getting the patients out in a 
timely manner (laughs). 
So at a ward level then how do you think your role is perceived by 
the other staff on the ward? 
Errm… (pause) I think it's still mainly they perceive you there to just 
make sure that the tablets are there with the patient ready for them to go 
[be discharged from the ward] (laughs). 
Natalie [5.152] 
 
Through working on the neuroscience wards the pharmacists develop an 
appreciation of the importance of the importance of timely drug supply. They 
identify this importance through the adverse clinical consequences of drug dose 
omissions and the pressure on their professional colleagues, notably nurses. 
Within standard models of medicines management in hospitals pharmacists 
permit the dispensing of medicines through the authorisation or clinical checking 
of prescriptions and medicine charts. In working in a ward environment the 
pharmacists attain a tangible appreciation of the benefit medicine supply has at 
a ward level for the clinical benefit of patients and the running of the ward. 
Pharmacists working at a ward level see their supply role to allow access to 
drugs working through the barriers to accessing drugs through the hospital’s 
medicines management processes and where necessary expediting that 
process. 
 
6.6 Chapter summary 
Gatekeeping is a prominent process, regulating access to drug therapies, within 
clinical pharmacy practice in neuroscience. Within NHS hospitals, the pharmacy 
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department remains the major repository for drugs, and pharmacists remain 
direct employees of the pharmacy department. Although the pharmacists 
distance themselves from, or do not readily identify themselves with, the 
traditional dispensing role of the pharmacy profession, they remain custodians 
to drugs. 
Pharmacists regulate access to drug therapy not by the traditional means of 
dispensing prescriptions, but through their analysis of patients’ drug regimes. 
The provision of a clinical check by the pharmacist authorises drug supply to 
occur.  
Gatekeeping assumes a certain prominence in neuroscience pharmacy practice 
because of the use of specialist drugs, or unconventional use of drugs, which 
may also be expensive.  For neurological disease, specialist drug therapies are 
increasingly provided through third party homecare providers. Neuroscience 
pharmacists also describe their increasing involvement in the regulation of this 
supply route for drug therapy. 
Aside from the clinical analysis of patients’ drug therapies (cf. 5.6, p.128), 
neuroscience pharmacists undertake assessment for compliance with 
organisational policies around drug use, and issues of cost and safety. These 
gatekeeping processes can form the basis of interaction between the 
pharmacist and the clinical teams in neuroscience. Where pharmacists are less 
integrated into the neuroscience services and not providing regular clinical input 
into patient care, interactions over gatekeeping issues lead to more prominent 
identities of the pharmacist ‘policing the formulary’, ‘being the accountant’ and 
‘being the safety net’.  
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Pharmacists can experience tension when situated within gatekeeping 
processes. They are cognisant of their professional and organisational 
obligations to ensure drug use fits within organisational frameworks. Yet at 
times, pharmacists can identify a genuine patient need for drug therapy, despite 
the intended drug use falling outside of the parameters of normal practice and 
rules.  
Pharmacists practicing at a ward level have a tangible appreciation of the 
benefits of timely drug supply, both for patient benefit and for the operational 
running of ward areas.  They describe a current pressure to rapidly admit and 
discharge patients, and identify a contribution to the operational efficiency of 
clinical services by facilitating the timely supply of drugs for patient discharges. 
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7 Integrating into the neuroscience service 
 
7.1 Introduction 
This chapter presents the process abstracted from the data of how pharmacists 
integrate into the clinical neuroscience service. Neuroscience pharmacists, as 
hospital based clinicians and often working within large clinical services, do not 
practice in isolation from other healthcare professionals. Aside from working 
with other clinical practitioners within neuroscience services, the pharmacists 
also work with other non-clinical i.e. non ward-based groups of staff. 
Pharmacists’ professional task of facilitating the optimization of safe and 
effective drug therapy for neurological disease, within organisational policies 
and constraints, is contingent upon the co-ordinated involvement of a range of 
professional groups, organisations, and patients. To achieve the commonly 
described goals of safe and effective drug therapy for neurological disease, 
pharmacists identify a requirement to form working relationships and integrate 
into the neuroscience service. This process was succinctly described by Billy. 
Well I would describe it [the role] as lead for pharmacy services 
integrating within the clinical and multidisciplinary teams first of all… 
Billy [8.6] 
  
This chapter illuminates the processes of pharmacist integration into the 
neuroscience service, the conditions that are necessary to bring about these 
processes and the value of integration to the pharmacists in their practice. The 
chapter begins by describing the pharmacists’ organisational position, sitting 
between the pharmacy service and the neuroscience service. 
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7.2 Being the face of pharmacy, the link with the neuroscience service 
Section 5.5 (p.115) illuminates a tension that can arise from the pharmacists 
identifying themselves as specialist clinical practitioners in neuroscience while 
also remaining as clinical generalists. This duality of identity arises partly from 
the participants’ simultaneous identity of themselves as a pharmacist belonging 
to a general pharmacy service, and a member of the multidisciplinary clinical 
teams within neuroscience services. Neuroscience pharmacists remain direct 
employees of the pharmacy service but in their state of organisational overlap 
with the neuroscience service they can function as a nexus between the two 
services.  
Acting as an organisational link to the neuroscience service, the pharmacist can 
be viewed as, what Megan observed of her senior colleague, “the face of 
pharmacy”. Being the face of a body or service connotes a representative and 
ambassadorial role. The role of the neuroscience pharmacist can serve as a 
form of pharmacy ambassador within the neuroscience service. I will outline this 
function in the next two paragraphs. 
Pharmacists represent the strategic medicines-management agendas and 
interests of the pharmacy service, or more widely the strategic agendas of their 
employing NHS Trust and NHS England. Pharmacists’ involvement in 
gatekeeping specialised drug therapies section (chapter 6) illustrates their 
awareness of strategic drug policies.  
Pharmacists are also attuned to the local drug needs of the neuroscience 
service they are situated within. By integrating into the neuroscience service the 
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pharmacists can begin to understand the needs of the service to support drug 
use, but remaining cognisant of the wider organisational issues and rules.  
Sally highlights how her newly created role has improved relations between the 
pharmacy and neurology departments by presenting a positive, helpful façade 
of the pharmacy service to the neurologists she works with. 
I think it's been quite reassuring to see that over the past three years 
[pharmacy’s] relationships with the neurology department are definitely 
much better and they're coming to us now whereas before they wouldn’t 
have come to us.  
Why do you think they weren't good? 
I think is just that pharmacy was always seen… I'm just trying to describe 
the consultants, they’re not very forthcoming consultants anyway and 
perhaps their experiences with pharmacy hadn't been particularly good 
up until that time. I think once I started sort of doing positive things for 
them they came to see me as a resource they can come to. 
Sally [13.95] 
 
Much like an ambassador, the pharmacists also need to be able to integrate 
into the local environment of the neuroscience service and establish 
relationships with key personnel. They need to understand local cultures and 
customs of how things are done in the local neuroscience service, what Beth 
describes as the etiquette. 
I first went along [to meetings] to see the formats of what was expected, 
you know of us, etiquette etc. 
Beth [4.271]  
 
Amongst the pharmacists interviewed there is variation in the size of the 
neuroscience centres they practice within. I have used numbers of inpatient 
beds and consultant medical and surgical staff as dimensional proxy measures 
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of the size of neuroscience services. I acknowledge the limited validity of these 
measures as constructs of the size and complexity of neuroscience services but 
seek to convey in some tangible way the variation in practice settings amongst 
the pharmacists.  
The neuroscience centres in which the interviewed pharmacists practice, range 
in size between locality services resourced with less than ten consultant 
medical staff and a small number of dedicated inpatient beds, to tertiary 
services occupying large dedicated hospital units and with many affiliated 
consultant medical staff.  
Megan, who practices in one of the larger neuroscience services, provides a 
flavour of the challenges pharmacists face in integrating into the clinical service.  
And how have you found that, moving [from the previous clinical 
role] to that environment [neuroscience department]? 
Errm (slight pause), difficult. I think it took about a year really to even 
settle in. I really enjoy it but I think it takes that long to get to know who 
people are, who does what. …  
But, I don't know, obviously it's very outpatient led out here so your 
consultants you mightn’t see them for ages but they're here. There's [a 
lot] of them (exasperated laugh). You don't see them that often. There's 
[sic] a lot of managers over here; there seems to be a lot more structural 
management over here. So I spent a year learning who’s what, who does 
what, who speaks to who, what meeting this is, what meeting that is, and 
now that I'm getting there I think now I’ll be able to get things done 
because I've bedded in if you like. 
Megan [12.124] 
 
Regardless of the size of the neuroscience service similar issues are faced by 
pharmacists in integrating into the clinical service. The next section sets out the 
process of how pharmacists reconcile their role within the neuroscience service.  
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7.3 Early stages of specialist practice: scoping the pharmacist role 
Section 5.2 (p.82) identified how, commonly the pharmacists have little prior 
experience of neurological disease before entering their role. Just as the 
pharmacists identified a need to develop their clinical knowledge of neurological 
disease and its treatment they also often identify a need to learn about the 
professional role itself, what it entails and the expectations of it.  
Sally and Michael entered into newly formalised posts with little guidance or 
expectation of how to perform the role, beyond a generic job description for a 
senior clinical pharmacist with pharmacy responsibility for a clinical directorate 
or service.   
… I came in[to the role] almost at a point of there not having been much 
of the pharmacy service. So you had to really establish, I had to definitely 
very much establish what we could do and what the value of us would be 
to them. 
And do you think that was very much you setting that out or did the 
directorate come to you and say well we have this agenda, or was it 
a joint thing? 
There was no agenda given to me so I devised one. 
Michael [1.53] 
 
Even within established pharmacist posts some of the data highlight a lack of 
both internal and external clarity around the functions of the role. Internal clarity 
is the clarity with which pharmacists perceive their role. External clarity is the 
clarity with which colleagues and stakeholders perceive the pharmacists’ role. 
Billy and Patti, on entering into established clinical pharmacist posts in 
neuroscience and stepping into the shoes of their predecessors, attempted to 
learn about their new roles by meeting with stakeholders of their role – 
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managers, senior medical and nursing staff. From these discussions both 
pharmacists appeared to form perceptions of an expectation to fit in, to continue 
the good work, but with little articulation of what the role would entail. The 
accounts of their discussions suggest there was little clarity from the 
neuroscience service around the purpose of the pharmacist role. 
I tried to get involved straight away and meet them [the medical staff] 
when I first started: just to ask them what they expected of me, that sort 
of thing. 
So you asked them [medical staff] what they expected of you? 
Yeah because obviously they’ve worked with pharmacists and 
[colleague] who is just leaving, they’ve worked with her for years and 
obviously [other colleague] had input as well. So again they’re obviously 
fortunately used to clinical pharmacists so it wasn’t as though it was a 
brand new thing. 
So I’m just curious to know what things they said as answers to 
that question. 
Well basically continue the good work was one sort of broad thing. 
Billy [8.113] 
 
My discussion with Patti revealed a similar experience to Billy. While there was 
an acknowledgement of Patti’s lack of experience in neurology, like Billy’s 
account there also appeared to be no clearly defined expectation from the 
neurology department towards Patti, of her role.    
When I was applying for the job I sort of went and met the directorate 
manager who is non-clinical and a couple of the consultants, one being 
the lead consultant. So I'd met them prior before my interview, before I 
got the job. I'm trying to think (laughs) what happened. I suppose I had 
an introduction where I think I was expected to make appointments to 
see some more other people. So I met with the specialist nurses, 
Parkinson’s nurses and the epilepsy nurses. I'd already met the ward 
manager and the matron. I was pretty much thrown into it really 
(laughs)…. 
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…Did you come away with any expectations from those 
conversations of what you felt they wanted from you? 
No (sighs), not really. I think they realised that I hadn't got any neurology 
experience so I didn't feel that they'd got any expectations of me at first . 
You know, other than just to settle in, just to gradually become part of 
their team. 
Patti [9.23] 
 
Lisa also moved into an established neuroscience post; she feels she did have 
a clearer expectation of the role through discussion with her predecessor, the 
person that had already performed the role. Not all pharmacists who entered 
into established roles had the same opportunity as Lisa because their 
predecessor had moved on to another organisation. In Lisa’s case, despite the 
clearer expectation of the role, it did not necessarily provide the preparation she 
had envisaged. 
But I don't think I was entirely prepared for it [the role] until it hit me. 
Lisa [7.65] 
  
The lack of clarity around the roles of neuroscience pharmacists may be 
explained by two factors: neuroscience as an emerging clinical pharmacy 
specialism; the broad scope of the role of the neuroscience pharmacist. An 
explanation of these causal factors is provided below. 
7.3.1 Neuroscience as an emerging clinical specialism 
 
A general perception formed by the pharmacists of their clinical pharmacy 
speciality, neuroscience, is as a relatively small and nascent clinical field. This 
perception is often formed by making comparisons with the collective profile and 
achievements of other clinical pharmacy specialisms. Below, Belinda’s hints at 
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issues of peer isolation in neuroscience (see section 5.2.2, p.84). Her views are 
drawn from comparisons with the clinical pharmacy specialism of renal 
medicine which further illuminates to her the emergence of neuroscience as a 
clinical pharmacy specialism. 
I think it's difficult within neurosciences because it's a relatively new 
speciality and there's a few of us. Like the renal pharmacists here, 
there's more of a group of them. Obviously is easier to band together and 
discuss things that come up within your directorate. So I think it's more 
difficult if you're a small group. 
Belinda [3.424] 
 
The study identified some empirical verification of the infancy of neuroscience 
as a clinical pharmacy specialism, through the identification of the relatively 
recent creation, within the last 10 years, of some of the posts the pharmacists 
are practicing within. These posts are either new or newly formalised; the 
previous pharmacy services provided to neuroscience wards were unfunded or 
provided on a more ad hoc basis.  
The consequence of being an emerging specialism and practicing in relative 
peer isolation can be a lack of assurance (see section 5.2, p.82) and clarity 
around the role both internally to the pharmacists and externally to 
stakeholders. 
7.3.2 Viewing a multifaceted role from one aspect 
 
The lack of external clarity around the role of the neuroscience pharmacist may 
be explained by the broad scope of their role and the broad groups of people 
the pharmacists interact with in the course of their practice. The interaction with 
members of the multidisciplinary team to acquire knowledge has already been 
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highlighted in section 5.4.2 (p.106). In the majority of practice, professional 
interaction occurs with at least the ward-based medical and nursing staff and 
clinical nurse specialists. Michael, who practices at a more strategic level within 
his role, provided one of the broadest lists of professional collaborators and 
stakeholders to his role. 
…what sort of people are you having to work with and liaise with to 
get those jobs done? 
Okay, so clinically the whole gamut-speech and language, dieticians, 
ODP's [operating department practitioners], consultants, junior doctors, 
rotational staff nurses etc. etc. clinically. But also more strategically, a 
broad range of anaesthetists, patient safety specialists, commissioning-
people from within the Trust and out with as in the PCT's and [local] 
specialist commissioning.  
So lots of negotiations  for cost sharing schemes the resource for change 
team and the turnaround team trying to get… and [neuroscience service 
managers], director of operations etc., clinical directors for getting cost 
improvement program projects pushed through, drug and therapeutics 
committee and drug and therapeutics chair for new therapies. Oh god, 
it's practically endless. 
Michael [1.19] 
 
I later asked Michael how he felt his role was perceived by the people he works 
with. 
It's interesting. I think (pause) if you take broad staff groups I think we’re 
seen very differently between them. I think our [neuroscience service 
manager] knows that I see patients but doesn't really think about it. She 
sees me as the one that gives her the financial reports on drugs and 
devising strategies maybe to save money.  
The consultants see me as a way of helping them get new therapies in 
and someone who points out risks issues or governance issues to them 
and tries to manage it and devises protocols to help do things. Almost 
like an administrative support for things to do with medicines and safety 
role…  
… I think the SPR's [specialist registrar doctors] and FY2’s [foundation 
year doctors] etc. on the ward, they're the ones who really see you as the 
guru of things relating to drugs and when they’ve got a problem they 
come to you. They see that you can sort them out and keep the patient 
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safe and make sure that everything’s flowing along nicely and help 
discharges.  
…where the nurses come in as well they see us as the discharger of 
patients and the supplier of drugs, which is funny. 
Michael [1.101] 
 
Michael’s response highlights a diverse set of expectations for his role. Within 
other interviews pharmacists identified different expectations for their roles.  
In digesting Michael’s response above I spontaneously externalised in the 
interview how I likened his role to that of a dodecahedron and he agreed with 
the analogy. As a three-dimensional multi-faceted object it is not possible to see 
all the faces of a dodecahedron examining it from just one viewpoint. 
Analogously, colleagues or stakeholders may only need to interact with the 
neuroscience pharmacist role over one specific issue relating to drug therapy 
such as how to use a drug more cost effectively, how to get permissions to be 
able to prescribe a drug, or how to administer a drug safely. Through these 
focused interactions colleagues or stakeholders do not necessarily form a 
holistic viewpoint of the pharmacist’s role.  
 
7.4 Finding the gaps to fit into the service: strategies for visibility 
Commonly, pharmacists seek early opportunities in their role to establish 
themselves within the neuroscience service. They identify gaps in the service 
for pieces of work they can do, where they can make an intervention and an 
impact; as Belinda identifies, doing something to “get my name about”. Belinda 
identified her strengths of expediting gatekeeping issues in drug therapy 
(section 6.5.2, p.171), and as a gatherer of clinical information (section 5.6.1, 
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p.128) to assist consultant neurologists with applications for the addition of new 
drugs to the hospital formulary, and producing shared care guidelines. What 
Belinda identifies, is that these are tasks consultant neurologists are not 
necessarily skilled in and furthermore, do not have the inclination to become 
skilled in. 
So I tried initially to be as useful as possible on the things that they 
weren't good at. So as well as trying clinically, I offered an awful lot to 
write formulary applications, to do the literature search for the formulary 
applications and that type of thing. Anything that would get my name 
about - writing shared care protocols, things like that. So I kind of offered 
to do the stuff that perhaps they weren't dead good at doing (laughs). 
Belinda [3.134] 
 
Although Lauren was provided with some signposting for her role early on, 
through the types of work (guidelines) she should produce, she too started to 
identify, “figured out”, other guidelines that could be written.   
And in terms of when you started [in the role] was there a list of 
requirements or jobs that you were given from the directorate? 
I think when you start in neuro ICU there were some guidelines that they 
wanted to put in place and the rest of them I just kind of figured out why 
don't we do this, or when things were introduced into the Trust tailoring 
them for the clinical area. 
Lauren [11.413] 
 
 
7.4.1 Recognising the role boundaries 
 
The strategy of finding gaps in the service to make an impact arises from an 
awareness of boundaries of the roles of others. Although the pharmacists might 
identify potentials areas of practice within the neuroscience service where they 
may be able to make an impact, they acknowledge there can be difficulties in 
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encroaching on practice if there is a perceived ownership of a service, or area 
of practice. 
I think if it's somebody, like if the service is somebody's baby, it's quite 
hard coming along and telling them what you think should be done, even 
if a small part of it should be done differently. It depends, some people 
take that well and other people don't like that much. But I do think that it 
helps if you're there from the beginning. 
Belinda [3.235] 
 
There can be an initial reluctance within the role to encroach on  the perceived 
roles of others. By acceding to the expectation to fit in, some of the pharmacists 
assume a position of what Billy describes “not stepping on anybody’s toes”. 
Pharmacists can be conscious of the roles of others. Without a clearly defined 
perception of their own role, pharmacists tend to err on the side of caution to 
avoid encroachment on the role boundaries of others. 
The reluctance to impinge on the role of others can be heightened where an 
issue is identified that needs to be challenged by the pharmacist and where 
there is a perception that their intervention will be negatively received. Section 
6.4 (p.159) illuminates reluctance in gatekeeping issues that pharmacists can 
experience and it evinces a desire to form positive working relationships within 
the neuroscience service. 
Not every pharmacist adopts an initial approach to practicing within role 
boundaries. Megan started to attend medical ward rounds relatively soon into 
her position, something that other pharmacists become more gradually involved 
in, through invitation (see section 7.5.2.1). In stepping out of the traditional 
pharmacist role boundaries, in a service where “they’re not used to seeing 
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clinical pharmacy”, Megan’s presence at a ward round was out of context to one 
of the neurologists, drawing a comment from him. 
… the first three or four [ward rounds] that I attended, one of our epilepsy 
professors who attended who's quite young, you know he's not sort of an 
old dragon, said to me, “Why are you here? Are you here to audit the 
drug charts?” And that's just so demoralising [resigned laugh] because 
no that's not why I'm here. 
And what was your response to that? 
No not at all. But I’ll have a look at them, you know just a bit of banter 
back with him. 
Megan [12.220] 
 
Megan was able to assert her reasons for being on the ward round and went on 
to recall an important intervention she made into the care of a patient on that 
ward round and justifying her participation. She believes she is slowly winning 
round the consultant medical staff to appreciating the clinical contribution of her 
role as a pharmacist. 
7.4.2 Redefining the role boundaries once established in post 
 
The initial strategy of taking on pieces of work and performing tasks to be 
helpful can have implications for subsequent practice. Initial good will and 
enthusiasm can lead to enhanced expectations and assumed responsibilities 
being formed of the pharmacist’s role by the neuroscience service. As 
pharmacists become established into their roles they can struggle to meet the 
increased demands from their workload and they start to identify the need to 
offload work. Some renegotiation can become necessary to deal with the 
workload and different strategies are taken by the pharmacists to address this.  
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Belinda’s challenges were heightened by a reduction in working hours. She did 
not completely renege on the work activities that she used to undertake for 
consultant neurologists but there was an element of education and negotiation 
required to reset the level of her involvement with drug formulary applications.  
I think that's what I tried to do, to see a gap that needed to be filled. But 
then in later years as the formulary applications increased (laughs) then 
it was kind of seen as my job and that was quite difficult when I dropped 
my number of days for them to, do you know what I mean?  What it's not 
actually - pharmacy don't always write formulary applications that you 
[neurologists] just sign the bottom of? It's meant to be written by you 
[neurologists] and I can help you with your literature searches but really 
you've got to sort of….  
Belinda [3.143] 
 
Michael has been more tactical with his initial approach of offering an enhanced 
pharmacy service, beyond what he was funded to provide, and then 
withdrawing that service to attempt to secure funding to re-establish and 
properly resource it. 
… I would deliberately provide over and above service that wasn’t funded 
to our neurology ward so that they could get some decent quality advice. 
And I did that purely off my own back and then got them to think 
actually… 
Because what I then did was stop providing the service and say it's not 
funded until they went ‘actually probably we should get that service 
funded because that was quite useful’. So it's been very much off my 
back (laughs) to get things pushed through 
Michael [1.62]  
 
Lauren sometimes sees the advantage of undertaking tasks that are not really 
hers if they can bring about bargaining power at later times.  
Were there things that were ever put to you to sort out and you 
thought, actually that's not really my job. Was there anything that 
you felt I'm not sure I should be doing this? 
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Yes [laughs] quite often. 
Were you ever able to say no to those? 
I think it's usually a balancing act - there are things that are not your job 
that would take two minutes to sort out and then you think oh actually I 
could do that and then that's a bit of leverage for when you need things 
done for you (laughs). 
Lauren [11.424] 
 
7.5 Antecedents for pharmacist involvement and the development of 
working relationships 
A relationship in the context of human experience defines the way in which two 
or more individuals are connected. Neuroscience pharmacists’ professional 
practice focuses on drug treatment for patients with neurological disease. In the 
main, pharmacists’ professional working relationships are formed over 
interactions relating to drug therapy. The formation of a working relationship 
between people confirms a conscious acknowledgement of an issue in which 
their roles are connected. This section describes the conditions (antecedents) 
that bring pharmacists into contact with members of the neuroscience service to 
germinate the formation of  working relationships.  
7.5.1 Identifying a need for pharmacist involvement 
 
Members of the multidisciplinary service identify the need to involve a 
pharmacist if they perceive there to be an issue in drug therapy that would 
benefit from the involvement of the pharmacist.  
Kate, Belinda, Lauren and Sally all describe developing closer working 
relationships with nurse specialists in MS over recent years. These enhanced 
working relationships have resulted from the introduction of a number of new 
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disease-modifying drug therapies (e.g. fingolimod) that require co-ordination 
over their supply and safety monitoring. Facilitating and arranging the supply of 
specialist drug treatments for neurological diseases is a common antecedent for 
collaborative working between pharmacists and clinical nurse specialists.  
I've got quite a good relationship with the MS specialist nurses, two of 
them, because obviously of the new drugs that we've been dealing with 
recently and home care. They sometimes come to me with home care 
issues… 
Sally [13.329] 
 
I work with the MS specialist quite a lot because they've got home care 
and I found since I got involved in home care they tend to contact me 
more… 
Lauren [11.267] 
 
There is not always a mutual recognition for the need to in involve a pharmacist. 
Some pharmacists describe the predominance within their clinical practice of 
providing pharmaceutical care to neurosurgical patients, where a higher 
proportion of inpatient beds are dedicated to neurosurgical admissions.  
Pharmacists perceive a general lack of interest in drug therapy from 
neurosurgical medical staff. In section 5.4.2.3 (p.110), pharmacists identify how 
neurosurgical ward rounds can often be very short in duration and lack focus on 
drug therapy. Against this background, pharmacists identify challenges in 
forming working relationships with the neurosurgical medical staff. 
There is variation in the extent to which neurosurgeons acknowledge the need 
to interact with pharmacists. Michael identifies how some neurosurgeons are 
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more receptive to than others based on their recognition of their need to be 
involved with drugs.  
Surgeons are, like there's [sic] a couple of them who I have very little 
dealing with at all because they kind of think well [pharmacists,] that’s 
drugs. I don't need to know anything about drugs in the neurosurgeon’s 
field, particularly the more established ones [think like that]. 
Michael [1.129] 
 
Kate identifies how the introduction of specific drug products (indocyanine 
green, Gliolan, fluorescein) into neurosurgical procedures has provided a focus 
for working relationships between neurosurgeons and pharmacists. 
Before, whatever we did on the wards wasn’t relevant because 
neurosurgeons weren’t really worried about drugs on the ward. Whereas 
now they've got so many different indocyanine greens and Gliolans, and 
fluorescein and all that kind of thing down there [in theatre] they have 
kind of had to work more closely with us. 
Kate [2.130] 
 
Kate describes the introduction of these drugs as a catalyst to improve working 
relationships with the neurosurgical doctors.  
7.5.2 Demonstrating the pharmacist role in practice  
 
Where there is an overt and mutual recognition for the pharmacists to become 
involved in a process, or service, working relationships can be established. 
Concurrently with these more spontaneous identification processes, the 
pharmacists begin to demonstrate their role within the neuroscience service. 
This process of demonstration takes place in several forums and tends to result 
in a more gradual establishment of the pharmacist role, and working 
relationships. This section summarises the processes of role demonstration. 
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7.5.2.1 Ward working and involvement in multidisciplinary ward rounds 
 
As already identified in section 5.4.2.3 (p.110), participation in multidisciplinary 
ward rounds is not universal within clinical pharmacy practice in neuroscience. 
For those pharmacists that do participate in ward rounds, their inclusion is a 
more evolutionary development within the role.  
Inclusion into the ward rounds can stem from observations by the 
multidisciplinary team that pharmacists can contribute to the care of the 
patients. While reviewing patients in neurology and neurosurgery wards, 
pharmacists pro-actively offer drug-related advice or are asked by members of 
the multidisciplinary team to provide advice or information in relation to drug 
therapies.  
Repeated interventions made by the pharmacists into patient care, particularly 
when ward rounds are happening, can lead to an acceptance amongst the 
medical, and multidisciplinary teams that the pharmacist can make useful 
contributions. This realisation can lead to the pharmacist’s inclusion in ward 
rounds, either by formal invitation or gradual inclusion, as Laura describes. 
I think we’ve extended more. The pharmacists have become more 
prominent in the ward rounds. It was not always the case so initially it 
was only [pharmacists] in situ [on the ward during] the ward rounds, the 
pharmacists were there. And with time and experience you get asked 
actually a lot more questions. Rather than just standing there you are 
very active member of that team. 
Laura [6.76] 
 
In Polly’s Trust, interventions made by pharmacists resulted in recognition by 
the medical staff of the contribution that pharmacists make to patient care. 
194 
 
Whilst these observations and acknowledgements resulted in an invitation to 
attend the ward rounds, lack of pharmacist time prohibited participation. 
And then we would talk to the consultants as well while they were on 
ward round too. Try and understand what they were doing, why they 
were doing it. So they actually had an awareness of the amount of 
interaction we were having with their juniors [doctors] too. 
So you did attend ward rounds as well? 
Not really. It was more that the ward round was going on and we were 
sort of in the same place at the same time but it wasn't official ward 
round attendance. We didn't have the capacity to do that. They had 
actually asked if, they said that at any point in time if you were able to 
join us you can but we actually just didn't have the capacity to do that.  
Polly [10.108] 
 
Table 5 (p.114) identifies some barriers to pharmacists attending ward rounds in 
the context of acquiring situational knowledge. Similarly, non-participation in 
ward rounds can also hinder opportunities for pharmacists to demonstrate their 
clinical knowledge and their provision of pharmaceutical care to patients, to 
other members of the multidisciplinary team. Pharmacists who do not 
participate in ward rounds tend not to identify their clinical input into patient care 
as an externally held perception of their role.   
Aside from the issues highlighted in Table 5, Lauren identifies reluctance in her 
junior colleagues to attend ward rounds. This hesitancy arises from the 
trepidation of being asked questions that they cannot answer. 
I think for the more junior pharmacists it's [attending ward rounds] more 
daunting I think they find. When I’ve asked them ‘just join the ward round’ 
I don't know if there is a fear will be asked all sorts of questions but I try 
to encourage them that they'll actually learn more. 
Lauren [11.146] 
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Beth has been through the process Lauren describes above. Her experiences 
confirm Lauren’s assertion of learning and her relative comfort now with 
challenging clinical questions suggests a feeling of being ensconced in the 
clinical team. 
And thinking about those early days and ward rounds were you 
being asked clinical questions fairly early on? 
Err yes. I think it’s just now that I just answer them with more confidence 
and I have a lot more experience. Whereas in those early days I would 
dread the questions now I look forward to them (laughs). Not that I know 
the answers all the time still that's for sure. It's just that I don't have [the 
worry of not knowing the answer] in my head.  
When I first started I would have been fretting a little bit about you know ‘I 
wonder what they going to ask me’ whereas now I hope it's going to be 
something I have to think about. 
Beth [4.379] 
 
7.5.2.2 Attending meeting forums 
 
Neuroscience pharmacists participate in range of meeting forums within the 
clinical services, most commonly describing clinical governance, infection 
control and general departmental meetings. The pharmacists identify how these 
meetings are usually attended by senior medical, nursing and managerial staff 
and find they provide a forum in which to demonstrate the value of their role.  
…going to risk and governance, and infection control [meetings]. You 
start seeing the same people at each meeting and then, you're taking 
back what you learn there, or what you're asked to do there. And then 
action points from there; delivering them on the ward. I think they do 
appreciate what effort we put in… 
Beth [4.69] 
 
Patti identifies how demonstration of her usefulness at departmental meetings, 
through her interaction with other neurologists, is favourably turning around the 
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perception of a neurologist she has previously experienced professional 
difficulties with. 
…well I get the impression that in the few consultant meetings I've been 
to that my consultant who wasn’t very pleased with my Botox idea has 
perhaps, seen other consultants involving me more. I think he’s perhaps 
come round to realise that perhaps I'm not that bad after all and has 
started to ask me more. So he possibly saw me as a pain (laughs) and 
then thought you know, well perhaps actually we could actually make use 
of this person (laughs). 
Patti [9.228] 
 
7.5.2.3 Establishing non-personal contact 
 
Pharmacists describe in the main, consultant neurologists and neurosurgeons 
only visiting wards to participate in ward rounds, providing a limited window of 
opportunity for the pharmacists to interact with them personally. Personal 
interaction with consultant staff is a challenge in practice which is more 
pronounced in larger neuroscience centres as a consequence of the hub-and-
spoke service model (cf. 1.5, p.14), as identified by Lisa. 
So I guess that’s where, maybe, I had a lot of contact with my 
consultants in my previous post that didn't really happen here. 
Lisa [7.124] 
 
This can result in a reliance on electronic (e-mail) communication with 
consultants.  
Our service is a bit bizarre from a neurology point of view. Most of our 
consultants work around the region and then just come into [the 
neurology unit] for one or two days a week. So I largely end up e-mailing 
them all, while they're out and about. They’re only really here when 
they’re on-call. 
Kate [2.229] 
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Sometimes you e-mail them [consultants], most of them have e-mail on 
their BlackBerry anyway don't they. Although you can ring them if it's 
really urgent… 
Sophie [14.255] 
 
Belinda and Laura identify how e-mail communication from medical staff making 
enquiries and requests for information, was a predominant method of contact in 
their early role. 
…but I would also receive a lot of medicines information enquiries via e-
mail and things from our consultants because we have, because we are 
the tertiary referral centre we have something like 30 consultants working 
between here and other centres. So a lot of them would e-mail me 
regarding enquiries about their patients both here and at the local 
centres in secondary care. 
Belinda [3.27] 
 
This form of early communication appears to be an early non-committal 
sounding out of the pharmacist by the consultants.  For Lisa, being approached 
personally by the consultants is more common now that she is personally 
known to them.  
Now I'm much more established they [consultants] know my face and are 
more likely to stop me on the wards and tell me about a patient and see 
what I think will ask me about whatever else… 
Lisa [7.137] 
 
Amongst the pharmacists there is recognition of the usefulness of e-mail 
communication but there appears a preference for personal contact.  
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I work on a Friday and that's our academic meeting so all the consultants 
are in on a Friday afternoon so I can still sort of get the chance to go and 
visit them face-to-face and they can still put a name to face really. But 
that is a worrying part to an extent that you sort of you see somebody's 
name come up an awful lot on e-mail but you don't necessarily have 
face-to-face contact. 
Belinda [3.39] 
 
Beth would prefer to communicate a service development personally to 
anaesthetists but will use e-mail as a back-up. 
So we’ll have to obviously start off actually having a meeting with all 
those involved or if meetings not possible then an e-mail to those, you 
know that particular group of anaesthetists to let them know what service 
we’ll be providing. 
Beth [4.150] 
 
7.5.3 Developing within the same Trust 
 
Several of the pharmacists identify that they started in their post when some of 
the consultants they work with currently, were also in more junior training 
positions. The pharmacists identify how the progression of their careers in 
tandem with these consultants has nurtured closer and more open working 
relationships.  
…a lot of our consultants, if they haven't been in post long it because 
they've been registrars here at some point. So obviously I've met them 
through that because I‘ve been in post for quite a while now so I tend to 
know them historically before they get to the consultant role  that they 
are.  
And those people you've been registrars with that are now 
consultants, does that relationship differ to the older consultants? 
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It tends to be more, a lot easier to… We have a lot more chatty 
relationship because obviously we've sort of, our careers have kind of 
matured together so it tends to be easier to contact them. I'm a lot more 
familiar with them. 
Belinda [3.49] 
 
Laura and Michael explicate this phenomenon by observing that at more 
formative stages of doctors’ careers, they utilise pharmacists’ knowledge to a 
greater extent to address gaps in their own knowledge base about drugs. These 
perceptions of pharmacists as being a knowledgeable and trustworthy 
information source, if formed during speciality training, can be maintained and 
strengthened through bonds of collaborative professional development. 
I'm in that age where I know them from SHO level to consultant level so 
you have got a different relationship now because they came to you for 
advice when they were in SHO. So they are more likely to come to you 
for advice when they are consultants. 
Laura [6.235] 
 
For me personally, it's been very beneficial that my first involvement in 
neurosciences was when I became the clinical pharmacist for the neuro 
critical care unit, because [the Trust] likes to grow its own… 
…a lot of the younger consultants I worked with when they were trainees. 
So that's anaesthetists, neurosurgeons, neurologists and they were 
learning from me when they came through. They as a result respect my 
knowledge and my role etc. 
Michael [1.35] 
 
 
7.6 Integration into the neuroscience service 
Integration into the neuroscience service is not a dichotomous outcome in the 
sense that a pharmacist is either integrated or not; it does not mark a transition 
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from the pharmacist’s position in the pharmacy service into the neuroscience 
service. In the main, pharmacists still retain their identity as a pharmacist, 
belonging to a pharmacy department (cf. section 5.5, p.115), and forming the 
organisational link with the neuroscience service. Integration is a process of 
movement along a continuum towards a state of the pharmacist being an 
accepted member within the neuroscience service.  
Pharmacists identify that integration into the clinical team is built upon the 
development of trust. Through the processes of demonstrating their contribution 
to patient care the pharmacists can also demonstrate an allegiance towards the 
neuroscience service. This process is always tempered against the gatekeeping 
processes that pharmacists undertake (chapter 6). 
Pharmacists identify how acceptance and integration into the wider 
neuroscience team, built upon trust, permits them to pursue their own agendas 
of developing their practice and developing the pharmacy service. The 
pharmacists begin to encroach on role boundaries, the process becoming more 
permissible through the pharmacists demonstration that they are working with 
the service to progress its aims. 
Beth’s involvement in surgical ward rounds has instilled a culture amongst the 
surgeons to review the drug chart and consider drug issues. This practice is 
facilitated by a good relationship with the medical staff and an enforcement of 
the practice by Beth. 
… and on the ward round it obviously-we’re electronic so we take a 
[computer] round the ward round so that they then actually, we all look at 
the medicine chart together because of the… Well on the days that I 
haven't been on the ward round, they do the ward round without looking 
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at the medicine chart so we get a lot of stuff resolved as we're going 
round on the ward round. 
Right. So on the days you’re not there then? 
We always have a pharmacist but say for example I'm 15 minutes late as 
per a few weeks ago then they'd done the first six beds without looking at 
the medicine charts of those patients. 
Right (laughs). What was your reaction to that? 
Well we re-did them (laughs). They know they should be looking at them 
themselves but I think it eases… It's a time pressure thing for them and 
they like, have a good deal of trust in us to bring issues to them you 
know, we work well together. 
Beth [4.76] 
 
In Michael’s practice, his ability to change practices with drugs like parecoxib 
and IVIg, is dependent upon trust amongst the staff that he is working with.  
So they end up trusting [emphasised] you. That's been hugely beneficial 
from being able to take my ideas forward, whether it's telling the 
anaesthetists to stop using parecoxib and they all say ‘well Michael says 
it so that's fine’ to pushing forward CIP projects like we don't dose IVIg 
differently for all neurosciences patients except Guillain Barres for the 
next month and they all said ‘well Michael said it so that's fine’. And it's 
just grown from having that kind of involvement at early stages and 
building it up. 
Michael [1.45] 
 
Integration within the neuroscience service and attendance at meetings also 
optimises their linkage function, reconciling the needs of the neurology service 
with how pharmacy services can work with them. As Polly identifies, the value 
of attending meetings is that she can link pharmacy to the neuroscience. 
It also meant that they had somebody there at the meeting while it was 
being discussed to give some insight which was really helpful to them. 
And then it meant that we could follow things up more quickly. Whereas 
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previously we didn't feel like anything was fed back to pharmacy to 
actually act on, change, help support. 
Polly [10.75] 
 
Integration into the neuroscience service is not passage through a gateway into 
tension-free clinical practice. Gatekeeping issues continue to arise; differences 
of opinion between the pharmacists and other clinicians still occur. Kate 
describes a difficult practice situation below but acknowledges the support of 
consultants because she perceives the support she provides for them.  
I guess having known them for a long time that kind of get to trust you 
and the work you do with them. Because we just had all the kind of with 
trying to switch, well we did switch botulinum toxin in the movement 
disorders clinic, and we’re in the process of switching back. But 
throughout that, consultants have been brilliant with me through what 
was a very difficult transition. 
Kate [2.261] 
 
7.7 Chapter summary  
Within clinical practice, pharmacists identify that their ability to influence and 
control the processes of drug use within neuroscience services is partly 
dependent upon their ability to integrate into and become an accepted member 
within the neuroscience service. Integration takes place through the 
development of working relationships. 
Early stages of the integration process involve the pharmacists learning about 
their professional role and understanding where it fits within the neuroscience 
service. The process of fitting into the service involves identifying opportunities 
where the unique contribution of the pharmacist can make a positive impact into 
the service. Conflict from encroachment on the roles of others, or impingement 
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on established practices is generally avoided in the early phases of the role to 
promote a positive façade of the pharmacist role.    
Establishment and acceptance into the neuroscience service is contingent upon 
a mutually identified need for the pharmacist’s involvement and opportunities for 
the pharmacists to demonstrate the value of their role. There can be barriers to 
opportunities to demonstrate the role. Integration into the neuroscience service 
is usually assumed by the pharmacists, to take time.  
Through the processes described in this chapter, the pharmacists identify the 
development of trust for their role as a marker of their integration and 
acceptance as a member of the neuroscience service. The establishment of 
trust then allows the pharmacists opportunities to pursue their own agendas and 
the wider agendas of the pharmacy service around drug use within the 
neuroscience service.  
204 
 
8 The grounded theory: Maintaining an overview of drug 
therapy for patients with neurological disease 
 
8.1 Presenting the theory 
The research questions that were set to guide this piece of exploratory research 
were to understand how pharmacists define their role within a neuroscience 
service and how they develop their role and how they develop their specialism 
in neuroscience.  
This chapter presents the grounded theory with the theoretically abstracted core 
conceptual process of maintaining an overview of drug therapy for patients with 
neurological disease. The grounded theory is diagrammatically summarised in 
Figure 10, overleaf. For succinctness, from hereon I refer to the core process in 
a shortened form of ‘maintaining an overview’.  
The core concept of maintaining an overview encapsulates the metaphysical 
essence of the role of the pharmacist in the clinical specialism of neuroscience 
while integrating the concepts of the theory through its identification as the basic 
social process. Maintaining an overview is the tension that pharmacists 
experience in both the transitional and established phases of specialist clinical 
practice in neuroscience. 
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Figure 10. Maintaining an overview of drug therapy for patients with neurological disease. 
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8.2 Explaining the theory 
Maintaining an overview is a conceptual phenomenon emanating partly in 
response to the often perceived breadth of the role of the neuroscience 
pharmacist. The neuroscience pharmacist role spans and serves two hospital 
services, pharmacy and neuroscience. In professional practice pharmacists 
identify the diversity of neuroscience services through their observations of the 
array of neurological diseases they encounter, the extent of disease-specific 
clinical subspecialisation amongst nursing and medical staff, and the sometimes 
complex organisational structures of neuroscience departments. 
Figure 10 illustrates the three conceptual categories, or processes, derived from 
analysis of the data, as to how pharmacists transition into and define specialist 
clinical pharmacy practice in neuroscience. Chapters 5, 6 and 7 have set out 
the processes of how pharmacists move along and navigate these pathways. 
Each process is represented by a pathway converging towards the centre 
where specialist clinical practice in neuroscience is performed. Each pathway 
narrows as it converges towards the centre, symbolic of the narrowing in focus 
of near-patient, specialist clinical practice. The properties at the outer edge of 
each pathway are the non-specialist, generalist properties of practice upon 
entering into the specialism of neuroscience. The properties at the inner 
convergent edges of each pathway are those perceived of specialist practice by 
the pharmacists.  Sometimes the pharmacists identify that their practice does 
not necessarily attain those properties of specialist practice.  
As pharmacists develop within their role in neuroscience, practice generally 
moves towards specialism. The variable and evolutionary nature of clinical 
practice means it can change and hence the arrows along each pathway are 
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double-headed. As practice moves inwardly in Figure 10, neuroscience 
pharmacists identify the need to still maintain the initial generalist properties of 
their practice at the outer edge of each pathway. The interview data illuminate 
that in making sense and constructing the reality of clinical practice, 
neuroscience pharmacists can experience tension in where they situate 
themselves along the continuum of each pathway. 
Maintaining an overview, represented by the circle and the double headed 
radial arrows in contact with the circle, is the basic social process arising from 
the situational tensions in the three pathways of Figure 10. For an aesthetic 
presentation I have represented the concept of maintaining an overview as a 
circle joining points of equal radial proximity along each pathway. However 
clinical practice does not necessarily evolve along each pathway at a uniform 
rate and the footprint of practice is unlikely to be represented by the blue circle 
in Figure 10. The footprint of practice drawn out from the apex points along the 
pathways is individual to each pharmacist, and furthermore there is situational 
variability within each individual role. In that sense, in the dimensions of the 
conceptual categories of the theory, there is no single template shape that fits 
exactly the role of every pharmacist practicing in neuroscience. 
The word overview may carry connotations of generality and non-specialism in 
practice but this is not the case. Maintaining an overview is not necessarily a 
prohibitive process to the development of specialist clinical practice. Within the 
interview data pharmacists do identify their development of clinical specialism 
and specialist practice; several pharmacists do identify areas of disease-specific 
specialism, commonly in Parkinson’s disease. However in maintaining an 
overview, pharmacists remain cognisant of the wider implications of drugs use 
208 
 
despite a developing clinical specialism in neuroscience. The tension between 
clinical specialism in neuroscience and a generalist overview results in 
pharmacy practice being dynamic in the sense that it is not statically situated 
along each pathway. The tensions are constantly changing in practice and so 
practice is continually moving backwards and forwards along each pathway. 
8.2.1 Stepping back to maintain an overview 
 
To maintain an overview of an object, situation or process one needs to be able 
to remove oneself or step back to view it externally in its entirety. Neuroscience 
pharmacists are professionally exposed to the implications of drug therapy 
through a range of lenses. The pharmacists are exposed to the individual drug 
needs of patients with neurological disease requiring drug therapy; they retain a 
professional cognisance of larger organisational issues and constraints for 
using sometimes complex and expensive drug therapies within the NHS.  
Beth identifies through her participation in neuroscience departmental meetings 
that her role has implications at several levels, amending my initial interpretation 
that meeting participation is useful for acquiring knowledge. 
It's difficult to explain in the right words but yeah having more knowledge 
and more awareness of what each individual thing you do impacts on at 
such a higher level, you know trust wide really. 
Beth [4.284] 
 
In practice, neuroscience pharmacists can sometimes need to step back along 
each of the conceptual pathways to view situations through a wider angle lens. 
Pharmacists step back to assess the implications of drug therapies for 
neurological disease in the context of other medical conditions the patient may 
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have and the concomitant drug therapies they may be prescribed for those 
conditions. In considering the wider clinical implications of drug use pharmacists 
utilise their broader, generalist clinical knowledge outside of neuroscience. This 
results in a tension of the pharmacists identifying themselves as clinical 
specialists or generalists (section 5.5, p.115) 
Pharmacists can be integrally involved in the care of patients with neurological 
disease but they need to step back and consider gatekeeping issues around 
proposed drug therapies such as organisational, financial and safety constraints 
for using a drug therapy (section 6.4.1, p.160). 
Pharmacists become integrated into the specialist neuroscience service, but 
they also need to be able to step back into the pharmacy service. By serving as 
a conduit for the funnelling of interaction between the two services of pharmacy 
and neuroscience, the pharmacists are required to have an overview of what is 
happening more globally, within their Trust and the NHS, and locally, within the 
neuroscience service. 
The process of pharmacists needing to step back in practice is best 
encapsulated by the viewpoint of Billy who identifies how stepping back can 
reveal a broader viewpoint of considerations for drug therapy. 
… it [pharmacy practice in neuroscience] is a balance between 
confidence and actually just stepping back and thinking what is actually 
going on, reflecting what's going on. And I think we have that, pharmacy 
hopefully has that where we can step back. 
So step back-what's the advantage of stepping back? 
So we can appraise the whole situation. Obviously you’ve got [a] 
consultant wanting to do a particular thing [with a drug] or [in] a different 
way. And they may not have thought of the whole picture… 
Billy [8.320]  
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8.2.2 Maintaining an overview as an active process 
 
Maintaining an overview is an active process and not a passive one. If an object 
has to be maintained it means that it does not remain static or the same, in the 
sense that physical or metaphysical forces are working to move or alter it. 
Within the theory, the forces working on the pharmacist’s role are metaphysical 
ones. The pharmacists enter into practice in the specialism of neuroscience and 
encounter highly specialised clinical practitioners. Consequently the 
pharmacists seek to develop their own specialism. These metaphysical forces 
seek to skew practice towards specialism (inwardly directional in Figure 10). 
The role of the pharmacists requires them to maintain generalist drug 
considerations in their practice; there is a metaphysical force heading outwardly 
in Figure 10. These opposing metaphysical forces create a tension. The 
pharmacists have a conscious awareness of these tensions; acknowledgement 
of the tensions is a factor in defining and shaping professional practice.  
 
8.3 Chapter summary 
This study resulted in a grounded theory which identified a basic social process 
running through contemporary pharmacy practice in neuroscience of 
maintaining an overview of drug therapy for patients with neurological disease. 
To assess the usefulness of the theory one needs to return to the original 
research questions and attempt to answer them. The questions were: 
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1. How do neurosciences pharmacists perceive and define their role within 
a neuroscience service?  
The theory explains that practice of pharmacists in neuroscience might be 
perceived as one of specialising generalists rather than pure specialists. That is 
not a value laden observation and it does not imply that one form of practice is 
inferior or superior. It is the conclusion drawn from a constructed reality attained 
through the generation of empirical accounts of practice, and subjected to an 
interpretive analysis through the grounded theory method. 
 
2. How do pharmacists specialising in neuroscience develop their role and 
specialism?  
The theory explains that there is tension in developing the pharmacists role and 
specialism in neuroscience. Pharmacists identify the need to develop 
specialism in neuroscience to develop as specialist practitioners. They also 
identify the core generalist needs of their pharmacist role. These opposing 
needs of the role create a tension within practice.   
 
The implications of the research findings in the context of the existing literature, 
and for clinical pharmacy practice in neuroscience, are discussed in the next 
chapter.  
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9 Discussion and recommendations 
 
9.1 Introduction 
I have adopted the recommendations of Holloway and Brown (2012) for the 
construction of this chapter. Firstly, in section 9.2, I will discuss the findings of 
the research in relation to current pharmacy practice and the existing literature.  
I will identify where I believe the study findings to make new contributions to the 
literature.  
I make frequent reference to studies in the literature and the findings of this 
study. To aid clarity when reading this chapter, where I refer to the study of 
neuroscience pharmacists I have emphasised this by the use of italicisation, 
e.g. this study. Where reference is made to specific findings within the study the 
section and page numbers are provided in brackets to enable cross referencing. 
Following an analysis of the findings, an assessment of the relative strengths 
and limitations of the research is provided in section 9.3. The recommendations 
for further research and for pharmacy practice in neuroscience, identified within 
this chapter in light of the research findings, are summarised in section 9.4. The 
chapter concludes with a reflective note on the effects of the research journey to 
my personal and professional development. 
 
9.2 Discussion 
This study set out to investigate the practice of pharmacy within the clinical 
specialism of neuroscience with some relatively loosely defined research 
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questions. Perhaps not unsurprisingly from using an inductive research 
strategy, analysis from the empirically generated data resulted in the 
identification of three conceptually broad processes: 
 Acquiring and utilising knowledge. 
 Gatekeeping access to drugs. 
 Integration into the neuroscience service. 
I will discuss these findings in relation to pharmacy practice and I will also draw 
on existing literature to compare the findings. Where I have been unable to 
locate appropriate literature in pharmacy practice, I have drawn upon the 
literature from other healthcare professions, notably nursing.  
I have discovered the substantive focus of this research, multidisciplinary 
hospital-based clinical practice, has identified concepts that have been explored 
more extensively within the literature of nursing practice. I observed within the 
nursing literature a frequent reference to the work of Patricia Benner, e.g. 
Benner (1984), and her work on developing expertise and competence in 
nursing practice. Her work emphasises the importance of experience in 
developing nursing practice; the findings from this empirical research of 
pharmacy practice in neuroscience draw some parallels to her work. The 
findings from this study also draw in concepts from the fields of education, and 
applied sociology. 
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9.2.1 Acquiring and utilising knowledge 
 
This study of neuroscience pharmacists identifies the prominence they place on 
the possession of knowledge to support their specialist practice (chapter 5). 
Clinical pharmacy practice within neuroscience is not task oriented in the sense 
that it does not entail the undertaking of manipulative or technical procedures 
on patients e.g. administering drugs, taking blood samples. The interview data 
confirm that dispensing, the traditional skill of the pharmacist, is largely a 
redundant aspect of the modern practice of hospital pharmacists. However, 
within neuroscience services, the role of the pharmacist is still associated with 
the function of supplying drugs (6.2.3, p.140); this finding is discussed further in 
section 9.2.2. 
As identified in section 1.4.4 (p.12), the discipline of clinical pharmacy is 
conceptualised around the application of pharmaceutical knowledge to 
individuals or groups of patients, to optimise outcomes from drug therapy. The 
finding that knowledge supports specialist pharmacy practice is therefore, 
perhaps not surprising. What this study identifies is that the knowledge required 
to support practice is more than a repository of facts, termed theoretical 
knowledge (5.2, p.82). Pharmacists also utilise experiential knowledge (5.3, 
p.96) and situational knowledge (5.4, p.103), to support and develop their 
practice.  
The possession of a specific body of knowledge or theory of knowledge is one 
of the defining characteristics of a profession (Traulsen and Bissel, 2004). 
Within the specialist clinical practice settings of this study, pharmacists perceive 
that at times, and certainly in the formative stages of specialist practice, medical 
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and specialist nursing staff possess greater knowledge, acquired through more 
extensive professional experience of neurological disease and its drug 
treatment. Pharmacists are not always in possession of the collateral 
knowledge of unique clinical situations in which the drugs are being used 
(situational knowledge) to be able to make totally informed judgements about 
the appropriateness of treatment. These findings raise a question as to how to 
define the unique body of knowledge of pharmacists practicing in neuroscience. 
The rest of this subsection discusses that question. 
Analysis of the data identified a distinction between specialist knowledge about 
neurological disease, and a broader generalist clinical knowledge. Figure 6 
(p.115) metaphorically presented these two types of knowledge as liquids in a 
cone, with specialist knowledge as a denser, deeper liquid and generalist 
knowledge a lighter, shallower liquid. De Jong and Ferguson-Hessler (1996) 
observed how levels of knowledge can often be presented as superficial 
(general) versus deep (specialist); they also observe a general inference that 
deep knowledge is superior to superficial knowledge.  
I do not intend to depict that for clinical pharmacy practice in neuroscience, 
specialist knowledge is necessarily a superior knowledge to generalist 
knowledge. Specialist knowledge undoubtedly assists pharmacists in informing 
an appropriate course of action when encountering patients with complex 
neurological disease but these scenarios do not represent the entirety of 
practice for the pharmacists. 
What this study identifies, is that the breadth of pharmacists’ knowledge and 
considerations for drug use, is a perceived strength of their contribution to 
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practicing within a specialist setting. The pharmacists’ knowledge and focus can 
go beyond the patient’s neurological condition, to consider their drug therapy 
more holistically, in combination with comorbid disease states and concomitant 
drugs. The self-perception of pharmacists practicing in hospitals, as generalists 
in drug therapy with a broader knowledge base, has previously been identified 
by Elvey et al. (2010).  
Section 1.5 (p.15) highlighted a momentum for specialist practice within UK 
clinical pharmacy; focusing practice within a specific medical speciality.  What 
this study of pharmacy practice in neuroscience reveals, within an inpatient 
hospital setting in particular, is the holistic overview of drug therapy that 
pharmacists maintain through their everyday activity of reviewing patients’ entire 
drug regimes. There can be a tension amongst pharmacists of how they define 
themselves: as generalist practitioners with a broad drug knowledge base or as 
specialist practitioners with a deep knowledge base in neurological disease and 
its drug treatment (5.5, p.115).   
Abramowitz (2009) commented how the early pioneers of clinical pharmacy are 
generalist pharmacists by modern standards, an acknowledgement of how 
pharmacy practice has evolved, with the establishment of specialism in practice. 
The aim of this research was not to define the parameters of specialist 
pharmacy practice in neuroscience but to better understand how specialist 
practice develops. The discovery of a tension between specialist and generalist 
practice is, I believe, a significant one which raises an important question that 
should be debated, of whether specialism in neuroscience, and perhaps any 
clinical speciality, should be pursued at the expense of losing a generalist 
overview of drug therapy.       
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Setting aside the debate between specialist and generalist practice, I will now 
look at the implications from the research findings for advancing specialist 
practice in neuroscience. Advanced, or specialist clinical pharmacy practice in 
neuroscience cannot necessarily be taught by methods of imparting facts 
through didactic teaching, reading of a textbook, learning of a protocol or 
guideline. Yet this form of knowledge is useful to signpost pharmacists in the 
early stages of practice (5.2.1, p.82). 
The empirical findings from this research identify that pharmacists can 
experience early difficulties in accessing appropriate learning and teaching 
materials about neurological disease, the theory of neurological practice. 
Therefore it seems imperative that any curricular framework for developing 
neurological practice is able to signpost pharmacists to appropriate reference 
and learning materials to develop their knowledge. The accounts of the 
pharmacists would suggest they could also benefit from appropriately tailored 
study opportunities. The Centre for Postgraduate Pharmacy Education has 
previously produced three learning programmes for epilepsy, multiple sclerosis, 
and Parkinson’s disease; these programmes would serve as useful templates to 
develop further learning self-learning packages8. 
A guided and targeted curricular framework has the potential to accelerate the 
learning of, and support for, new practitioners in the field of neuroscience. The 
framework should be explicit in highlighting the deficiencies and controversies 
of current evidence bases and illuminate heuristic methods to help pharmacists 
explore local practice, reflect on their professional experiences, and develop 
their own experiential practice base.  
                                                             
8 I acknowledge I was content guardian for this programme for several years. 
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Having identified the limits of taught theoretical knowledge to support pharmacy 
practice in neuroscience the discussion now turns to the more tacit forms of 
knowledge identified to support practice: experiential knowledge and situational 
knowledge.  
This study generated two constructs, experiential knowledge (section 5.3, p.96) 
and situational knowledge (section 5.4, p.103), that support advancing clinical 
practice in neuroscience. These knowledge forms have also been identified in 
other studies that have examined the acquisition of expertise in nursing 
practice, notably the notion of experiential knowledge (Morrison and Symes, 
2011). These knowledge types are further discussed sequentially below. 
Bonner and Greenwood (2006) studied the acquisition of clinical expertise in 
renal (nephrology) nursing. Their grounded theory method research identified 
how experiential learning, gained from repeated undertaking of tasks, creates 
familiarity and a positive enforcing feedback loop, to support confidence and 
competence in practice. The grounded theory produced from the research 
explains how as nursing practice develops in nephrology, it focuses on the 
individual patient. The processes in renal nursing practice are congruent with 
the processes identified for practice development in neuroscience clinical 
pharmacy (5.6, p.128), of how the reassurance of seeing drugs used in clinical 
practice supports more confident practice. 
Smith et al. (2003) studied the acquisition and use of knowledge in anaesthesia, 
through ethnographic research. Their study identified that the clinical knowledge 
used by anaesthetists comprised several subtypes.  
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 Social knowledge or knowledge about the patient, which may be 
considered coterminous with situational knowledge (cf. 5.4, p.103) in the 
practice of neuroscience pharmacists. 
 Theoretical or ‘textbook’ knowledge (cf. 5.2, p.82). 
 Electronic knowledge which is information gleaned from anaesthetic 
monitoring equipment, a knowledge form not applicable to clinical 
pharmacy practice. 
 Experiential knowledge (cf. 5.3, p.96).  
 
As with advancing clinical pharmacy practice in neuroscience, expert practice in 
anaesthesia was identified as a practitioner not being dependent on theoretical 
knowledge alone, but having the ability to collate and reconcile different types of 
knowledge.  
The observations of Smith at al., of anaesthetic practice, also identified the 
utilisation of knowledge about individual patients. The concept of knowing 
individual patients will form the basis of the next discussion of how pharmacists 
utilise situational knowledge. 
As identified in this study, situational knowledge enables pharmacists to make 
judgements about drug therapies in the context of individual patients. Situational 
knowledge provides pharmacists with an awareness of factors that may affect 
patients’ ability to take drug therapy, or their likely response to it. This individual 
patient focus seen in clinical pharmacy practice draws some parallels with a 
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concept in the nursing literature of knowing the patient, a complex construct, 
entwined with the concept of holistic patient care. 
Knowing the patient has often been empirically studied in relation to critical care 
nursing (Kelley et al., 2013 , Tanner et al., 1993) with the notion of identifying 
changes in acutely unwell patients. However the importance of ‘knowing the 
patient’ has also been identified in studies of treating more chronic conditions 
such as chronic obstructive pulmonary disease (Risor et al., 2013).  
The spectrum of clinical scenarios encountered within clinical pharmacy 
practice in neuroscience, ranges from acutely critically unwell patients, to 
patients with long term conditions. Across the range of the acuity of patient 
illness, pharmacists identify the importance of understanding the individual 
history of the patient and their condition. However, the challenges pharmacists 
face can be the difficulty of eliciting this information, resulting from their limited 
interaction with patients and, sometimes, distal proximity to the therapeutic 
discussions that occur within the multidisciplinary teams and ward rounds.  
The importance of time, and the chronicity of patient interactions to support a 
practitioner in knowing their patient, has been highlighted in the reviews of the 
topic by Radwin (1996) and Zolnierek (2014). Both reviews noted within the 
empirical evidence, time pressures within nursing practice, in getting to know 
the patients. In the current era of the NHS, post-Francis report into care failings, 
the concept of patient centred care is taking prominence (The King's Fund, 
2013). There are real challenges for pharmacists in particular to deliver patient 
centred care if their workload does not allow the time to elicit the appropriate 
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patient information which enables them to make individualised decisions about 
drug therapy. 
Pharmacists practicing in neuroscience identify clinical nurse specialists as 
sources of patient specific knowledge, gained from the nurses’ knowledge of 
knowing the patient. The data illuminate how collaborative working, not just with 
clinical nurse specialists, but other healthcare professionals such as speech 
and language therapists, helps the pharmacists to contribute to the optimisation 
of drug therapy for patients with sometimes complex medical and drug needs. 
Kelley et al. (2013) have also identified how intensive care nurses interrogate 
different information sources to learn about their patients.   
The findings of this study of clinical pharmacy practice in neuroscience add to 
the literature that identifies how clinically practicing healthcare professionals 
require different forms of knowledge to apply their particular expertise to patient 
care. The importance of multidisciplinary working for pharmacists to optimally 
obtain the information they require to exercise pharmaceutical care and 
contribute to the care of patients is also illuminated.  
The empirical findings from clinical pharmacy practice in neuroscience 
corroborate findings in the existing literature that identify clinical experience as a 
source of knowledge to support practice. Pharmacists identify that gaining 
sufficient clinical exposure to neurological disease can be a challenge of 
practice (5.3.2, p.99). This can be a result of the diversity and sometimes rarity 
of neurological diseases. Pharmacists also identity how they are not afforded 
the same level of clinical exposure of others, when they compare their own 
practice to that of nursing and medical colleagues.  
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Not all pharmacists practice their entire role in direct clinical situations; they 
work within other non-directly patient facing pharmacy services such as 
dispensaries and medicines information (cf. table 1, p.11). Attending ward 
rounds (sections 5.4.2.3, p.110, and 7.5.2.1, p.193) is identified as a pivotal 
process for knowledge acquisition and for influencing prescribing decisions, yet 
not all pharmacists attend these rounds.  
Within the findings of this study, the role of the clinical pharmacist has clearly 
evolved from dispensing and drug supply, but they do not practice purely in 
clinical settings, when compared to nursing and medical staff. Pharmacists 
support other aspects of pharmacy services and clinical areas, and also have 
non-clinical aspects to their role. This is a double edged sword for pharmacists: 
while the development of experiential knowledge can be stifled, participation 
within other services enables pharmacists to maintain the knowledge needed to 
hold a broad overview of drug therapy.    
Waterfield (2010) has questioned whether pharmacy, in this context defined as 
the practice of pharmacists, having evolved from the drug dispenser and supply 
role, is now a knowledge-based profession. The findings from this study would 
support ‘yes’ as an answer to that question in the context of clinical practice in 
neuroscience. However in advancing the knowledge and practice in 
neuroscience through the development of a curriculum, there needs to be a 
rethinking of what knowledge is and how that is defined. 
De Jong and Ferguson-Hessler (1996) describe deeper knowledge as a form of 
processed knowledge. Figure 7 (p.130) summarises the processing of clinical 
knowledge that occurs through clinical practice. Entry level, theoretical 
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knowledge is cognitively processed by the pharmacists through its comparisons 
with real life practice (experiential knowledge) within an increasing range of 
situational contexts using situational knowledge. The integration of the three 
knowledge types can be more tacit and difficult to define because the composite 
application occurs within highly contextualised individual clinical cases.    
The Advanced to Consultant level framework (Competency Development & 
Evaluation Group, 2009) is a framework for developing and credentialing expert 
pharmacy practice in the UK. The RPS Faculty accreditation criteria closely 
mirror the ACLF framework.  Within this framework, one of the competencies for 
advancing specialist practice is the ability to demonstrate ‘specialist 
pharmaceutical knowledge’; the detail of the knowledge is to be defined through 
a curriculum. At the time of completing this thesis, a curriculum for neuroscience 
is in the early stages of development by the UKCPA neuroscience group. 
This study shows that theoretical knowledge, learning the “what” of neurological 
disease, can be insufficient alone to support clinical pharmacy practice. 
Neurological diseases can be too rare and heterogeneous for treatment 
approaches to fall within prescriptive guidelines. That is not to say that where 
robust evidence bases exist for clinical practice they should not be applied. 
However the teaching of clinical pharmacy for neurological diseases should 
inculcate the ethos of experiential learning, the individualised patient, and 
multidisciplinary care. This approach should begin at the undergraduate stage 
of pharmacy teaching and continue through all levels of pharmacy practice. 
Furthermore the analysis identified how neuroscience pharmacists learn from 
multidisciplinary colleagues. Notably two pharmacists, who attained a 
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prescribing qualification from a multidisciplinary course, altered their clinical 
assessment of patients. These findings suggest a potential role for 
multidisciplinary learning, illuminating to pharmacists more lateral ways to 
assess and consider patient care and the role of drug therapy.   
9.2.2 Gatekeeping access to drugs 
 
Neuroscience pharmacists, as pharmacy service representatives within 
neuroscience services, are posited as the link between the two services and are 
the conduit through which drug therapies can be accessed. Although devolved 
of dispensing responsibilities, neuroscience pharmacists still maintain an 
identity as drug suppliers. Pharmacy technicians have the potential to relinquish 
some of the traditional supply roles from pharmacists. Yet technician posts are 
not established in all neuroscience centres and there needs to be a greater 
understanding of the role for pharmacy technicians in pharmacy services for 
neuroscience. 
Historical sociological analyses of pharmacy have questioned its place as a true 
profession, partly based on its conflict of interest between commercial (cost) 
and patient interests (see Traulsen and Bissel (2004) for a further discussion). 
While acknowledging myself as a pharmacist, I refute these writings in relation 
to UK clinical pharmacy practice on the basis of several factors: 
 They are based on US pharmacy practice. 
 They are based on community (retail) pharmacy practice. 
 UK healthcare policy identifies (in general) pharmacy as a profession to 
deliver direct patient care and public healthcare initiatives. 
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Yet gatekeeping drug access on the basis of cost is a process of clinical 
pharmacy practice within neuroscience, and amongst some pharmacists, an 
innate professional identity of ‘Being the accountant’ (6.3.2, p.153). Chiarello 
(2013) studied gatekeeping processes amongst community (retail) and hospital 
pharmacists in the US. I initially discounted this study for comparison on the 
basis of differences in the NHS and US healthcare systems; on further reflection 
I identify some commonality between the two systems.  
Healthcare provided by the NHS remains free at the point of access for eligible 
citizens. Hospital care is provided by acute NHS Trusts which is paid for by 
local or national commissioning bodies depending on the nature of the service 
provided (cf. 1.3, p.3). Specialist neurological services tend to deal with rare or 
complex conditions where drug use can be beyond standard commissioning 
arrangements. The requirement for neuroscience services to obtain funding 
permission to provide sometimes specialist and expensive drug therapies to 
patients draws some parallels between the NHS commissioning bodies in the 
UK and healthcare insurers within US systems as, in effect, financial 
underwriters for these treatments.  
Chiarello used the term ‘fiscal gatekeeping’, a construct approximating the 
combination of ‘Policing the formulary’ (6.3.1, p.149), and ‘Being the accountant’ 
(6.3.2, p.153). Hospital pharmacists were identified as having less autonomy in 
respect of fiscal gatekeeping by being more orientated to the interests of the 
hospital; being more remote to patients and less inclined to advocate on their 
behalf. These findings draw some parallels to the UK practice of neuroscience 
pharmacists. Neuroscience pharmacists can be constrained by organisational 
policies and cognisant of the financial implications of drug use. However 
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neuroscience pharmacists can experience tension in these processes by their 
understanding the patient needs, and displaying empathy to medical staff.  
Neuroscience pharmacists are not always remote to the patient, especially 
patients being treated within hospital wards, where the pharmacists 
predominantly practice. 
At times, the pharmacists expressed uncertainty over commissioning 
arrangements. This may reflect the dynamic changes that are occurring within 
the NHS. Given the sometimes complex use of drugs within neuroscience 
services it is imperative that pharmacists practicing within this field have a 
robust working knowledge of commissioning processes within the NHS. A 
curriculum for advanced practice in neuroscience should reflect these needs. 
Section 6.5 (p.164) identifies the hegemony of the neuroscience medical teams 
in prescribing decisions that are based on clinical judgement. This position of 
the medical team is constructed by the pharmacists’ perceptions that ultimate 
responsibility for patients’ care lies with the medical team. Pullinger and Dean 
Franklin (2010) identified a reluctance amongst hospital pharmacists to 
document patient care issues in medical notes, citing one of the factors as 
pharmacists’ perceived lack of ownership of the medical records and therefore, 
right to contribute within them. Neuroscience pharmacists will document issues 
of patient care in the medical notes where they perceive issues of patient 
safety.  
9.2.3 Integrating into the neuroscience service 
 
The pharmacists identify that integration and acceptance into the neuroscience 
service, particularly by medical staff, is a key antecedent to optimising their 
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involvement in neurological services and patient care. This finding illuminates 
the role of the neuroscience pharmacist through a more sociologically focused 
lens.  
Empirical research by Kammeyer-Mueller and Wanberg (2003), within a range 
of employment settings, identified how the early stages of new roles, termed 
organisational entry, influence long term retention within an organisation and 
role productivity. Knowledge about the role is a predictor for successful 
integration into it. This study of clinical pharmacy practice in neuroscience 
identifies how there can be a lack of clarity around the function of the 
pharmacist’s role in neuroscience services. 
The literature highlights lack of role clarity as a wider issue within healthcare 
organisations. Jones (2005) identified amongst the literature of advanced 
nursing posts how, a lack of role clarity for nursing, was cited as a barrier to 
advanced nursing roles within hospital settings. Advancing nursing and 
pharmacy roles are by their evolutionary nature, dynamic and therefore often 
difficult to define. These study findings highlight that work needs be undertaken 
by the UKCPA neuroscience group to raise and define the profile of clinical 
pharmacy within neuroscience services. Furthermore, the UKCPA neuroscience 
group should produce a recommended induction programme for clinical 
pharmacy posts in neuroscience. This programme should identify key personnel 
with whom to meet and establish working relationships and activities to be 
undertaken within an induction period. 
Trust was identified as a key factor to neuroscience pharmacists developing 
successful working relationships, particularly with doctors (see section 7.6, 
228 
 
p.199). This finding echoes other research examining collaborative working 
relationships  between pharmacists and doctors, undertaken mainly in primary 
care practice settings, and extends the concept of trust as pivotal in 
collaborative working.    
Much of the US based literature for pharmacists’ collaborative working draws on 
a model developed by McDonough and Doucette (2001). This model proposes 
five progressive stages for collaborative working between pharmacists and 
doctors:  
0. Professional awareness 
1. Professional recognition 
2. Exploration and trial 
3. Professional relationship expansion 
4. Commitment to the collaborative working relationship 
The model was developed for discrete working relationships. Neuroscience 
pharmacists often work with a large group of doctors, at varying levels of 
medical seniority. However the model does have some relevance to clinical 
pharmacy practice in neuroscience. The model identifies that initial attempts to 
move through the stages are instigated by pharmacists (cf. 7.4, p.185). The 
model also identifies how the exchange characteristics between the pharmacist 
and doctor, i.e. what and how they interact over, determine progression through 
the stages. Further literature has examined these processes and their findings 
echo this study of clinical pharmacy practice in neuroscience. This literature is 
discussed below. 
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Snyder et al. (2010) studied the development of working relationships between 
doctors and pharmacists in a US primary care setting. They concluded that 
establishment of pharmacist trustworthiness was a key underpinning of the 
development of collaborative working relationships. Establishment of 
trustworthiness was a time dependent process, contingent upon the 
pharmacists displaying interventions into patient care. The findings from this 
study draw parallels, but also extend the model of professional relationship 
development through more indirect means of patient benefit. For example, 
neuroscience pharmacists assist to secure access to drug therapies for the 
patients of neuroscience services, demonstrating to the medical staff their 
alignment to a commitment for patient care.  
Liu et al. (2010) examined the factors that brought about collaborative working 
between pharmacists and doctors within a United States, primary care based, 
formal drug management programme. Under this programme, pharmacists 
review patients’ drug therapies and make recommendations for change to the 
primary care doctor. Trustworthiness and professional interaction between the 
pharmacists and physicians were predictors for the development of 
collaborative working in formal drug management programmes.  
Kozminski et al. (2011) studied the integration of pharmacists into care teams 
within US care homes. Their study identified that it took up to six months for the 
pharmacists to feel integrated into the care teams. Similarly, the study of 
Makowsky et al. (2009), of hospital pharmacists’ collaborative working, 
demonstrated the development of mutual trust and respect was facilitated by 
repeated working with individual doctors and nurses.    
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The empirical findings from clinical pharmacy practice in neuroscience support 
existing literature that the integration of pharmacists into healthcare teams is a 
time-dependent process. This is an important finding to acknowledge. 
Neuroscience pharmacists commonly described being supported by more junior 
pharmacists on a rotational basis. Pharmacists in rotational posts should be 
actively supported and encouraged to become involved within the 
multidisciplinary teams of neuroscience services. 
What permeated through this research was the clear professional identity, as 
pharmacists, the participants held, illustrating their professional socialisation. 
Professional socialisation is the process by which individuals develop 
professional identity, through institutionalised training, and occurs aside to the 
requisite formal knowledge they develop in their training (Blane, 1997).  Nimmo 
and Holland (1999) assert that pharmacists’ professional socialisation begins 
with entry into undergraduate training and continues upon the transition into 
qualified profession practice.  
The landscape of healthcare provision is changing, partly through the evolution 
of professional roles. For example, a number of non-medical professions, 
including pharmacists, are now able to prescribe drugs. The demarcation of role 
boundaries between healthcare professionals are less pronounced, requiring 
greater tolerance and understanding of professional roles.   
Several neuroscience pharmacists identified how early collaborative working 
with trainee neurology medical staff could seed the formation of good 
professional relationships. Hind et al. (2003) found that healthcare students 
from differing health disciplines quickly gained an intra-professional identity but 
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held positive attitudes towards other professions and were willing to participate 
in inter-professional learning. They recommended inter-professional 
involvement in the early stages of healthcare careers. The findings from this 
study also support the notion that early inter-professional working is essential to 
establish collaborative, inter-disciplinary working as the norm of practice. 
Neuroscience pharmacists identified several advantages to attending 
multidisciplinary ward rounds, eliciting useful situational information about 
patients (5.4.2.3, p.110), their ability to influence prescribing decisions, and 
demonstrate their contribution to patient care (7.5.2.1, p.193).  Miller et al. 
(2011) evaluated the effect of pharmacists’ participation in ward rounds upon 
their clinical interventions using a prospective, non-randomized, controlled study 
design. The number of interventions and the rate of intervention acceptance 
were compared within the same Trust between pharmacists who attended 
consultant-led ward rounds, and a control group of pharmacists who provided a 
traditional ward pharmacy service, but did not attend ward rounds. A statistically 
significant increase in the number of interventions made and the rate of 
intervention acceptance was observed for those who attended ward rounds.  
For neuroscience pharmacists to make their optimal contribution to the inpatient 
care of patients within neuroscience services, their inclusion on multidisciplinary 
ward rounds should be become an established and ubiquitous practice. I 
acknowledge there are potential organisational issues to achieve this, as there 
are several barriers to pharmacists’ participation (see Table 5, p.114).  
However this study strengthens the existing literature that supports the 
requirement of pharmacists to directly demonstrate their clinical contribution to 
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other members of the healthcare team. By doing so, pharmacists can integrate 
into healthcare teams and collaboratively contribute to the care of patients with 
neurological disease.  
 
9.3 Strengths and limitations of the research 
This study contributes a further piece of qualitative research into UK pharmacy 
practice. It is the first attempt to collate the experience of a group of 
pharmacists who frequently describe working in isolation within their own 
specialism. By using a flexible set of exploratory procedures afforded by the 
grounded theory method I believe that the research has enabled an insight into 
the practice of a group of specialist pharmacy practitioners. The findings of the 
study could not have been generated through a questionnaire or survey study 
design, or other form of quantitative research that sought to measure the 
practice of pharmacists. The study findings have implications for developing 
pharmacy practice and research, which are summarised in section 9.4.  
This study reveals how a specialist clinical pharmacist role is constructed within 
a multidisciplinary hospital setting, from working with and alongside other 
healthcare team members. With an increasing emphasis in the NHS of 
multidisciplinary and cross-sector working it is important to understand how 
contemporary pharmacist roles are assimilated into healthcare teams.  
Elvey et al. (2013) examined professional identity amongst pharmacists from a 
cross section of pharmacy practice settings, not just hospital. Nine identities for 
pharmacists were constructed from the analysis and the authors concluded the 
range of professional identities could either reflect role ambiguity, or merely a 
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flexibility of roles. This more focused study, of neuroscience pharmacists, did 
not set out to define a professional identity per se, but the data do reveal a 
number of identities and a complexity for the role (7.3.2, p.183); in this sense, 
there are some similarities to the findings of Elvey et al.  
I do not present this substantive grounded theory as a unifying explanatory 
framework for the practice of every neuroscience pharmacist, or indeed for 
every participant in the study. The intention of the research was not to produce 
a generic job description. Qualitative research is not concerned with producing 
generalisable results (Barbour, 2000). Of note however, is that the data were 
generated from pharmacists practicing within a range of acute provider Trusts 
across NHS England. I hope that pharmacists who practice within neuroscience 
will identify with the conceptual processes of the theory. 
Charmaz (2006) acknowledges grounded theories as being ephemeral: they 
have a finite application in that they are contextualised within a time and a 
place. Independently, and towards the conclusion of this study, an opportunity 
arose for a group of neuroscience pharmacists from across the UK to meet 
together for the first time. This meeting opportunity has resulted in a 
rejuvenation of the UKCPA neuroscience group. It is my hope and intention that 
this work will generate discussion amongst neuroscience pharmacists. As well 
as providing resonance, I hope that my analysis will also be challenged by my 
professional peers, and that it will spur some people to disprove or amend the 
theory. Consequently, and collectively as a group, we will continue to develop 
clinical pharmacy practice within neuroscience.  
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I acknowledge that by using constructivist grounded theory, the theory 
presented represents a construction of the neuroscience pharmacist role 
through the pharmacists themselves, and framed through my analysis and 
presentation. I chose to construct the reality of this role through the pharmacists 
because I approached the substantive area from a viewpoint of wanting to 
understand and help to support professional practice. The pharmacists, also as 
the people who perform the role, would provide rich data to deepen the 
understanding of this area of pharmacy practice. 
Using the grounded theory method, sampling proceeds with theoretical 
sampling (3.3.2.2, p.69). In this study, data were generated from research 
interviews, with sources who can help to develop the conceptual analysis.  I did 
experience difficulties in recruitment to the study; in retrospect, recruitment was 
always going to be challenging when studying a very small, defined group of 
pharmacists. While I believe that I did achieve theoretical saturation I would 
have liked to interview some less experienced pharmacists to scope the journey 
of development into the specialism of neuroscience. I explored the early 
experiences of established pharmacists to develop and theoretically saturate 
the categories. I acknowledge that these pharmacists’ perception of their early 
experiences may have been rendered over time however they often provided 
rich sources of data, through their extensive practice experience. 
The focus of the research on clinical practice within a multidisciplinary setting 
has elements of ethnography. Observational data of the pharmacists in practice 
may have helped to add further validity to the interview data by observing 
pharmacists’ interactions. Observational episodes were not able to be 
undertaken due to the resources allocated to the study and the practical 
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challenges of reaching study sites where the pharmacists practice, throughout 
England. I still believe however that I was able to attain rich data through 
interviews to construct and illuminate the grounded theory. However 
observational research has the potential to develop the theory further by 
discovering and understanding processes through generating data beyond the 
conscious recollection of the pharmacists within the research interviews. 
In section 1.1 (p.1), I set out my axiomatic position towards the research by 
reflexively acknowledging my professional alignment towards the substantive 
area. This study does not define a value of the role of the neuroscience 
pharmacist, but a concept that identifies a process for the role. The premise of 
the central concept is that neuroscience pharmacists maintain an overview of all 
aspects of drug therapy for patients treated within neurological services.  
The grounded theory has resulted in a construct for the role of neuroscience 
pharmacists of maintaining an overview of drug therapy. The extant literature 
examining the effects of pharmaceutical care studies largely studies 
interventions in single disease states (see section 2.2.2, p.28). Pharmaceutical 
care in specialist neuroscience centres could be constructed by intervention 
studies capturing all aspects of patients’ drug therapy, including non-
neurological drugs. 
This study was an examination of pharmacists’ roles within multidisciplinary 
specialist settings. The processes identified within the grounded theory are 
those constructed through the accounts and interpretations of the pharmacists 
and is a valid and justified research approach. What this research project has 
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not done is directly identify how the role is perceived by colleagues and 
stakeholders.     
Multisource assessment, sometimes called 360 degree feedback, has been 
employed as a method for the appraisal of professional roles, by garnering 
opinions from colleagues and stakeholders. Multisource assessment has also 
been used a research method to examine healthcare roles, for example, non-
medical consultants within the NHS (McSherry et al., 2007). Other studies have 
combined data from post holders and stakeholders to examine professional 
roles (Abbott, 2007 , McIntosh and Tolson, 2009 , Stevenson et al., 2011). This 
form of research could identify how aligned neuroscience pharmacists’ 
perceptions of their role are to those of stakeholders and is a potential future 
research project. 
 
9.4 Recommendations from the research 
This study, as a piece of applied pharmacy practice research, has findings with 
implications for both pharmacy practice and the research of practice. Both these 
threads are inextricably linked because research should be informed by 
professional practice (Smith, 2010). Therefore the recommendations are 
presented in one list below:  
1. There should be an open discussion and acknowledgement amongst 
pharmacists and stakeholders of the generalist drug overview that clinical 
pharmacy can bring to neuroscience services.  
2. A curriculum for advanced pharmacy practice in neuroscience should be 
developed. The curriculum should be developed in conjunction with the 
237 
 
RPS Faculty (1.4.2.1, p.8), to support those who wish to pursue 
accreditation through this body. The following factors should be 
considered in the development of the curriculum: 
a. The curriculum should encompass the broadness of neurological 
disease but acknowledge that practice will vary for each 
pharmacist and their exposure is dependent on the service profile 
of the service they practice within. Pharmacists should be able to 
tailor the curriculum to their practice. 
b. A curriculum should signpost people to relevant reference sources 
for self-learning. Heuristic learning opportunities should be 
highlighted for professional self-development.  
c. A curriculum not only needs to concentrate on the clinical aspects 
of drug use but generic commissioning arrangements around drug 
use within the NHS. Knowledge of these processes will equip 
pharmacists to navigate issues in gatekeeping drug therapies with 
greater clarity.  
d. A generic induction guide for clinical pharmacy posts in 
neuroscience should also be produced aside to a curriculum. This 
document should identify key activities which need to be 
undertaken and key personnel within neuroscience services to 
meet, during the induction process.    
3. In conjunction with a curriculum, more educational events for 
pharmacists should be organised for neurological disease. Consideration 
should also be given to organising collaborative multidisciplinary 
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educational events around neurological disease, for example with the 
British Association of Neurological Nurses (BANN). Such events could 
bring together the diverse knowledge of the professions, enriching the 
learning process beyond consideration of just the drug therapy for 
pharmacists and all involved, and promoting collaborative working. 
4. More opportunities for peer networking should be provided for 
neuroscience pharmacists. The study has highlighted the challenges of 
practicing in isolation, especially in the early stages of the role. Work is 
beginning to take place with the UKCPA neuroscience group; this work 
should continue and attempt to reach out to as many pharmacists as 
possible, using virtual or digital forums that can circumvent the 
geographical spread of neuroscience pharmacist posts. A mentoring 
system should be explored, to support pharmacists entering into 
neuroscience and to pharmacists practicing in isolation.  
5. Pharmacy and neuroscience services should explore ways for more 
comprehensive pharmacist inclusion within multidisciplinary ward rounds. 
This study identifies the importance of ward round participation for 
pharmacists to glean knowledge about individual patients, optimising 
their interventions. The study also identifies the problems pharmacists 
can experience in challenging prescribing decisions retrospectively.    
6. Further research should be undertaken to quantify clinical pharmacy 
service provision within hospital-based neuroscience services. This work 
should also identify the provision of medicines management technicians 
and how those roles are employed. A research study could be 
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considered which examines the interventions made by neuroscience 
pharmacists. Potential research questions to explore within the study are: 
a. What is the relative proportion of interventions made in direct 
relation to patients’ drug therapy for their neurological condition, 
compared to non-neurological co-morbidities? 
b. How do factors like ward round participation and length of time 
within the role affect the number of interventions made by 
pharmacists and the rate of acceptance from the multidisciplinary 
team? 
7. Research should explore stakeholders’ views of the role for clinical 
pharmacists in neurological services. 
 
9.5 A final reflection on the research journey 
I entered into this research project with the notion of wanting to examine clinical 
pharmacy practice in neuroscience but with no strong inclination of how I would 
go about it. As an (up and down) intellectual endeavour, I am grateful for the 
opportunities qualitative research afforded me to think differently about my 
professional world, and the world in general.  
A feature of qualitative research, and the grounded theory method, that stands 
out to me, is the breadth of its application. I have read literature and met people 
from other professional walks of life that I cannot imagine would have happened 
had I undertaken a quantitative pharmacy practice research project. 
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Like other pharmacists who have undertaken qualitative research (Tonna and 
Edwards, 2013), I do not feel that I can make claims to be any kind of expert in 
all its forms but my eyes have been opened to its potential for further research. 
Undertaking a research project through a more interpretive, humanistic lens has 
re-affirmed to me that healthcare, receiving it as a patient and delivering it as a 
professional, is a strong human experience. That affirmation, combined with 
reflections on my personal and professional experiences that have occurred 
concurrently to my DPharm and research journey, have strengthened my belief 
in the principles and the immense value of the NHS and I am proud to be 
working within it as a pharmacist. 
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Appendix 1: Search strategy for pharmaceutical care in 
neurological disease 
 
1. pharmacist*.ti,ab,ab 
2. PHARMACISTS 
3. "clinical pharmacist".ti,ab,ab  
4. "clinical pharmacy".ti,ab,ab  
5. (pharmacy AND service).ti,ab,ab  
6. "pharmacy service".ti,ab,ab  
7. 1 OR 2 OR 3 OR 4 OR 5 OR 6  
8. neuro*.ti,ab  
9. epilep*.ti,ab,ab  
10. EPILEPSY/ OR EPILEPSY, POST-TRAUMATIC 
11. MEDLINE; 9 OR 10  
12. parkinson*.ti,ab,ab  
13. "parkinson's disease".ti,ab  
14. PARKINSON DISEASE/  
15. 12 OR 13 OR 14  
16. "multiple sclerosis".ti,ab,ab  
17. MULTIPLE SCLEROSIS 
19"motor neuron disease".ti,ab,ab  
20. "motor neurone disease".ti,ab,ab  
21. MOTOR NEURON DISEASE/  
22. "amyotrophic lateral sclerosis".ti,ab  
23. AMYOTROPHIC LATERAL SCLEROSIS 
24. 19 OR 20 OR 21 OR 22 OR 23  
25. "myasthenia gravis".ti,ab  
26. MEDLINE; MYASTHENIA GRAVIS/  
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27. 25 OR 26  
28. headache.ti,ab  
29. HEADACHE/ OR CLUSTER HEADACHE/ OR HEADACHE DISORDERS/ 
OR HEADACHE 
DISORDERS, PRIMARY/ OR HEADACHE DISORDERS, SECONDARY/ OR 
POST-DURAL PUNCTURE 
HEADACHE/ OR POST-TRAUMATIC HEADACHE/ OR TENSION-TYPE 
HEADACHE/  
30. migrain*.ti,ab  
31. MIGRAINE DISORDERS 
32. 28 OR 29 OR 30 OR  
33. 16 OR 17  
34. MEDLINE; 7 AND (8 OR 11 OR 15 OR 24 OR 27 OR 32 OR 33) [Limit to: 
English Language and Humans and Publication Year 2000-2014 and (Age 
Groups Young Adult 19 to 24 years or Young Adult and Adult 19-24 and 19-44 
or Middle Age 45 to 64 years or Middle Aged 45 plus years or All Aged 65 and 
Over or Aged 80 and Over)] 
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Appendix 2: Literature of pharmaceutical care in neurological 
disease 
 
The summary table begins on the following page. 
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Author(s) / 
Year 
Title / Context 
(Broad aim) 
Organisational / 
clinical  setting 
 
Methodology  
 
Data collection and 
analysis 
Findings and comments 
Epilepsy      
      
Bond, C. A. 
Raehl, C. L. 
(2006) 
Effect of 
pharmacist 
managed AED 
therapy under the 
umbrella of 
‘collaborative 
drug therapy 
management’ 
 
Hospital inpatients 
with epilepsy (US 
Medicare system –  
multi-site) 
Quantitative 
(naturalistic 
study - large) 
Comparing 
institutions with 
pharmacist 
managed AEDs 
vs not. 
Retrospective data 
collection – clinical 
(mortality, LOS) and 
economic 
(Medicare/drug/lab 
costs) outcomes). 
Improved clinical and economic 
outcomes (statistically significant). 
120% higher mortality without 
pharmacist involvement.  
Case mix index comparable 
between the 2 hospital sets but no 
other general performance 
indicators compared. 
Study undertaken within US 
healthcare system. Details of how 
collaborative drug therapy 
management specifically works 
with epilepsy lacking. 
      
Bhattacharya, 
D. 
Fogg, A. 
Staufenberg, 
E. et al 
(2008) 
 
Pharmacist 
management of 
epilepsy 
Pharmacist led 
primary care epilepsy 
clinic (UK) – single 
intervention of 30 min 
interview and 
medication review 
(n=50) 
 
Conference 
abstract 
Quantitative 
(Service review) 
Psychological well being 
(GHQ-12) 
Satisfaction of meds info 
(SIMS).  
Non-parametric stat 
analysis 
Statistically significant 
improvement in both scores. Most 
common intervention – giving 
details of epilepsy charity. 
Suggests epilepsy services in the 
area poor? Access to epilepsy 
nurse specialist? 
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McAuley, J.M. 
Miller, M.A. 
Klatte, E. 
et al 
(2009) 
 
Patients with 
epilepsy 
perceptions of 
community 
pharmacist 
involvement. 
 
Primary Care (US) 
(n=75). 
Survey design  Descriptive statistics of 
survey response. 
Most common reasons to consult 
pharmacist were for information on 
drug interactions and adverse 
effects. Evidence to support survey 
design lacking. Yes/no answers so 
limited opportunities to probe 
reasons and limitations of 
extrapolating from UK to US. 
 
Brown, C 
(2012) 
Pharmacist led 
management. 
Primary care (UK) 
0.4wte pharmacist 
undertaking 
structured clinic 
reviews and action 
treatment plans. 
Quantitative Largely descriptive 
statistics of pharmacist 
activities. Quality 
measures – 
questionnaire but no 
example or evidence it is 
validated and sensitive. 
Reduction in emergency 
admissions and hospital 
appointments (no statistical 
analysis).High proportion (82/86) 
described good experience of the 
service. Note interaction with 
community matron, GP, 
neurologist, epilepsy nurse 
specialist – no assessment of their 
views. 
 
      
Fogg, A., 
Staufenberg,E. 
Small, I. 
Bhattacharyya, 
D. 
(2012) 
Pharmacist-led 
epilepsy 
consultation 
study – feasibility 
study. 
Primary care (UK). 
Practice pharmacist 
led single intervention 
of 30 min interview 
and medication 
review (n=106). 
Quantitative. 
Pre-intervention 
and 2 months 
post-
intervention. 
Self-reported adherence 
(MARS) 
QoL (QOLIE-10) 
Psychological wellbeing 
(GHQ-12) 
Satisfaction of meds info 
(SIMS) 
Side effects (epilepsy 
diary)  
Non-parametric stat 
analysis 
67% completion rate (f/u at 2 
months) 
Stat significant improvement in 
MARS, GHQ-12,  
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Headache 
 
     
Wenzel, R. 
Schommer, J. 
(2002) 
 
Patient 
satisfaction with 
pharmacist 
education. 
Hospital outpatient 
(tertiary referral) clinic 
(US). 
Quantitative Questionnaire Favourable assessment of 
pharmacist for headache 
counselling. Patients also 
attending monoamine oxidase 
inhibitor clinic invited to complete 
questionnaire; results not 
presented – not favourable 
assessment? 
 
Gahir, K. K. 
Larner, A. J. 
(2004) 
Consultation to 
community 
pharmacists by 
headache 
sufferers.  
 
100 consecutive 
admissions to tertiary 
referral headache 
service (UK). 
Quantitative Survey – descriptive 
statistics. 
15% patients had consulted a 
community pharmacy – authors 
(neurologists)  conclude 
community pharmacy underused 
but more training required. 
 
Weitzel, K 
Presley, D. 
Showalter, M. 
et al 
(2004) 
 
Pharmacist 
managed 
headache clinic. 
Primary Care Clinic 
(US). 
n/a Largely descriptive 
statistics of patient 
demographics and 
recommendations. 
Author acknowledge limitations: 
No outcome data. 
No patient satisfaction 
assessment. 
Hoffmann, W. 
Herzog, B. 
Muhlig, S. 
(2008) 
Effect of 
‘pharmaceutical 
care’ (intensive 
counselling) on 
frequency of 
headache and 
migraine 
Community 
pharmacies 
(Germany). Patient 
recruitment: people 
buying OTC 
headache drugs 
(n=482)  
Quantitative Before and after 
telephone interviews to 
measure: 
No. days with headache. 
No. and severity of 
headaches. 
QoL measures (self-
administered). 
No improvement in headache 
frequency or severity but QoL 
scores ‘statistically’ better. 
Findings perhaps not surprising if 
pharmacists could not alter drug 
therapy. 
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Skomo, M. 
Desselle, S. 
Berdine, H. 
(2008) 
Effect of 
pharmacist 
intervention 
(counselling) on 
seeking medical 
care by 
migraineurs 
 
Migraineurs within a 
university population 
(US) – primary care 
Described as 
‘quasi-
experimental’ – 
looks 
quantitative 
Self-administered 
questionnaires 
Outcomes don’t appear to match 
the aims – difficult to understand 
the effect of pharmacist 
intervention. 
Skomo, M. L. 
Desselle, S. P. 
Shah, N. 
(2008) 
 
Migraineurs 
perceptions of 
the role 
community 
pharmacists can 
play in their 
condition 
 
Migraineurs within a 
US population (US) – 
primary care 
Qualitative – 
phenomenology  
Focus groups – 
‘inductive’  content 
analysis 
Many communication barriers exist 
between patients and pharmacists.  
Focus groups potentially within a 
very specific population of people 
educated to degree level and 
beyond.  
      
Stepkova, M. 
Vanhecke, S. 
Putman, K. 
De, J. et al 
(2011) 
Comparing 
‘intensive’ vs 
‘standard’ clinical 
pharmacy on 
clinical outcomes 
for migraineurs  
 
 
Primary Care 
community pharmacy  
(Belgium) 
Conference 
abstract 
Quantitative – 
randomisation 
to intensive vs 
standard 
p’ceutical care 
Standardised 
questionnaires pre and 
post intervention 
  Medication use 
  Migraine specific 
assessment tool 
(MIDAS) 
  QoL – EQ-5D 
 
No significant difference in 
medication use and quality of life. 
Stat significant differences in 
average MIDAS score and 
headache days but no actual 
scores provided so difficult to 
interpret the clinical significance. 
Harris, A. 
(2012) 
 
Pharmacist 
involvement in 
headache clinic 
with telephone 
follow up. 
Hospital outpatients 
(UK) 
Conference 
abstract 
Quantitative 
Questionnaire of patient 
within clinic of their 
satisfaction. 
Questionnaire developed 
from RCGP  
47% response rate. Raw 
presentation of responses which 
are very favourable towards 
pharmacist involvement. 
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Motor 
neurone 
disease 
 
     
Jefferies, K.A. 
Bromberg 
M.B. 
 
Pharmacist 
involvement 
within multi-
disciplinary clinic 
 
Hospital outpatients 
(US) 
n/a Largely descriptive 
statistics of interventions 
made by pharmacist 
2 interventions per patient on 
average 
Education on 2.5 topics per patient 
on average 
Movement 
disorders 
 
     
Schroeder, S. 
Martus, P. 
Odin, P. 
et al  
(2011) 
 
Pharmacist 
identification of 
drug-related 
problems (DRPs) 
in patients with 
Parkinson’s 
disease against 
defined checklist 
 
Primary care 
(Germany) 
Community 
pharmacists (n=33) 
reviewing outpatients 
with IPD (n=113) 
Quantitative Baseline demographics 
and QoL scores (PS-23; 
PDQ-8 (abbreviated 
PDQ-39); EQ-5D/EQ-
5D-VAS). 
Descriptive statistics of 
interventions made) 
331 DRPs identified and 474 
interventions proposed (patient 
advice most common – c. 20%) 
215 outcomes recorded for the 331 
identified DRPs although by 
different groups – physician, 
patient so lack of consistent 
assessment. No follow up Qol 
assessment so difficult to assess 
overall impact. 
 
Poon, L. H. 
Lee, A. J. 
Chiao, T. B. et 
al 
(2012) 
Effect of a 
pharmacist in 
movement 
disorders clinic 
Outpatient movement 
disorders clinic (US) 
Quantitative 
(review of pilot 
study) 
Quantification of 
interventions 
Anonymous 
questionnaire to 
colleagues and patients 
(5 point Likert scale) 
 
General favourable assessment 
from survey data 
69 recommendations accepted in 
131 patients – unclear whether all 
recommendations accepted. 
Recommendations followed up in 
terms of patient outcome but 
grading of this not entirely clear – 
who was it done by? 
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Neurosurgery 
 
     
Weant, K. 
Armitstead, J. 
Ladha, A 
(2009) 
 
The cost-
effectiveness of a 
clinical 
pharmacist in a 
neurosurgical 
team 
Neurosurgical 
patients (US) 
Quantitative Cost comparisons pre 
and post introduction of 
pharmacist into 
neurosurgical team. 
Statistically significant reductions 
in drug costs per patient admission 
(approx. 25% ) and length of 
patient stay. 
Direct cause and effect cannot be 
assumed as study not 
designed/powered to test this 
hypothesis. 
Authors note no other significant 
service/protocol changes during 
study period. 
 
Bourne, R, 
Dorward, B. 
(2011) 
Quantifying 
pharmacists 
interventions and 
clinical 
significance 
 
Hospital pharmacists 
in tertiary referral 
neurosurgical 
intensive care unit 
(UK) 
Quantitative Prospective collection of 
all interventions, coding 
and significance 
assessment using 
validated rating scale.  
Significant interventions made with 
high acceptance rate by medical 
staff. 
Limitations are short duration of 
the study. 
      
      
General 
 
     
Welty, T. 
(2006) 
 
Clinical 
pharmacy 
practice in 
neurology and 
neurosurgery 
 
Specialist hospital 
setting (US) 
n/a Commentary paper on 
the evolution of specialist 
clinical pharmacy 
practice 
Notes neuroscience as a small 
medical speciality and also small 
clinical pharmacy specialism – 
comparative observations to UK 
practice. 
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Barnes, J. 
(2011) 
Primary care 
involvement with 
patients with long 
term neurological 
conditions 
Primary care (UK) n/a Description of role and 
examples of input 
Pharmacist involved with the care 
of patients with Parkinson’s 
disease and multiple sclerosis. 
      
      
Barnes, J. 
(2012) 
 
Primary care 
involvement with 
PD and MS 
 
Primary care (UK) n/a Further description of 
role from 2011 paper 
Note initial resistance from 
neurologists. 
Swain, L. D. 
(2012) 
Identifying 
pharmacist 
interventions and 
quantifying 
patient 
satisfaction 
Hospital outpatient 
neurology clinic (US) 
Quantitative Prospective collection of 
data and  
192 recommendations 
(interventions) in 56 patients. Most 
common reasons were to 
discontinue (29%) or add (24%) 
medication. Does not indicate if 
recommendations accepted. High 
levels of patient satisfaction 
      
 
  
264 
 
Appendix 3: Ethical approval and NHS research approval 
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Appendix 4: Study information leaflet 
 
 
A study of the clinical pharmacist’s role within the specialism 
of neurosciences 
 
INFORMATION SHEET 
 
 
You are being invited to take part in a research study.   
 You do not have to say yes. 
 If you do not want to take part in the study then you do not have to say 
why. 
 
Before you decide, it is important for you to understand why this research is 
being done and what it will involve.  Please take some time to read the following 
information carefully and discuss it with others if you wish.   
 
What is the purpose of this study? 
This study aims to understand how clinical pharmacists specialising in the area 
of neurosciences develop their role and speciality by discussing your 
experiences and opinions of your role. 
 
Why have I been asked to take part? 
You have been asked to take part because you are a clinical pharmacist 
working within the clinical specialism of neurosciences. 
 
Do I have to take part? 
Taking part in the study is entirely voluntary and you do not have to if you do not 
wish to do so. 
 
What will happen to me if I take part? What will I be asked to do? 
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 You will be asked to take part in a telephone interview which should last 
between 30 and 60 minutes. 
 You can choose when the interview will take place. 
 During the interview you will be asked some general questions about 
your professional role and your experiences of it.  
 You may be asked to clarify some of the things that you say in the 
interview or asked some further questions relating to what you said. 
 The interviews will be taped. 
 
What do I have to do? 
 Please return the form that came with this letter indicating whether you 
do or do not wish to take part in this study 
 If you do not want to take part then you will not be contacted again 
 If you do wish to take part in the study then please indicate the best 
means of contacting you with the appropriate contact details 
 
What are benefits of the study? 
The study aims to achieve a better understanding of your specialist clinical 
pharmacist role. By doing so we hope we will develop a better understanding of 
how to try and support you professionally. 
 
What are the possible disadvantages and risks of taking part? 
There are very few risks in taking part in interviews. You will have to give up 
some of your time. If there is a professional issue or incident that you do not 
want to discuss then you do not have to. The researcher would have a 
professional obligation to consider reporting any incident mentioned during the 
interview that was an illegal act or a gross breach of the General 
Pharmaceutical Society's code of ethics. You can stop the interview at any time.  
 
 
Will my taking part in the study be kept confidential? 
 Some professional information about you will be collected and stored in 
password protected computer system. This includes: 
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o Your name, age and gender 
o The number of years you have been registered as a pharmacist 
and the number of years you have worked in your current role 
o The Agenda for Change grading of your current post  
o Your level of academic qualification (e.g. BSc, MPharm, etc.) 
 This information will not be stored on a laptop or memory stick 
 All interview tapes will stored in a locked drawer in the researcher’s 
hospital office 
 The transcript of your interview will not contain your name; a code will be 
used and these codes will be stored electronically and securely as 
described above 
 All interviews and electronic and paper copies of transcripts will be 
destroyed at the end of the study. 
 
What if there is a problem or something goes wrong? 
The researcher is accountable to the following person: 
Dr Amanda Plummer, Clinical Services Manager 
Pharmacy Department, Royal Hallamshire Hospital, Glossop Road, 
Sheffield, S10 2JF 
Tel: 0114 2712424 
  
What will happen to the results of this study? 
 Your interview will be analysed along with the interviews conducted with 
other pharmacists.  
 The results will be written up as a research report to be submitted for the 
award of a Doctor of Pharmacy degree. 
 The results will also be written as papers to be submitted to peer-
reviewed journals. 
 You will be offered a copy of these reports to read them if you wish.  
 You will not be identifiable in any of these reports. 
 
Who is organising and funding the research? 
This research is being undertaken by a hospital pharmacist at Sheffield 
Teaching Hospitals NHS Foundation Trust who is also undertaking a research 
degree (DPharm) at the University of Bradford.  
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Who has reviewed this research? 
This research has been reviewed by the ethics committee at the University of 
Bradford. 
 
What if I want more information? 
You can contact the researcher 
Mr Ben Dorward, Lead Neurosciences Pharmacist 
Pharmacy Department, Royal Hallamshire Hospital, Glossop Road, 
Sheffield, S10 2JF 
Tel: 0114 2713225 or 0114 2434343 (asking for bleep 2580) 
E-mail: B.J.Dorward@student.bradford.ac.uk 
 
Thank you for reading this.  
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Appendix 5: Study consent form 
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Appendix 6: Examples of coding and memo writing 
 
Coding example 
The transcript below is an example of how I coded interview transcripts. It also 
illustrates how I analysed my interview technique, using footnotes. This extract 
also illustrates how I originally missed a key code of ‘proving value’ (illuminated 
in yellow) which I subsequently identified from a later re-analysis.  
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Example of a memo on knowledge 
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Examples of memos 
 
These are excerpts from memos that I made after interviews. 
 
Interview 1 (21/11/2012) 
Overall, I felt that my first interview went OK. The interview lasted just over 46 minutes 
and I felt it came to a fairly natural ending. What was difficult was the cognitive 
challenge of processing the information coming from the participant to decide what to 
ask next. I think I coped reasonably well at the beginning but struggled as the interview 
went on. Although I was making notes on paper I wasn’t capturing the thread of the 
interview and having read the interview transcript I can identify missed opportunities to 
probe question responses further (e.g. line 237 – should have probed further as to why 
the matron, ADO and clinical director were key personnel) and the interview became 
less coherent its focus in the latter half. That said I can identify points in the interview 
where I identified previous statements and attempted to link them in the conversation 
such as line 323 where I picked up on ‘niche’ and from reviewing the transcript I can 
see that the participant had used this word 5 times up to this point of the interview.  
 
Interview 4 (05/06/2013) 
 
Research technique issues  
This interview went better than the previous one in terms of the interview process. Half 
an hour before this interview I sat down and I thought quite closely about the interview 
process. I had written down 3 statements and I consciously read those. 
I am a researcher not a pharmacist – talk about ‘pharmacists’ and not me or ‘us’ 
No I do not know what pharmacists mean when they ask me that. I need 
respondents to explain that further to me. 
I am trying to undo 14 years of professional experience. That’s impossible but I 
need to ‘bracket’ those experiences and perceptions as best that I can 
  
There are some long and slightly uncomfortable pauses (for me at least) within the 
interview but this strategy did elicit some further responses from the interviewee. One 
example is line 293 to 303 in the response to a question around differing professional 
perspectives of an issue. In previous interviews I would have probably been inclined to 
interject the silence with a further question or more specific question which may have 
then missed some data that could have been provided from the response to the original 
question. 
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There was a telling statement towards the end of the interview: 
I: Right. I think that was actually a very good response actually. I don't 
have anything further to ask. Was there anything you wanted to add that I 
had not discussed in the interview? 
R: No I don't think so. I mean I had a read through your of your proposal. I 
wasn't really sure in terms of what you are going to ask me actually initially. 
Have you got everything you needed? 
This section of interview highlights 3 issues to me 
1. Some apprehension on behalf of the interviewee about what they were going to 
be asked. I wish in retrospect I had asked how the actual experience compared 
to their expectations. If this is raised within a subsequent interview I will ask.  
2. An illustration of the ‘power asymmetry in qualitative research interviews’ 
(reference Kvale). The question ‘Have you got everything that you needed?’ 
implies to me an expectation on behalf on the interviewee to provide the 
information I, as the interviewer, require.  
3. A realisation that I am probably taking the interviewees slightly outside of their 
comfort zone. As a professional peer I feel that I do have some empathy with 
that as I think it unlikely that participants will have been exposed to this form of 
interviewing. My standard opening question of asking participants to describe 
their role does tend to elicit a very descriptive response. I think true qualitative 
researchers might consider this to be inefficient interviewing but I think it can be 
a good tactic for settling the participants and asking a fairly routine question. I 
also need to allow participants time to answer my questions because they are 
not straight forward questions to answer. 
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Appendix 7: Evaluation of the research quality 
 
The table overleaf provides a defence for the rigour of the research set against 
the criteria of quality in qualitative research devised by Spencer et al. (2003). 
The appraisal questions are taken directly from this document. I have 
interpreted some overlap with these questions and consequently some 
responses have been repeated within the table to answer all questions.   
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Appraisal questions Responses in relation to this study 
How credible are the findings? The findings have been illuminated with interview data to illustrate the analysis. 
Where found, I have included negative cases i.e. those that disagree with the prevailing 
findings, to illustrate the limitations of the grounded theory.  
In section 9.3 (p.232) I have acknowledged the limitations of the research and I been explicit in 
stating the grounded theory is not a unifying theory for clinical pharmacy practice in 
neuroscience. 
The findings were orally presented to a small group of neuroscience pharmacists on 25th 
September 2014 and were positively received as representative of contemporary practice.  
 
How has knowledge been extended by the 
research? 
This research has illuminated the construction of the role of clinical pharmacists within a 
multidisciplinary specialist service. The research has identified how different forms of knowledge 
are required to support clinical pharmacy practice, congruent with empirical findings from 
studies of advanced practice in nursing and medicine. The research identifies ways to support 
clinical pharmacy practice in neuroscience. 
 
How well does the evaluation address its 
original aims and purpose? 
In section 8.3 (p.210) I have answered the initial research questions to the study through the 
findings of the grounded theory. 
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Scope for drawing wider inference – how well 
is this explained? 
I have been explicit in stating the results as a substantive grounded theory of specialist clinical 
pharmacy practice in neuroscience. The participants for the study were drawn from across a 
range of NHS Trusts. The intention was not to produce generalisable results. However further 
studies, of other clinical pharmacy specialisms, would identify the wider relevance of these 
findings, helping to develop a wider theory for specialist clinical pharmacy practice. 
 
How clear is the basis of evaluative 
appraisal? 
 
The research did not set out to explore the effect of an intervention; it was an exploratory study 
of clinical pharmacy practice in neuroscience.  
How defensible is the research design? 
 
I have set out the reasons for using research interviews and the use of telephone interviews to 
circumvent the geographical spread of the participants. I utilised an evolving interview structure 
to explore emerging concepts from the study. 
  
How well defended is the sample design/ 
target selection of cases/documents? 
I set out the recruitment process in section 3.3.1 (p.61). The study population is a small one but 
I attempted to identify and recruit as many neuroscience pharmacists as I could. Although 
grounded theory research is not concerned with generalisable findings I recruited pharmacists 
from a range of NHS Trusts and was able to generate rich data about pharmacy practice in this 
area. 
 
Sample composition/case inclusion – how 
well is the eventual coverage described? 
Figure 3 (p.64) summarises the recruitment strategy for the study. I acknowledged a 
predominance of more experienced pharmacists within my sample. 
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How well was the data collection carried out? The process of data collection is described in section 3.3.1 (p.61). Research interviews were 
audio recorded and transcribed verbatim so that no data were lost. 
  
How well has the approach to, and 
formulation of, the analysis been conveyed? 
 
The data analysis took place in accordance with grounded theory methods. I utilised coding of 
data, raising the level of theoretical abstraction to create the grounded theory.  
Contexts of data sources – how well are they 
retained and portrayed? 
A brief overview of the participating pharmacists is provided is section 3.5 (p.75). 
Where it is appropriate, I have included the interview questions to contextualise the participants’ 
responses. 
 
How well has diversity of perspective and 
content been explored? 
 
I have acknowledged outlying cases within the findings. The grounded theory accounts for 
variation in the three conceptual processes identified from the study data. 
How well has detail, depth and complexity 
(i.e. richness) of the data been conveyed? 
I have retained in vivo codes. 
Within the interview data there are examples of where I have probed with questioning to elicit 
further meaning to participants responses.  
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How clear are the links between data, 
interpretation and conclusions – i.e. how 
well can the route to any conclusions be 
seen? 
 
I have presented the conceptual processes separately and then the grounded theory, to explain 
how these processes are brought together. 
How clear and coherent is the reporting? 
 
I have attempted to present the study findings in a structured manner and by introducing and 
summarising each main chapter. 
I have separated the study findings from the discussion and wider literature to enable the reader 
to judge these in their own right. 
I have diagrammatically summarised concepts and processes that emerged from the data to aid 
clarity in their presentation. 
 
How clear are the assumptions/theoretical 
perspectives/values that have shaped the 
form and output of the evaluation? 
 
I have set out my epistemological and ontological perspectives towards the research in section 
3.2.2 (p.51). I have acknowledged at the outset of the research my professional alignment 
towards it. 
What evidence is there of attention to ethical 
issues? 
I have set out the ethical considerations of the research in section 3.4 (p.71). The key 
considerations that I have addressed are informed consent by participants and maintaining 
anonymity.  I have used pseudonyms to present the data findings. 
 
281 
 
Appendix 8: Poster presentation of the emerging grounded 
theory 
 
The poster overleaf was presented at a University of Bradford research day on 
2nd April 2014. It presents the emerging findings of the grounded theory. The 
poster illustrates the emergent nature of this grounded theory research through 
the way that the categories of the final theory have developed from the ones in 
this poster.    
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Appendix 9: Previous published research from the candidate 
 
BOURNE, R. S. and DORWARD, B. J. (2011) Clinical pharmacist interventions 
on a UK neurosurgical critical care unit: A 2-week service evaluation. 
International Journal of Clinical Pharmacy, 33 (5), 755-758. 
Abstract 
Objective 
To identify the input of specialist critical care pharmacists into patient care, 
promoting safe and effective medication therapy; by quantifying medicines 
related interventions on a Neurocritical Care Unit.  
Setting 
UK 19-bedded Neurocritical Care Unit providing a tertiary referral service for 
Neurosurgical and Neurology patients. 
Method 
Prospective observational study of clinical pharmacist interventions conducted 
over a two week period in July 2010. Interventions were recorded, categorised 
and independently assessed by a panel of 5 healthcare professionals for 
potential patient harm if the intervention had not been made.  
Main outcome measure 
Quantity and potential severity of clinical pharmacist interventions recorded. 
Results 
246 interventions were made in 55 patients over the 10 day observational 
period. A median of 7.0 (1.5; 12.0) and 2.0 (1.0; 4.0) interventions were made in 
Level 3 and 2 patients respectively. Mean potential severity of patient harm per 
intervention was 3.7 (1.12); range 0.8-7.0. Thirty-two interventions (13.0%) were 
high patient risk. Central Nervous System medicines comprised the most 
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common therapeutic group affected (37.8%). Medication errors accounted for 
eighty-seven of the 246 interventions (35.4%).  
Conclusion 
The results of the clinical pharmacist intervention evaluation demonstrated an 
important role for critical care pharmacists in the safe and effective use of 
medicines in a UK Neurocritical care unit.  
Introduction 
Critical care patients are some of the most vulnerable to medicines related 
harm. This is due to the acuity of their illness, multi-organ failure, polypharmacy 
and proportion of intravenous drug use 1. It is therefore understandable that 
pharmacists make some of their most significant clinical contributions in critical 
care areas, but this also requires the greatest resource allocation 2. 
The national United Kingdom (UK) standards for levels of clinical pharmacy 
service to critical care areas and the specialist training required for these posts 
have been clearly identified by the Department of Health 3,4. However there 
remains significant inter and intra-hospital variation in the levels of critical care 
pharmacy services. In Sheffield, there was a requirement to evaluate the clinical 
activity of pharmacists in the care of critically ill patients in the Neurocritical 
Care Unit, to support the development of enhanced clinical pharmacy services.  
Aim of the study 
To identify the clinical pharmacists input into patient care, promoting safe and 
effective medication therapy; by quantifying medicines related interventions on 
the Neurocritical Care Unit, made by specialist pharmacists with appropriate 
critical care training and service commitment time.  
Method 
The Neurocritical Care Unit in Sheffield Teaching Hospitals NHS Foundation 
Trust is a 19 bedded unit (6 Level 3 beds, 13 Level 2 beds) providing a tertiary 
referral service for Neurosurgical and Neurology patients.  
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A prospective observational study of medication interventions made as part of 
daily patient review by a specialist clinical pharmacist with critical care training 
4. The evaluation was conducted by two clinical pharmacists over a two week 
period in July 2010.  All pharmacist interventions made on review of patients on 
the Neurocritical Care Unit were recorded. Interventions were recorded, 
categorised and assessed for patient harm if the intervention had not been 
made. Assessment of patient harm used a visual analogue scale ranging from 0 
(no patient harm) to 10 (patient death). A panel of five healthcare professionals 
(3 x clinical pharmacists; 1 x specialist nurse; 1 x intensive care consultant) 
independently assessed the potential patient harm with the average of the five 
scores presented. This is a valid and reliable method to assess medication 
errors 5.  
Descriptions of parametric data are as the mean and standard deviation (SD); 
non-parametric data are presented as the median and interquartile range (IQR). 
Statistical analysis was undertaken using Sigmastat 3.1 (Systat Software Inc. 
California, USA). Registered STH Audit Department Service Evaluation No. 
3379.   
Level 3 care refers to patients needing advanced respiratory support alone or 
requiring a minimum of two organs supported (usually referred to as an “ICU 
patient”). Level 2 care refers to patients receiving single organ support but 
includes basic respiratory and cardiovascular support (commonly known as a 
“HDU patient”) 6.  
Results 
Interventions 
246 interventions were made in 55 patients (43 (78.2%) Level 2; 12 (21.8%) 
Level 3) over the 10 day evaluation period. Patients in whom an intervention 
was made had a median of 3.0 (1.0; 5.0) interventions recorded; range 1 - 28.  
177 patient episodes of a daily drug therapy review were undertaken in the 10 
days, demonstrating that for every 7 patients reviewed per day; approximately 
10 medication interventions are made.  
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Mean severity of potential harm assessment was 3.7 (1.12), range 0.8 to 7.0. 
Eighty-seven of the 246 interventions (35.4%) were classified as medication 
errors. 
Daily activity 
Averaged over the 10 day period there were 25 interventions per day. 
Critical Care Level 
141 interventions were made in 127 Level 2 patient episodes (daily drug 
therapy review); 105 interventions in 50 Level 3 patient episodes. There were 
2.1 interventions per Level 3 patient per day; 1.1 per Level 2 patient per day. A 
median 7 interventions were made per Level 3 patient (1.5; 12.0); range 1 to 28. 
A median of 2 interventions were made per Level 2 patient (1.0; 4.0); range 1 to 
12. 
Acceptance of Interventions 
221 of the 246 interventions (90%) were accepted; 15 were not accepted and 
10 were lost to follow up. Level 3 and 2 interventions showed similar levels of 
acceptance; Level 3 91.4%; Level 2 89.4%. 
Drug related problem 
The most common drug related problem was Non-conformity to guidelines/best 
practice/Contra-Indication; 66 interventions (26.8%), followed by Administration 
related, 49 (19.9%), Adverse drug reaction 28 (11.4%) and Drug without 
indication 22 (8.9%) [Figure 1].  
Insert Figure 1 near here 
  
Reason for Intervention 
The primary reason for the medicines intervention was for Patient safety/ Risk 
reduction, 115 interventions (46.7%); followed by Therapeutic optimisation 86 
interventions (35.0%); then Information transfer (7.7%); Financial (5.3%); 
Guideline conformity (3.3%) and Infection control (2.0%).Medicine interventions 
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The most common intervention related to Optimisation of medicine 
administration, 71 interventions (28.9%), followed by Drug discontinuation 51 
(20.7%), Dose adjustment 42 (17.1%) and Addition of new drug 34 (13.8%) 
[Figure 2]. 
Insert Figure 2 near here 
Therapeutic Category  
Ninety-three of the 246 interventions (37.8%) were recorded for drugs with 
implications primarily for Central Nervous System (CNS) activity. The other 
most common interventions affected Muscle/ Joint (primarily analgesia) 
(16.3%); Gastro intestinal system (primarily gastric motility; antiemetics) 
(12.6%); Infection (antibiotic use, dosing, monitoring) (10.6%); Blood 
(electrolytes) (8.5%). 
Source of interventions 
211 of the 246 interventions (85.8%) were proactive i.e. instigated by a 
pharmacist. Of the 35 reactive interventions (prompted by medical/ nursing 
staff), the majority were when the pharmacist was on the ward versus contact 
by bleep/phone, 32 of 35 (91.4%).  
Medicines Reconciliation 
Forty patients had medicines reconciliation completed by the pharmacists 
during the evaluation period, a mean of 4 (1.3) patients per day. The latter did 
not include patients admitted from other wards with prior medicines 
reconciliation. Interventions directly related to medicines reconciliation 
accounted for 29 of the 246 interventions (11.8%). 
Discussion 
Pharmacists with specialist critical care training identified a significant number 
of medicine interventions (246 in 55 patients with a mean potential severity of 
harm of 3.7); without which patient care would have been compromised in terms 
of increased clinical risk or reduced efficacy of therapy provided. As such, the 
high incidence of interventions made demonstrates an important service 
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provided by an appropriate clinical pharmacy service in terms of improving 
patient safety and clinical outcomes. Optimum Neurosurgical outcomes for 
patients also require similar high quality use of medicines in immediate post-
operative periods. The latter include optimising anticonvulsant therapy, delirium 
prevention and management, reducing adverse CNS effects, therapeutic drug 
monitoring and management of drug interactions. Other clinical areas identified 
as areas that would benefit from further pharmacy support were acute pain 
management (“Muscle/Joint”), post-operative nausea and vomiting (PONV)/ 
gastric motility (“Gastro intestinal system”) and antimicrobial optimisation (e.g. 
dosing in multi-organ failure, septic shock, therapeutic drug monitoring) 
(“Infection”). 
Acceptance of the pharmacist interventions was high, 90% (even including 
patients lost to follow up as non-acceptance). The acceptance rate is 
comparable to the results reported for other critical care pharmacist 
interventions studies 7,8. 
The majority of interventions (86%) were instigated proactively by the clinical 
pharmacist as part of their independent patient review. As such these represent 
interventions that had not been identified by other health professionals such as 
medical or nursing. Appropriately trained and experienced clinical pharmacists 
are specialists in medicine use, which is their primary area of focus. One-third of 
the interventions were classified as medication errors, which identify 
opportunities for further pharmacist training and support of medical/ nurse 
prescribers.  
Although Level 3 patients accounted for only one-fifth of the number of patients 
an intervention was made in, they accounted for 47% of the medicines 
interventions and a median 7 interventions were made per Level 3 patient. As 
would be expected, patients with the highest level of illness receive the most 
medicines, primarily by the IV route and as such would be expected to require 
the highest level of pharmacy input as reflected by the interventions made.  
The intervention study was conducted over a relatively short period of 2 weeks. 
The evaluation design and timescale were chosen based on available staffing to 
undertake the study and requirement for the report to be presented to the Trust 
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in July 2010. A longer evaluation period would have provided further data on the 
pharmacist interventions made. 
The financial impact of the interventions was not calculated even though 25% of 
the interventions were either made for a Financial indication or recommended a 
Drug discontinuation. However, the overall impact on patient care with reduction 
in harm and Length of Stay can be extrapolated from the existing literature 9,10. 
Conclusion 
There was a high incidence of medicines related interventions made by the 
critical care pharmacists, the majority of which were accepted and acted upon. 
One in eight interventions represented potential for severe patient harm if not 
identified and corrected. 
The results of the clinical pharmacist intervention study demonstrated an 
important role for critical care trained pharmacists in the pharmaceutical care of 
Neurocritical care patients to improve patient care and reduce clinical risk.  
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